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Magnetic hyperthermia (MH) is an anti-cancer treatment which exploits the heat 
produced by tumour-targeted magnetic nanoparticles (MNPs) subjected to an 
alternating magnetic field (AMF). A problem limiting the clinical use of MH, 
however, is the inability to adequately localise the MNPs at the tumour site. A 
cellular approach using mesenchymal stem cells (MSCs) as carriers has been 
proposed as these cells are believed to home to sites of tissue injury and tumour 
growth, however problems with MNPs uptake and toxicity retard progress and need 
to be overcome. The aim of this project was to find an alternative approach in MH 
treatment, creating engineered human MSCs able to biosynthesise MNPs. To achieve 
this goal, MSCs were transfected with either, or both, M. magneticum AMB-1 mms6 
and mmsF genes. M. magneticum AMB-1 is a genus of magnetotactic bacteria, 
containing magnetosomes, which are lipidic organelles containing single crystals of 
magnetite. M. magneticum-AMB1 mms6 and mmsF genes are important for final 
crystal morphology and are known to play a role in crystal synthesis and growth 
respectively. The originality of this study was in using mms6 and mmsF genes, which 
were codon-optimized for mammalian expression, alone or in combination, for 
transfection of human MSCs, which have known tumour homing capacity. The 
transfected MNPs-bearing MSCs, able to migrate into the tumour tissue, were 
subjected to AMF in MH experiments in an attempt to induce cancer cell death. 
mms6 and mmsF gene expression, following transfection, was investigated in the 
human osteosarcoma cell line MG63 by reverse transcription polymerase chain 
reaction (RT-PCR). The cellular ultrastructure of transfected MG63 cells was 
investigated by transmission electron microscopy (TEM), revealing the presence of 
nanoparticles. The magnetism of transfected MG63 cells was proved by 
superconducting quantum interference device (SQUID) and supported by in vitro 
MH experiments. Then, human MSCs were transfected with mms6 and mmsF genes, 
alone or in combination. The effect of transfection experiments and MNPs synthesis 
on MSCs markers of stemness, cell proliferation and differentiation ability were 
investigated. The MTB genes expression in human MSCs was assessed by RT-PCR 
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and cell magnetism was confirmed by SQUID, in vitro MH experiments and by 
magnetic force microscopy (MFM). Then, in vitro studies of MH were undertaken to 
establish whether mms6 transfected MSCs expressing MNPs supported a MH effect 
when exposed to an AMF. Cells were initially exposed to an AMF of 565.3 kHz 
frequency in monolayers and in 3D arrangements and cell death/viability was 
assessed. Subsequently, the effect of the same AMF on 3D models of mixed 
populations of mms6-expressing MSCs and cancer cells was assessed. The results 
indicate that viability of MNPs-expressing MSCs and adjacent cancer cells is 
reduced following AMF exposure. In vivo studies of MH were undertaken following 
intracardiac injection of mms6-expressing MSCs in tumour-bearing mice 
(epidermoid carcinoma). The expression of mms6-expressing MSCs inside mice 
organs was confirmed by RT-PCR, fluorescence microscopy and 
immunohistochemistry. The effect of the application of an AMF of 565.3 kHz on 
mice tumours was studied with different techniques (tumour size and volume 
measurement, multiphoton microscopy, haematoxylin and eosin staining, and 
activated Caspase 3 expression), to understand if MNPs created inside mms6-
expressing MSCs, following AMF exposure, could lead to cancer cell death. Results 
indicate that mice tolerate the treatment well, however no appreciable tumour 
reduction or necrosis was evident.  
Overall the results suggest that mms6 transfection alone confers the highest 
magnetisation to MSCs compared to mmsF alone or mms6+mmsF co-transfected, 
and that mms6 expression in human MSCs does not have an adverse effect on 
important cell functions. mms6-expressing MSCs, when exposed to an AMF, show 
reduced viability and enhanced cell cytotoxicity in vitro. When co-cultured with 
cancer cells in 3D models in vitro, mms6-expressing MSCs are able to reduce 
viability of adjacent cancer cells confirming the potential applicability of mms6-
expressing MSCs for MH treatment. In vivo proof of concept experiments show that 
mms6-expressing MSCs can locate to the tumour tissue, and mms6-expressing 
intracardiac injected MSCs mice exposed to AMF tolerate the treatment well. 
However, the number of mms6-expressing MSCs able to localize to the tumour tissue 
in this experiment was too low to give an appreciable tumour reduction, so more 
experiments are needed to enhance the experimental protocol. A number of 
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improvements are required to progress this novel technique towards clinical 
application. Gene transfection and MNPs production need to be optimised, the best 
frequency for MH needs to be established and MSCs delivery to the tumour has to be 
significantly increased to allow concentration of MNPs. The study has helped to 
increase our knowledge on the creation of magnetic human MSCs to potentially use 










Magnetic hyperthermia (MH) is a new treatment for cancer, in which synthetic 
magnetic nanoparticles (MNPs) are delivered to the tumour. When the tumour is 
exposed to an alternating magnetic field (AMF), MNPs release heat and kill it. A 
problem limiting the clinical use of MH, however, is the inability to adequately 
localise the MNPs at the tumour site. A cellular approach using mesenchymal stem 
cells (MSCs) as carriers has been proposed as these cells are believed to home to 
sites of tissue injury and tumour growth, however problems with MNPs uptake and 
toxicity retard progress and need to be overcome. 
Magnetotactic bacteria produce and contain crystals of magnetic iron. The 
mechanism by which these structures are created is becoming clear, and two genes, 
named mms6 and mmsF, are particularly involved. The aim of this work was to 
establish whether it was possible to insert these bacterial genes into MSCs, to see 
whether these cells can produce MNPs and to establish whether they can be used for 
MH and killing of cancer cells. Following insertion of the genes into MSCs, I was 
able to show that the MSCs expressed the genes and formed MNPs, something they 
could not do without the genes. mms6 appeared to be the best gene for producing 
MNPs, so it was chosen for the next experiments. Importantly, experiments 
suggested that the treatment used to express the mms6 gene inside MSCs did not 
have adverse effects on the function of these cells. 
Experiments in the laboratory demonstrated that the MNPs produced inside mms6-
expressing MSCs were subsequently found to be heated and kill the MSCs when 
exposed to a magnetic field and, significantly, also tumour cells that were grown 
alongside the MSCs. However, when these MNPs bearing MSCs were injected in 
mice which had tumours, and then exposed to AMF, no significant evidence of 
tumour killing was seen.  
Overall, results indicate that the mms6 gene can be used to make MSCs produce 
MNPs without interfering with the function of these cells. Moreover, mms6-
expressing MSCs and adjacent tumour cells are killed by AMF in laboratory 
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experiments. However, a similar effect could not be seen in live animals. A number 
of optimisations are required before it will be possible to use this novel technique for 
treating cancers in patients. These include improving the way the bacterial genes are 
expressed inside MSCs and the MSCs homing to tumour site, increasing the number 
of MNPs that are being made by MSCs and establishing with certainty the best form 
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A431 ecad-GFP - Human squamous carcinoma e-cadherin GFP expressing 
AC - Alternating Current 
AFM - Atomic-force microscopy 
ddH20 - Distilled water 
DMEM - Dulbecco's Modified Eagle's medium 
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FACS - Fluorescence-activated cell sorting 
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GFP- Green Fluorescent Protein 
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HT - Hyperthermia 
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MFH - Magnetic Fluid Hyperthermia 
MFM- magnetic force microscopy 
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MH - Magnetic Hyperthermia 
MHT - Magnetic Hyperthermia Therapy 
MM - Magnetosomes Membrane  
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MSCs - Mesenchymal stem cells 
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MTB- Magnetotactic Bacteria 
O/N-overnight 
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RNA -  Ribonucleic Acid  
ROS - Reactive Oxygen Species 
RT-PCR- Reverse transcription polymerase chain reaction 
SHP -Specific Heating Power 
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TEM - Transmission Electron Microscopy 
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1.1. Magnetic Hyperthermia 
1.1.1. Magnetic Hyperthermia: a possible cancer therapy 
Hyperthermia (HT) is a therapeutic tumour treatment which increases the 
temperature at the tumour site. The temperature raising changes the physiology of the 
tumour cells leading to selective death through apoptosis (Moy & Tunnell, 2017; 
Peeken et al., 2017; van Loo et al., 2002). Accordingly to the temperature values 
reached during the treatment, HT could be classified in three categories: diathermia, 
where temperature is lower than 41°C, typically  employed for rheumatic diseases; 
moderate hyperthermia, which causes stress to the cells in the temperature range of 
41–46 °C; and thermoablation, where the temperature goes up to 56 °C, causing cells 
necrosis (Kumar & Mohammad, 2011; Mallory et al., 2016).  
Depending on the area of interest, HT treatments could also be grouped into local, 
regional, or whole body. Local HT refers to a delimited area of interest; regional HT 
considers a larger area, such as the whole organ; whereas in whole body HT the 
entire body is exposed to HT treatment, when metastasis occurs. Among all three 
treatments, local HT is the most studied due to the possibility to treat a defined area 
of the body (Habash et al., 2006; Toraya-Brown & Fiering, 2014). 
After the HT treatment, several alterations occur in the cell, such as the reduction in 
the transmembrane transport,  the destabilisation of the membrane potential and the 
changes in the structural proteins (Coss & Linnemans, 1996; Lepock, 2003; Moy & 
Tunnell, 2017). Furthermore, also the synthesis of the nucleic acid and the DNA 
repairing enzymes are affected by the temperature increase, altering the conformation 
of the DNA and leading to cell death (A. C. Silva et al., 2011). 
In Magnetic Hyperthermia Therapy (MHT), the heating of the target tissue is 
obtained by injecting Magnetic Nanoparticles (MNPs) in situ and then exposing the 
body part to an alternating current (AC) magnetic field (Mertz et al., 2017; 
Shaterabadi et al., 2017; Suriyanto et al., 2017). Magnetic energy is converted in heat 
by MNPs and transferred to the tumour tissue, as illustrated in Figure 1 (Cole et al., 
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2011; Deatsch & Evans, 2014; Pollert et al., 2009). Temperature, which can reach up 
to 56°C, affects cancer cell function and metabolism, leading to cell apoptosis. 
Cancer cells, indeed, are more sensitive to the increases in temperature than the 
surrounding healthy cells.The reason for this enhanced sensibility could be ascribed 
to the chaotic cancerous tissue blood vasculature. Indeed, while the vascular 
architecture of  the healthy tissue is hierarchically organised into arteries, capillaries 
and veins, the fast proliferation of cells inside the tumour tissue leads to an 
inefficient and leaky vasculature (Hervault & Thanh, 2014; Mallory et al., 2016). 
The dysregulation in the vasculature organisation is also responsible for  the 
‘enhanced permeability and retention (EPR) effect’, a typical feature of the solid 
tumors characterised by a limited lymphatic drainage and wider fenestrations and 
gaps between endothelial cells, which favour the nanoparticles accumulation into the 
tumour tissue due to "passive targeting" (Aslan et al., 2013; Maeda et al., 2006).  
Moreover, tumours  show a poor heat dissipation when a temperature above 42°C is 
applied, due to a reduced blood flow in comparison to the normal tissues (Bogart et 
al., 2014).The reduced blood flow favours the rising of temperature in the tumour 
tissue, favouring cancer cells apoptosis and the creation of hypoxia, acidosis and 
energy deprivation, all factors which contribute to the enhancement of the 
hyperthermia effect on cancer cells.(Corbet & Feron, 2017; Damaghi et al., 2015; 





1.1.2. Cellular modifications induced by Hyperthermia 
HT treatment impairs cellular environment, from the cell membrane, which becomes 
more fluidic and less stable, to the DNA and RNA repair system. Although all these 
cellular changes do not seem to be strictly linked with the cell death in vitro, cells 
exposed to HT treatment show membrane blebbing, a typical feature of apoptosis. 
(Hildebrandt et al., 2002).  
Figure 1. Schematic representation of the MHT treatment in tumour tissue. 
Solid tumours are characterised by a poor lymphatic drainage and wider fenestrations and gaps 
between endothelial cells, all factors contributing to the "enhanced permeability and retention (EPR) 
effect". For this reason, the accumulation of MNPs is favoured in tumour tissue respect to the healthy 
tissue: MNPs in circulation passively enter the tumour tissue through the gaps and fenestration 
between endothelial cells and there are retained because of the limited lymphatic drainage. 
When the body part is exposed to an alternating current (AC) magnetic field, the magnetic energy is 
converted in heat by MNPs and transferred to the tumour cells, which die, while the surrounding 
healthy cells are not affected by the treatment. 
Original image taken from (Cole et al., 2011). 
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When HT occurs, membrane potential changes, the presence of sodium and calcium 
in the cytoplasm increases as well as the potassium-efflux (Calderwood & Hahn, 
1983; Konings & Ruifrok, 1985; Majda et al., 1994; Stevenson et al., 1981). Very 
little is known about pH fluctuations happening during HT treatments. Karino et al. 
registered pH values of tissues exposed to different temperatures (41°C, 43°C and 
45°C), showing that the pH of tissues slightly elevates at the beginning of heating at 
41°C and 43°C, to gradually reduce, whereas at 45°C the pH decreases (Karino et al., 
1988). 
The cytoskeleton is another cell component affected by HT application. Cytoskeleton 
orchestrates many cell functions, such as cell division, macromolecules transport, 
protein synthesis regulation and intracellular organelles distribution and anchoring. 
The three systems composing cytoskeleton are actin filaments, intermediate 
filaments and microtubules. HT exposure re-arranges all these three systems: actin 
microfilaments disassemble, intermediate filaments aggregate in a tight ring around 
the nucleus and microtubule network weakens (Pawlik et al., 2013). 
1.1.3. Hyperthermia activates heat shock proteins (HSPs) 
Heat shock unfolds proteins, which become insoluble and concentrate at the nuclear 
matrix, influencing DNA synthesis and repair mechanism (Hildebrandt et al., 2002). 
Among all the cellular proteins, Heat Shock Proteins (HSPs) are probably the most 
representative of the cell response when a changing of temperature occurs in the cell 
environment. These chaperones are divided among families, depending on their 
molecular mass: the small HSPs with a molecular mass< 40 kDa, and the HSPs with 
a molecular mass>40 kDa,  which are HSP60, HSP70, HSP90 and HSP100 proteins 
families. In addition to act in the regular protein synthesis and in many stress-related 
cellular responses, HSPs have also been observed to cover a prominent role in cell 
protection from heat. When a heat shock occurs, the proteins of the cell matrix 
denature, liberating many hydrophobic protein sequences that could potentially 
interact with other proteins, leading to a loss of protein function. HSPs bind 
unselectively these hydrophobic regions, saving the proteins function. In moderate 
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HT, it was observed that  the production of HSPs increases, a mechanism that seems 
aimed at the cell protection against hyperthermic cell death (Buchner, 1996; Ciocca 
et al., 1993; Fuller et al., 1994; Jaattela, 1999; Kaur et al., 2000; Samali et al., 1999). 
However, a high heat shock can overwork the HSPs function, so that the proteins 
aggregation and the misfolding phenomenon can no longer being stopped. In certain 
cancer cells, HSPs were found to create complexes with the tumour specific peptides, 
which are presented by antigen presenting cells with major histocompatibility 
complex (MHC) class I molecules (Menoret & Chandawarkar, 1998; Suto & 
Srivastava, 1995; Tamura et al., 1997). Multhoff and Issels suggested that the HSP70 
and HSP72 could appear on the cell surface of some types of cancer cells after heat 
exposure, probably acting as foreign antigens by themselves and  trigging the 
immune response against tumour cell (Botzler, Li, et al., 1998; Botzler, Schmidt, et 
al., 1998; Multhoff et al., 1997; Multhoff et al., 1995; Multhoff et al., 1999; Roigas et 
al., 1998). A correlation between HSPs and p53 protein (transcription factor) or 
retinoblastoma (Rb) was proposed, suggesting that HSP 70/72 can interact with the 
mutated form of p53, but not with the wild-type p53. These findings suggest that 
tumours in which p53 or Rb is mutated are more thermoresistant than those with 
wild-type proteins (Agoff et al., 1993; Finlay et al., 1988; Matsumoto et al., 1994; 
Matsumoto et al., 1997; van Bree et al., 1999). 
Besides, the heat stress influences also the endoplasmic reticulum (ER), in which 
unfolded proteins accumulate leading to cell death (Han et al., 2013; F. J. Li et al., 
2001). The stress on ER could be monitored by the increasing levels of cytosolic 
calcium and glucose related proteins (GRP) 78 and 94 (Hou et al., 2014). 
1.1.4. Hyperthermia stimulates the Reactive Oxygen Species 
(ROS) production 
Reactive Oxygen Species (ROS) arise from normal cell respiration and are a 
common by-product in all the aerobic organisms. Although ROS determine damages 
in lipids, protein, and affects mitochondrial membranes constituents, their presence 
in cell cytosol is well tolerated when it is balanced by the neutralising action of 
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antioxidants and of superoxide dismutase 1 (SOD-1), an enzyme involved in the 
destruction of superoxide radicals.  The SOD-1 level is consistently lowered by heat 
stress, with the consequent enhancing of free ROS (El-Orabi et al., 2011). HT 
reduces SOD-1 protein levels and activity. As a consequence, the superoxide anion 
O
-
2, precursor of many ROS, remains free to react with other radicals in the cytosol, 
like nitric oxide (NO), creating the potentially harmful oxidant peroxynitrite 
(ONOO-), detrimental for the cell (Beckman & Koppenol, 1996).  
1.1.5. The effects of Hyperthermia on gene modulation, cell 
cycle and DNA  
The effect of HT on gene modulation was studied by Ahmed et al., who unveiled two 
gene networks in U937 cells, called A and B (Ahmed et al., 2015). In gene network 
A, the pathway is anti-apoptotic, and the core gene is IL1B, involved in cellular 
maintenance; while in gene network B, the pathway is pro-apoptotic and it is centred 
around the gene MAPK8, which belongs to the MAP kinase family. In gene network 
A, many HSPs proteins are  involved to protect the cell from heat stress, whereas in 
gene network B act caspases proteins, which lead to cell death. 
Heat stress also modulates the cell cycle. The thermal shock stimulates the 
serine/threonine-specific protein kinase ATM-and Rad3 related (ATR) which 
activates Checkpoint kinase 1 (Chk1), determining the arrest of the cycle progression 
at the G2/M phase (Furusawa et al., 2012). The ATR-Chk1 pathway is thought to play 
a pivotal role in the apoptosis inhibition after HT: its inactivation triggers the 
caspase-3 cleavage, promoting apoptosis. 
The damages of HT on DNA have been object of discordant reports; however, the 
current idea is that HT induces double strand brakes (DSB) in G1 and G2 cells, as 
indicated by the presence of ᵧH2AX, a typical mark of DSB. Moreover, HT stops the 





1.1.6. Hyperthermia-induced apoptosis 
It is known that HT kills the cells by inducing apoptosis, a programmed cellular 
suicide program; however, more work is needed to clarify the mechanism underlying 
the whole process (van Loo et al., 2002). Tumour cells of solid tumours are more 
prone to HT damages, due to their vascular architecture, rich of hypoxic and low-pH 
regions and definitively more complex than normal cells (Reinhold & Endrich, 1986; 
Song et al., 1995; Vaupel & Kelleher, 1995). 
The effect of HT can either affect or not cell survival, depending on the signal 
pathway that is trigged after heat shock: if HSPs are activated, the cell can survive 
below an acceptable threshold of temperature; otherwise, it can undergo apoptosis. 
The apoptosis mechanism can be triggered by the extrinsic or the intrinsic pathway 
(Figure 2). In the extrinsic apoptotic pathway, HT activates Fas ligands, the cytokine 
tumor necrosis factor (TNF)-related apoptosis-inducing ligand TRAIL, and the TNF-
α ligand that stimulate death receptors on the cell surface (Ahmed et al., 2015; Reap 
et al., 1997). Fas could either activate the downstream caspases-a situation which 
seems favoured by the heat stress- or the mitochondrial amplification loop. In the last 
case, other effectors such as caspase-8, Bid and cytochrome c release are involved, 
until cytochrome-c binds to Apaf-1 and caspase-9 apoptosome complex (Tran et al., 
2003). 
The ligand TRAIL binds to death receptor TRAILR1 (DR4), and TRAILR2 (DR5) 
expressed prevalently on the surface of the tumour cells, triggering the apoptosis 
signal. When it happens, the surface of the Fas-associated death domain is exposed, 
recruiting caspase-8 and caspase-10 with the formation of the death signalling 
complex. Caspase-8 can either activate caspase-3 in cooperation with Caspase-10 or 
participate in the mitochondrial apoptosis pathway (Yoo & Lee, 2007). TNF-α binds 
THFR1 and TNFR2 receptors, inducing apoptosis through extrinsic pathway. When 
HT is repeated, FLIP protein, which inhibits caspase-8, is down-regulated, favouring 
the TNFR-mediated apoptosis signalling. 
Regarding the intrinsic apoptosis pathway, Caspase-2 plays a pivotal role in cell 
death by acting on microtubules organisation and forming a complex with the 
10 
 
adaptor protein named RAIDD. The complex Caspase-2/RAIDD cleaves Bid, 
forming tBid, which stimulates a cascade of events: mitochondrial outer membrane 
potential (MOMP), cytochrome c release, the formation of Apaf-1-caspase-9 
apoptosome (Bonzon et al., 2006; Bouchier-Hayes et al., 2009; Ho et al., 2008; Tu et 
al., 2006). Bim is another actor involved in the intrinsic apoptosis signalling, 
following an independent pathway and activating the Bax/Bak cascade. Bim triggers 
Bax/Bak-independent activation of caspase-3 in the absence of MOMP, and it is also 














Figure 2. Extrinsic and intrinsic apoptotic pathways triggered by HT.  
Extrinsic apoptotic pathway: HT activates the ligand TRAIL,  Fas ligands, and the TNF-α ligand. 
TRAIL binds to death receptor DR4 and DR5, starting the apoptosis signal; as a consequence, the 
surface of FADD  is exposed, and forms the death signalling complex with the help of caspase-8 and 
caspase-10. Caspase-8 can either activate caspase-3 in cooperation with Caspase-10 or participate in 
the mitochondrial apoptosis pathway. Fas could either activate the mitochondrial amplification loop 
(involving caspase-8, Bid and cytochrome c) or  the downstream caspases. TNF-α binds THFR1 and 
TNFR2 receptors, inducing apoptosis through extrinsic pathway. The repetition of HT favours the 
down-regulation of the FLIP protein, which inhibits caspase-8 and favours the TNFR-mediated 
apoptosis signalling. 
Intrinsic apoptosis pathway:  Caspase-2 acts on  microtubules and forms a complex with RAIDD. The 
complex Caspase-2/RAIDD cleaves Bid, creating tBid, which stimulates the mitochondrial outer 
membrane potential (MOMP), cytochrome c release, and  the formation of Apaf-1-caspase-9 
apoptosome.  The intrinsic apoptosis signalling could be triggered also by the  independent pathway 
which involves Bim. Bim favours the  Bax/Bak-independent activation of caspase-3 in the absence of 
MOMP, and it is also destroyed by heat stress, together with actin and tubulin.   




1.2. Basic Physics concepts of 
Magnetic Hyperthermia 
1.2.1. Magnetic field induced by a coil 
Before to start with the description of the main mechanisms that underlay the heat 
transmission in MHT, it is worth to state the basic concepts of the magnetism 
induced by a coil (solenoid). A current I, which flows through a long coil, called 
solenoid, creates a uniform magnetic field inside the coil, like the one generated by a 
bar magnet. The magnetic field is indicated by the symbol B, and it is expressed in 
Tesla, T (Figure 3). The magnetic field is more concentrated and uniform in the 
centre of a long solenoid, and it could be calculated as (hyperPhysics, n.d.): 
        
where µ is the permeability, n is the number of coils, called "turn density" of the 




Figure 3. Representation of the magnetic field generated by a current flowing in a solenoid.  
The current I (red arrows), flows through the solenoid (the long coil with many turns) and creates a 
uniform magnetic field inside the coil. The magnetic field is indicated by the symbol B and it is 
represented in the picture by the blue lines. The magnetic field is more concentrated and uniform in 
the centre of a long solenoid. 





The parameters that define the magnetic strength H of an electromagnet, are: 
 number of the turns of the coil (n); 
 current (I) flowing through the coil; 
 type of core material used. 
The magnetic field strength could be increased by increasing the current or the 
number of turns. Flux density ϕ (defined as the magnetic field produced in a given 
area), the magnetic field B and the magnetic strength H are related by the formula 




     
 
 
   
where A is the area and µ is the permeability, considered constant (µ0) for  non-
magnetic material, such as wood or plastic, but it varies with the flux density for 
ferrimagnetic materials. 
B and H could be plotted in a graphic, and the resulting curve is called 
Magnetisation Curve, Magnetic Hysteresis Curve, or B-H curve. The curves are 
different for each material investigated (Figure 4). In Figure 4, the flux density 
increases with the magnetic field strength until a point in which the flux density 
reaches the magnetic saturation. This happens because, at molecular levels, all the 
molecular magnets of the material are aligned with the magnetic field: at this point, 
the flux density will not increase anymore, even if the magnetic field strength 





1.2.2. Magnetic Hyperthermia heating is due to magnetic 
hysteresis loss and relaxations losses. 
The two main challenges of MHT are: 1) to deliver MNPs to the tumour region 
through a safe and reproducible method and 2) to improve the specific heating power 
(SHP) of the MNPs, in order to use the minimum amount of MNPs (Dutz & Hergt, 
2014). When MHT is clinically applied, MNPs need to absorb an efficient amount of 
energy to be therapeutic: a condition achieved when MNPs are subjected to an AMF 
generated by a coil outside the patient's body.  
Figure 4. Representation of B-H curves (Magnetisation curves) of different materials.  
In all the materials investigated, the flux density (y axis) increases with the magnetic field strength (x 
axis) until a point in which the flux density reaches a "plateau", called magnetic saturation. This 
happens when, at molecular levels, all the molecular magnets of the material are aligned with the 
magnetic field: at this point, the flux density will not increase further, even if the magnetic field 
strength is increased. 






However, speaking of induction heating is misleading. Indeed, the inductive heat 
production mechanism depends on: 1) the electrical conductivity of the medium and 
2) the induced electrical voltage, both of them too low for MNPs to give rise to a 
sensible heating effect. The induced electrical voltage, in particular, is determined by 
the eddy current loops in the MNPs, which are too small for MNPs, but could 
become considerable when treating a human body, leading to serious consequences 
(Dutz & Hergt, 2014).  
Nowadays, two mechanisms are recognised as responsible for the tumour heating by 
MNPs in an external magnetic field: the magnetic hysteresis loss, occurring in 
particles with multi-magnetic domains, and the relaxation losses, that are present in 
superparamagnetic or single-domain particle (Figure 5), (Beik et al., 2016). 
 
Figure 5. Relaxation losses and hysteresis loss. 
These two mechanisms are responsible for MNPs heat generation under AMF. The relaxation losses 
(Néel and Brownian) are present in superparamagnetic or single-domain particle, while the magnetic 




1.2.3. The magnetic hysteresis loss 
Large ferro- or ferri-magnetic particles contain different sub-domains, each of them 
with a precise magnetisation direction. When a magnetic field is applied, the 
domains with the same magnetic direction of the magnetic field axis grow, while the 
others with different direction shrink. The phenomenon, also knew as "domain wall 
displacements", is not reversible: the curve to increase the magnetic field amplitude 
is not coincident with the one to reverse the magnetisation. Such behaviour is called  
‘hysteresis behaviour’ and produces heat under an AC magnetic field (Mornet et al., 
2004). Magnetic hysteresis loss is defined as the coupling of magnetic spin with 
crystal lattice. The electromagnetic energy is transferred to the lattice under the form 
of heat, often named magnetic loss. The amount of energy loss during one cycle of 
the magnetic field is given by the area of hysteresis loop (Figure 6), which is defined 
by the formula  (Carrey et al., 2011a ):  
           
    
     
 
 where M(H) is the magnetisation of the magnetic materials, H is the magnetic field 






Figure 6. Representation of magnetic hysteresis loop.  
a) A not magnetised material, put in a magnetic field, will show a magnetisation that increases to a 
maximum point (b), the magnetic saturation. c) When the magnetic field intensity is decreased to 0, in 
the material there will be still a residual magnetic field (remanence). d) In order to bring the material 
magnetisation to 0, a certain amount of magnetic field oriented in the opposite direction is required. 
This will flip the magnetic field direction (e). Decreasing the magnetic field intensity, there will be a 
residual magnetic field direction in the opposite direction (f). To get rid of the magnetic field, it 
should be increased and it will drop the magnetic field intensity to 0. Then, the material can be 
magnetised again and the cycle will start again (b). 




Three parameters define the hysteresis loop of magnetised materials: saturation 
magnetisation (Ms), the remanent magnetisation (Mr) and coercivity (Hc), all 
involved in the hysteresis heating mechanism. Saturation magnetisation is the 
maximum magnetisation that could be achieved by increasing the external magnetic 
field, the remanent magnetisation is the magnetisation retained by ferrimagnetic 
materials when the magnetic field is slowly reduced to zero and coercivity is  the 
remanent field lost by the ferrimagnetic material when the negative field is applied to 
demagnetised the material (Shi et al., 2015). In macroscopic magnetic materials, it is 
possible to find magnetic domains, which are regions in which all the individual 
magnetic moments of the atoms are aligned in the same direction, resulting in a 
uniform magnetic direction. When the magnetic particle size decreases, these multi-
domains are no longer energetically favoured, and so each nanoparticle represents 
only a single magnetic domain. According to Heider et al., the transition from 
multidomain to the single domain of magnetite, one of the most used materials for 
MNPs creation,  is achieved when the particles have a diameter of 30 nm (Heider et 
al., 1987). The single domain particle shows an energy barrier that prevents the 
moment alignment toward the magnetic field, a condition which could be reversed 
with a great amount of energy. The energy barrier that should be overcome to reverse 
the total magnetisation of single domains particles is higher than the one of multi-
domains particles (Heider et al., 1987). 
1.2.4. Néel relaxation and the Brownian relaxation. 
The second mechanism involved in the dissipation of heat is present when single-
domain superparamagnetic particles are in an AC magnetic field. These particles do 
not show any domain wall, and so there is no hysteresis loss, but heating is provided 
by Néel and Brownian relaxation losses (Figure 7). Again, it should be done a 
distinction between nanoparticles immobilised, only subjected to the Néel relaxation 
loss, and particles free to move in a suspension, which show Brownian relaxation 







MNPs with a diameter comprised between 10 and 60 nm show two antiparallel 
crystallographic directions, separated by energy barriers: this behaviour is due to 
their magnetic anisotropy (magnetism that varies from point to point of the MNPs). 
The two magnetic stable orientations determine the magnetic axis of the nanoparticle 
which could flip and reverse its direction. Let's call τN the average time necessary 
for the nanoparticle magnetisation to randomly flip as a result of thermal 
fluctuations, and τm the time at which the magnetisation of the nanoparticle is 
measured. If τm>>τN, the magnetisation will flip many times during measurement, 
leading to a total magnetisation equal to zero, while if τm<<τN, the magnetisation 
will not have the time to flip, and so the measured magnetisation will be the one 
registered at the beginning of the measurement. The temperature at which τm=τN is 
called the blocking temperature (TB). In this case, the state of the nanoparticle-
superparamagnetic or blocked-  will be determined by the measurement time: below 
the TB, nanoparticles are in the superparamagnetic state, characterized by single 
domain behaviour, with the system coercivity and retentivity equal to zero; above the 
TB the direction is randomized, due to the small nanoparticles size (Shi et al., 2015). 
The blocking temperature is influenced by the volume of nanoparticles and the 
anisotropy constant of the material, called the energy barrier.  
Figure 7. Schematic representation of the Néel and Brownian relaxations in a magnetic particle. 
(a) Néel rotation (the magnetic moment rotates within each particle, but the particle does not rotate); 




Néel relaxation occurs when a particle overcome an energy barrier in the presence of 
an AMF. The magnetisation of the nanoparticle does not vanish immediately when 
the magnetic field ceases, but the microscopic magnetisation vanishes with the 
typical relaxation time τN (Dutz & Hergt, 2014): 
          
   




Where τ0 is a length of time, characteristic of the material, called the attempt time, K 
is the magnetic anisotropy, and V is the particle volume, k is the Boltzmann constant, 





 seconds. K*V determines the energy barrier against reversal of 
magnetisation. 
The relaxation time decreases with the decreasing particle volume. Néel relaxation is 
the only relaxation process present when the nanoparticles are immobilised, as in 
tumour tissue (Shi et al., 2015). 
When the magnetic nanoparticles are in suspension, and so they can rotate freely, 
another process of relaxation occurs, called Brownian relaxation. In this case, it 
should be taken into account the fractional losses due to the viscosity of the carrier 
liquid. The Brownian relaxation time is described by Beik et al. in the formula (Dutz 
& Hergt, 2014): 
      
     
   
 
 
where Vh is the hydrodynamically effective volume, which could differ from the 
geometrical volume, due for example to the adhering fluids layers. 
Nanoparticles tend to reverse the magnetisation by either the Néel or the Brownian 
process, following the energetically easiest way, that is the one which shows the 
smaller relaxation time (Figure 8). The effective relaxion time (τ) is described by the 




    
     
 
The transition between Néel or Brownian relaxations happens when τN= τB, but for 
smaller diameter, the Néel relaxation is favoured instead of the Brownian relaxation. 
When nanoparticles are dispersed in blood vessels, the Brown relaxation is present, 
while when the nanoparticles are injected directly in the tumour, and so are not freely 




Figure 8. Coercivity and relaxation losses dependency on particle size. 
a) Maghemite nanoparticles coercivity depends on particle size, taken from (R. Hergt et al., 2008).  
b) Particles relaxation frequency depends on their size, magnetic type and suspension media. Adapted 




1.2.5. The Specific Absorption Rate (SAR) 
In clinical applications, the measure of the rate at which the energy is absorbed by 
the human body, when it is exposed to an AMF, is determined by Specific 
Absorption Rate (SAR). SAR is defined as (Mornet et al., 2004): 




where C is the specific heat capacity of the heated medium and 
  
  
 is the initial slope 
of the temperature versus time dependence.  
SAR is influenced by a multitude of other parameters, such as viscosity and heat 
capacity of the tissue/liquid in which nanoparticles are suspended, size, size 
distribution, shape and chemical composition of nanoparticles (Mornet et al., 2004). 
Indeed, with the nanoparticles size reduction, thermal fluctuations are more frequent. 
If the changes in the external magnetic field are too slow respect to the relaxation 
time, particles show superparamagnetism, and so it can be assumed that frequency of 





 behaviour. The transition is also influenced by 
Néel and Brownian relaxation.  
In general, when frequency is low, the nanoparticles magnetisation M follows the 
driving AMF H, and it is said that M and H are in phase; however, when the 
frequency increases, M and H are no longer in phase, because M cannot follow the 
rapid increase of H. In magnetic multi-domains materials, in addition to that, when 
the frequency is high, loss peaks due to the domain wall resonance could appear 
(Dutz & Hergt, 2014).  
                                                 
1
 Ferromagnetic behaviour is displayed by materials which have a high susceptibility to magnetisation. 
Their susceptibility depends on the applied magnetizing field and could persist also after the magnetic 
field ceases. Iron is a ferromagnetic material, in which all the neighbouring atoms display parallel 
magnetic alignments (oxforddictionaries, n.d.). 
2
 Superparamagnetic behaviour is a form of magnetism displayed by small ferromagnetic or 
ferrimagnetic nanoparticles. When nanoparticles are small, their magnetisation can randomly flip 
direction under the influence of temperature, with a typical time between two flips called the Néel 
relaxation time (Wikipedia, n.d.). 
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1.2.6. Physical parameters which influence nanoparticle 
interaction 
The nanoparticles size and volume have been correlated to the heat dissipation in a 
model which defines the hysteresis losses as the primary mechanism of MNPs 
heating of any size (Carrey et al., 2011b). The heating properties of MNPs are 
influenced by several parameters: the frequency and amplitude of magnetic field, the 
particle geometry and shape, the particles size and distribution, the anisotropy (Hergt 
et al., 2004; Hugounenq et al., 2012; Vallejo Fernandez & O'Grady, 2013; Walter et 
al., 2014). Magnetic dipoles, in particular, play an important role in HT. When 
present in a complex biological system, indeed, the nanoparticles tend to be 
inhomogeneously distributed, creating the intercellular clustering of nanoparticles, 
bunched up in the endosomes or another cellular compartment (Branquinho et al., 
2013; Lunov et al., 2011). A study on different configurations of nanoparticles, 
respectively homogeneously dispersed in water or blocked in a polystyrene matrix, 
shows that when the nanoparticles are blocked inside the matrix, the strong dipole 
interactions impeded the magnetic moment, so Néel relaxation contribute to heating 
is reduced  and the heating is caused by hysteresis loss (Sadat et al., 2014). Also the 
concentration influences nanoparticle behaviour. Indeed, at high concentration, 
nanoparticles tend to create magnetic dipoles with an enhanced heat dissipation from 
magnetic hysteresis loss, lowering the SAR  (Fortin et al., 2007; Gudoshnikov et al., 
2012; Haase & Nowak, 2012; Urtizberea et al., 2010). Instead, when nanoparticles 
are normally concentrated, the superparamagnetic particles follow the Néel and 
Brownian relaxations, according to the classical Langevin behaviour, that is 
reversible magnetisation curve with zero retentivity and coercivity. When the 
nanoparticles concentration is high, however, they do not follow anymore the 
Langevin function, but instead the dipole interactions change their anisotropy and 
their magnetic behaviour. It was also observed that in the presence of an AC field, 
nanoparticles tend to create chains, lowering the SAR (Branquinho et al., 2013). The 
dimerization of the nanoparticles and their arrangement into chains, as well as the 




1.3. MNPs required features for 
Magnetic Hyperthermia applications 
There is a vast research aimed to create MNPs with the highest SAR and the 
minimum toxic effect for the body. The most interesting MNPs features are: 1) type 
of magnetic material they are made of, 2) particle size, and 3) particle coating. 
For the MNPs creation, metals as iron, cobalt and nickel and metal oxides as Fe3O4, 
γ-Fe2O3, MnFe2O4 and CoFe2O4 are normally used. However, their degradation when 
introduced inside the body could produce reactive oxygen species (ROS) and free 
radicals. These products trigger lipid peroxidation, DNA damages, protein alteration, 
and cell apoptosis (Liu et al., 2015). To overcome these issues, MNPs are usually 
subjected to surface treatments that make them stable and safe for biomedical 
application.  According to Nandwana et al., MNPs surface modifications should 
satisfy different requirements, as: 1) do not agglomerate, 2) be biocompatible and 
possibly be able to be functionalized, 3) avoid nonspecific cell interaction, and 4) 
increase the MNPs pharmacokinetics. MNPs are normally coated with 
dimercaptosuccinic acid (DMSA), Polyethylene glycol (PEG), dextran, chitosan, 
liposomes, gold and silica (Nandwana et al., 2015). 
The preferred MNPs size for clinical application is below 20–30 nm, under the 
superparamagnetic limit. Nanoparticles could be created either by mechanical 
attrition (top-down method) or by chemical synthesis (bottom-up method), but the 
latter method is the most used as it creates MNPs of uniform composition and size. 
Chemical methods typically used for MNPs creation are co-precipitation, 
microemulsion, thermal decomposition and/or reduction, hydrothermal synthesis, 
and polyol synthesis (Nandwana et al., 2015). 
1.3.1. In vitro and in vivo Magnetic Hyperthermia application  
Magnetic Fluid Hyperthermia (MFH) refers to Hyperthermia treatment that uses 
MNPs  suspended in a fluid. MFH  has frequently been used in synergy with other 
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treatments, such as chemotherapy and radiotherapy. It was observed that MFH 
increases  Caco-2  cell membrane fluidity, enhancing the effect of chemotherapy, in 
MFH-treated cells (Alvarez-Berrios et al., 2013; Hernandez et al., 2010; Meenach et 
al., 2012). The effect of the combined treatments also affects the immune system: 
indeed there is a production of heat shock proteins, which stimulate the immune 
system against melanoma tumour cells, opening new routes for the treatments of the 
metastasis (Sato et al., 2010). Sadhasivam et al. used surface modified carbon-
encapsulated iron oxide nanoparticles (CEIO-NPs) with polyethylene glycol-folic 
acid (PEG-FA) against  HeLa cells. The folate receptors expressed on the surface of 
the cell were targeted by the nanoparticles, which entered inside the cell, leading to 
cell damage after MFH (Sadhasivam et al., 2015). 
MFH was successfully employed as a single treatment using poly (lactic-co-glycolic 
acid) (PLGA)-functionalised magnetic nanocapsules, effectively killing neoplastic 
4T1 and MCF-7 breast cell lines by apoptotic cell death (Estevanato et al., 2012). 
Cell apoptosis was also obtained by delivering herceptin-conjugated MNPs to SK-
BR-3 cells and exposing the cells to an AMF (J. Zhang et al., 2011). 
In vivo experiments of MFH on mice bearing pancreatic cancer locally injected with 
20-nm MNPs, determined the tumour growth inhibition and the survival 
prolongation. After 30 minutes of exposure, it was also registered an increase in 
temperature up to 47-51 °C  (L. Wang, Dong, et al., 2012). Wang et al. applied NMH 
to ultra-small magnetic iron oxide (USPIO) on cervical lymph node metastasis of 
rabbit pyriform sinus carcinoma, obtaining an apoptosis of 100% of treated cells. It 
was also reported chromatin and cytoplasm condensation, endoplasmic reticulum 
membrane fusion, and bubble formation. Studies regarding the in vivo and in vitro 
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Table 1. List of in vitro experiments in which MFH was applied.  
[KHz; KA/m; min] indicates [Kilo Hertz; Kilo Ampere per meter; minutes]. 
1
Specific Absorption Rate 
(SAR). 
2







epidermal growth factor receptor (HER2) aptamer as a targeting moiety. 
6
CREKA is a tumour homing 
peptide that recognizes fibrin associated plasma proteins overexpressed in cancer cells. Table adapted 





























































































Table 2. List of in vivo experiments in which MFH was applied.  







Nucant multivalent pseudopeptide. 
4
Chitosan oligosaccharide-stabilized 




1.4. Non-thermal effect in Magnetic 
Hyperthermia 
Observations from different research groups suggest that the heating effect due to the 
AMF application to the cells bearing MNPs seems not to be the exclusive mechanism 
involved in the cell death, but that at least another non-thermal mechanism exists, 
generated by AMF, which leads to cell death. Indeed, Villanueva et al. (Villanueva et 
al., 2010) observed that  30 minutes of AMF application (f¼100 kHz, H¼15 mT) on 
HeLa cells using perovskite-based MNPs were sufficient to cause cell apoptosis, 
even if the observed temperature increase was less than 0.5 °C. Along with 
Villanueva et al., Asin et al. in 2012 , obtained 100% of  cell dead when an AMF of  
260 kHz and 12.7 kA/m was applied for 15 min to magnetically loaded dendritic  
cells (DCs), with a temperature rise of only 1-2 °C. All these findings show that 
some other non-thermal mechanism should happen in cells exposed to MH, as 
observed by Asin et al. in 2013 (Asin et al, 2013), where the supernatant of the 
AMF-exposed cells was used to kill control cells, not exposed to AMF. The controls 
death was explained as a mechanical effect: the MNPs, due to AMF exposure, cause 
the breakage of the endocytic vesicles/lysosomes in which are confined, determining 
the release of toxic content in the cytoplasmic medium.  
Many scientific works investigated the cellular heating, thought as the simple 
consequence of the so-called "intracellular hyperthermia". Huang et al. found an 
increase of temperature only in the cell membrane, while the cytoplasm temperature 
was unchanged; others studies calculated that the temperature of MNPs is reduced 
below one tenth if measured at a distance of 3nm from the nanoparticle, making 
difficult to attribute the excessive peak temperature registered for MNPs only to the 
magnetic heating effect (Huang et al., 2010; Riedinger et al., 2013). Probably other 
actors, not yet unveiled, are involved in the cellular heating process. The cell heating 
represents still a mystery, and until now the models that tried to estimate the heating 
effect inside the cell environment appeared too naive, and macroscopic temperature 
sensors are probably not sensitive enough to adequately describe the MNPs cellular 
surrounding. It was also theoretically hypothesised that MNPs, under the effect of an 
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AMF, could generate ultrasound waves that could enrich the panorama of therapeutic 
applications (Carrey et al., 2013).  
Wild-type cells loaded with MNPs and exposed to AMF could have phenotypic 
responses. Indeed, the interaction between the MNPs and the magnetic field 
influences the ROS generation, which increases in cells exposed to the AMF 
(Connord et al., 2015). ROS exert their detrimental effects on all the cell 
macromolecules, such as  protein, carbohydrate, lipids and DNA, causing damages to 
the cells (L. Chen et al., 2017).  
The catalytic ROS production is favoured by the release of Fe
2+
 produced by MNPs 
by Fenton reaction, that is increased by the exposure to the magnetic field(Connord 
et al., 2015; Domenech et al., 2013). The ROS production is also favoured by  the 
magnetic field generated by MNPs in their immediate proximity, that changes the 
pair spin states and promotes the free radical production. (Binhi & Chernavskii, 
2005; Jia et al., 2014), It was shown that Fe3O4 MNPs could promote ROS 
generation both in the presence of an AMF (60 kA/m,292 kHz) than in a statical 
magnetic field (Binhi & Chernavskii, 2005; Wydra et al., 2015).  
Other effects promoted by AMF application are lysosomal membrane 
permeabilization (Domenech et al., 2013), cell cytotoxicity and apoptosis, as seen in 
hepatocytes exposed to a static magnetic field (0.4 T) for 1 h (Bae et al., 2011), and 
in rat pheochromocytoma cells incubated with MNPs-SiO2 and then exposed to 





1.5. Clinical application of Magnetic 
Hyperthermia 
Magnetic Hyperthermia was firstly applied clinically by Jordan et al. (Jordan et al., 
2001).  
After that,  the technique was employed in many different applications, summarised 
by Beik et al. in Table 3 (Beik et al., 2016). In all of them, the magnetic field 
strength was modulated accordingly with the area subjected to the treatment, from 2 
to 18 KA/m. 
The efficacy of the thermal therapy approach is measured by the thermal dose unit, a 
method by which "the time-temperature profile of an arbitrary treatment regime is 
normalised to cumulative equivalent minutes (CEM) of treatment at 43 °C", and 
which is defined by the formula (Sapareto, 1982; Sapereto et al., 1978): 
               
 
 
    
 
Where t indicates the time spent at temperature T, and RCEM  stands for the ratio of 
exposure times required to result in the same survival for a 1 °C rise in temperature 
T. For many cell types, RCEM is considered to be 0.5 above 43 °C and 0.25 below 43 
°C. 
Regarding application of MHT in human, Maier-Hauff et al. tested a combined 
treatment of Nano-Magnetic Hyperthermia (NMH) and radiotheraphy (RT) on 14 
patients suffering of recurrent glioblastoma multiforme (Maier-Hauff et al., 
2007). During the treatment, repeated in average 6 times for each patient, the 
thermotherapy was combined with 30 Gy of radiotherapy dose. In 90% of the 
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Table 3. Summary of clinical trials on NMH using MNPs.  
The table compares the median T90, median CEM43, and patient survival for radiotherapy alone or 
radiotherapy in combination with NMH. [Median T90] indicates temperature exceeded for 90% of 






NBTXR3 are hafnium oxide crystallites and phosphate groups in an 




1.6. Magnetotacic Bacteria 
1.6.1. The discovery of Magnetotactic bacteria (MTB) 
Magnetotactic Bacteria (MTB) are Gram-negative organisms able to align with 
external magnetic fields. This ability is given by chains of linearly arranged 
subcellular magnetic organelles, called magnetosomes (Figure 9), (Barber-Zucker et 
al., 2016; Bazylinski & Frankel, 2004; Blakemore et al., 1980; Nudelman & 
Zarivach, 2014). Magnetosomes are lipidic membranes filled within crystals of 
magnetite (Fe3O4), greigite (Fe3S4) or maghemite (γ-Fe2O3), that are believed to 
originate from MTB cytoplasmic membrane (Gorby et al., 1988; Rong et al., 2012). 
Magnetosomes in MSR-1 species are formed principally by proteins, which surround 
the magnetosome, and by lipids (Grunberg et al., 2001). 
The length of the magnetosome crystal iron oxide core, determined by Transmission 
Electron Microscopy (TEM) investigation, measures between 5 and 120 nm (Kolinko 
et al., 2012). Magnetospirillum AMB-1 and MSR-1 strains are characterised by 
magnetosomes of cubo-octaedral geometry, sized between 30 and 50 nm 
(Alphandéry et al., 2008). This size makes magnetosomes single-domain crystals, 
that are crystals with the maximum possible magnetic moment per unit volume. In 
AMB-1 and MSR-1, there is only one magnetosome chain composed by 15-30 
magnetosomes, while  Magnetobacterium bavaricum (Mbav) strain shows more 
chains, each of them consisting of more strands of magnetosomes (Komeili, 2012). 
MTB were discovered by Salvatore Bellini, a medical doctor at the University of 
Pavia, who for first noticed MTB in fresh waters around Pavia in a period which 
spans from the late 1950s to 1963. He observed that those bacteria were able to 
accumulate in water droplets following the North direction. Bellini performed 
different experiments to demonstrate the sensitivity of the MTB to the magnetic 
field, but the findings of his researches, written in Italian, were only diffused to the 
small audience of a few Italian universities. It was only several years later that 
Bellini's discoveries were translated into English, with the help of Frankel (Bellini, 
2009; Bellini, 2009; Frankel., 2009). The men who introduced MTB to the scientific 
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audience was Blakemore, who found the bacteria in sediments collected near Woods 
Hole (Massachusetts) and noticed that their swimming direction was always the 
same, independently from the external stimulus given, but it changed when a magnet 
was brought near. Blakemore also studied the internal morphology of MTB, 
describing the magnetosome and the chains of the magnetosomes, providing an 
explanation for the MTB movement along the magnetic field (R. Blakemore, 1975; 
Komeili, 2012).  
Figure 9 Transmission Electron Microscopy (TEM) pictures of Magnetospirillum 
gryphiswaldense.  
The central chain made of single magnetosomes is visible in the cell body, indicated by the arrow. 
Picture adapted from (Schuler, 2008). 
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1.6.2. Ecology of Magnetotatic Bacteria 
The ecology of MTB reveals that these bacteria prefer to live in aquatic zones where 
oxygen and redox compounds are horizontally stratified, gathering close to or below 
the oxic-anoxic transition zone (OATZ). OATZ is a particular zone created by two 
opposite gradients, one formed by the oxygen coming from the surface and another 
created by the sulphide produced by the sediments of the bottom (Figure 10). In 
OATZ, oxygen levels are very low, creating the perfect environment for MTB, which 
dislike increasing oxygen conditions (Bazylinski & Frankel, 2004; Frankel et al., 
1997). Moreover, it was found by Blakemore that MTB of the North hemisphere 
swim northwards, while MTB of the South hemisphere swim southwards, and in 
both the cases MTB point to the lower part of their habitat, where oxygen levels are 
very low (Blakemore et al., 1980). In both the hemispheres, MTB on the oxic side of 
OATZ move across different stratifications by swimming down geomagnetic field 
lines, whereas those on the anoxic side swim up. The MTB located on oxic side of 
OATZ rotate their flagella counterclockwise (CCW), whereas the ones present on the 
anoxic side swim up along geomagnetic field lines (Bgeo) by rotating their flagella 
clockwise (CW). MTB showing north or south-seeking behaviour show also different 
magnetic polarity. This typical MTB mechanism of moving toward OATZ, 
exploiting magnetic field through their magnetosomes, is called "magneto-aerotaxis". 
According to the "magneto-aerotaxis" hypothesis, moving along the magnetic field, 
MTB follow a vertical route toward different stratifications, being helped in this 
sense to find OATZ respect to other bacteria that possess only chemotactic and 
aerotactic mechanisms. However, this hypothesis is not fully validated by evidences. 
Frankel et al. found out magnetosomes also in the Equator,  very far from North and 
South Poles, while MTB believed to migrate toward south were found in the North 
hemisphere (Frankel et al., 1981; Shapiro et al., 2011; Simmons et al., 2006).  
Moreover, Spring et al. observed that the number of magnetosomes inside MTB 
exceeds the one required for MTB movement along magnetic field (Spring et al., 
1993). Taken together, these findings are not completely against the "magneto-
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aerotaxis" hypothesis: it could be possible indeed that MTB follow other routes to 
find other chemical compounds more abundant in areas which are different from 
OATZ. Due to the ambiguity of the magnetosomes role, other hypotheses have been 
raised about the presence of magnetosomes in MTB.  For example, it is possible that 
magnetosomes participate to iron storage or cell detoxification, but this assumption is 
not convincing (Shapiro et al., 2011; Simmons et al., 2006), or maybe magnetosomes 
could be involved in the cell movement, helping the MTB to turn along the magnetic 
field (Philippe & Wu, 2010). Another hypothesis is that magnetosomes could be 
involved in MTB energy production, exploiting the redox changes to oxidise 
magnetite in maghemite and producing energy for the cell ("magnetosome battery 
hypothesis", proposed by (Kopp & Kirschvink, 2008). 
 
  
Figure 10. Schematic representation of  Magneto-aerotaxis in the northern (NH) and southern 
(SH) hemispheres.  
MTB exploit magnetic field to find their optimal oxygen concentration at the microaerobic oxic–
anoxic transition zone (OATZ). To move across different stratifications, in both the hemispheres, 
MTB on the oxic side of OATZ swim down geomagnetic field lines (Bgeo), whereas those on the 
anoxic side swim up along Bgeo. The MTB on oxic side of OATZ rotate their flagella 
counterclockwise (CCW), whereas the ones on the anoxic side rotate their flagella clockwise (CW). 
MTB showing north or south-seeking behaviour show also different magnetic polarity, indicated by 
arrows. Image adapted from (Bazylinski & Frankel, 2004) 
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1.6.3. The magnetosome formation 
The magnetosome formation is a well-modulated process, orchestrated by a high 
number of genes, most of which belong to a genomic area that is highly conserved 
among different species, called Magnetosomes Island (MAI). The MAI is a region of 
130 kb (Ullrich et al., 2005) which contains 106 annotated Open Reading Frame 
(ORF). To better understand its function, the MAI was divided into 14 independent 
regions, named R1-R14 by Murat et al.  (Murat et al., 2010). The MAI contains five 
different polycistronic operons, named: mamAB, feoAB1, mamGFDC, mms6, 
mamXY, the most conserved of which is mamAB (Figure 11). Without MAI or the 
operon mamAB, there is no magnetic phenotype (Murat et al., 2010; Lohsse et al., 
2011). The other operons, such as mamGFDC, mamXY and mms6 in MSR-1, vary 
from strain to strain, so to explore magnetosome formation researchers preferred to 
focus on genes of MSR-1, considered as a model of MTB-related and specific genes. 
The magnetosome formation is a multi-steps process. The major ones are named:  
magnetosome membrane formation, magnetosome protein sorting, magnetosome 
alignment into chains, and biomineralization. The principal genes involved in these 
processes are all contained in the conserved mamAB region (Murat et al., 2010). The 
MAI is such a critical region, which could recreate alone the entire pathway of 
magnetosome biogenesis. Indeed, when the 30 genes of which MAI is composed 
were introduced using expression cassettes in Rhodospirillum rubrum, a non-
magnetic bacterium, it became magnetic (Kolinko et al., 2014). This experiment is 
the proof of principle that it is possible to transfer the magnetic properties of MTB in 
a non-magnetic bacteria. 
 
  
Figure 11. Schematic representation of the genomic magnetosome island (MAI). 
In the MAI are present the five operons containing the genes involved in the magnetosome biogenesis. 
The genes are coloured according to the features of their encoded proteins. Original image adapted 
from (Uebe & Schuler, 2016) 
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1.6.4. The magnetosome membrane formation 
Magnetosomes membrane (MM) has been investigated for a long time, as it is 
believed to be one of the major players in magnetosomes biomineralization and cell 
protection from magnetosomes toxic products. The MM creates a specialised 
environment inside the bacterium, where pH, iron and redox are finely tuned, acting 
as a "nano-reactor" for crystals formation (Uebe & Schuler, 2016). However, the 
fragility of the magnetosome membranes made investigations arduous. The 
magnetosome membrane biogenesis was clarified by using Electrical capacitance 
tomography (ECT). ECT is a technique which takes images from frozen samples at 
different angles using an electron beam; images are then assembled in a 3D 
reconstruction by using an algorithm. ECT images reveal that magnetosome 
membrane could originate as an invagination of the inner membrane (Komeili et al., 
2006; Tocheva et al., 2010). Magnetosome vesicles remain as invagination along all 
the entire mineralisation process, either empty or filled with iron. Moreover, 
invaginations originate from different non-specific spots of the MTB inner 
membrane, suggesting that vesicles formation process is less regulated respect to the 
vesicles formation in the eukaryotic cell (Faini et al., 2013). The formation of 
vesicles seems a necessary condition for the biomineralization process happening; 
however, the opposite is not true, as MTB show vesicles in iron deprived conditions  
(Fukuda et al., 2006; Grunberg et al., 2004; Komeili et al., 2004; Murat et al., 2010; 
Scheffel et al., 2006). It was speculated that magnetosomes, integrating within the 
inner cell membrane, could guide cell movements along the magnetic field, without 
any additional mechanism. However, the proposed mechanism is not valid for all the 
magnetic bacteria, as in uncultured magnetic cocci and in Mbav, magnetosomes were 
found clearly far from the inner membrane (Jogler et al., 2011). 
The genes involved in membrane invagination are mamB, I, L, Q and Y, as their 
deletion cause the absence of magnetosomes vesicles in AMB-1. Their presence is 
necessary but not sufficient for membrane invagination, as they are unable to restore 
wild-type magnetosomes membranes in  ΔmamAB experiments (Murat et al., 2010).  
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In particular, MamB seems to have a function in magnetosome membrane 
invagination and iron transportation; whereas mamI and mamL are integral 
membrane proteins associated with the MM (Uebe et al., 2011). MamB is believed to 
act as a landmark protein, which directs the formation of multiprotein complexes to 
induce invagination in the later steps of magnetosome biogenesis. MamY is another 
protein associated with membrane invagination (Tanaka et al., 2010), and it is 
believed to be involved in constriction of the cell membrane to create the 
magnetosome cell membrane, in deformation of MM and in magnetite growth. 
MamQ is an MM integrated protein; it is well conserved among different MTB 
phyla, and it is believed to have a role in membrane bending. 
1.6.5. The magnetosome protein sorting 
Magnetosomes proteins are usually targeted to the MM, or to the cytosolic side of it, 
as a consequence of a process which is still ignored. MamA, a highly conserved 
magnetosome-associated protein, moves freely and independently from magnetite 
formation (Barber-Zucker et al., 2016).  When MamA is removed in AMB-1, a large 
number of magnetosomes is empty; however, it does not influence magnetosome 
formation (Komeili et al., 2004). In vitro, MamA binds different proteins, forming a 
multiprotein complex that surrounds the magnetosome membrane. MamA acts as a 
multiprotein interaction site, forming homo-oligomers with central pore cavity (Pan 
et al., 2012; Yamamoto et al., 2010; Zeytuni et al., 2011).  
MamE, a predicted integral membrane protein containing a transmembrane region 
(TM), has a role in protein sorting and crystal biomineralization initiation (Quinlan et 
al., 2011; W. Yang et al., 2010). As MamE deletion in AMB-1 causes misplacing of 
different proteins, it is likely that MamE physically interacts with the other proteins 




1.6.6. The magnetosome alignment into chains 
MTB sense the magnetic field by aligning their magnetosomes, each of them made 
of a single-magnetic domain, in a linear chain. Unlike the single magnetosome, 
insufficient to detect the magnetic field, the magnetosome chain forms a larger 
magnetic dipole that can identify and respond to the magnetic field, functioning as a 
needle (Frankel & Bazylinski, 2006). Two proteins are suggested to be involved in 
magnetosome alignment, MamK and MamJ. MamK, an actin-like protein, is 
supposed to have a crucial role in magnetosomes alignment, providing a track to 
which magnetosomes could move on (Bennet et al., 2015; Draper et al., 2011; Pradel 
et al., 2006). MamK, containing an ATP-binding site with ATPase activity,  guides 
singles magnetosomes in a single chain located in the mid-cell, and it is also believed 
to be involved in the filaments dissociation (Draper et al.,2011; Sonkaria et al., 2012; 
Ozyamak et al., 2013; Pradel et al., 2006; Rioux et al., 2010; Taoka et al., 2007; 
Uebe & Schuler, 2016). In  AMB-1 mutants lacking MamK, the protein function is 
partially replaced by a MamK-like protein, codified outside the MAI region (Rioux 
et al., 2010), but the resulting magnetosomes show a reduction in size and are not 
well organised  (Katzmann et al., 2010).  
MamJ is a protein not conserved within all MTB, which is co-transcribed with 
MamK. MamJ is present on a structure which connects the two ends of the cells, and 
it is believed to play a role in magnetosome chain organisation (Draper et al., 2011; 
Katzmann et al., 2010; Scheffel et al., 2006). It is assumed that MamJ cooperates 
with MamK in the organisation of magnetosomes into chains (Scheffel et al., 2006). 
Strong magnetic field disturbs MamJ and MamJ/MamK interaction  (Körnig et al., 
2014), but not the filaments created by MamK. It was also demonstrated that MamJ 
relies on other magnetosomes proteins for its localisation, such as MamE and 
MamK, whose presence is essential for MamJ correct localisation in MSR-1, but not 





Biomineralization is a process lead by living organisms that exploit organic 
molecules for crystal nucleation and growth under mild condition (Amemiya et al., 
2007). The MM protects the internal environment of the magnetosome, which 
provides the chemical conditions required for the biomineralization. The process of 
crystal maturation is fine tuned and depends on extracellular iron: to explain it, the 
following mechanisms have been proposed. In the first one, the extracellular iron 
enters  into cell cytoplasm by cytoplasmic membrane transporters and then it is 
transported into MM vesicles by magnetosome-specific transporters; in the second 
proposed model iron is transported across the cytoplasmic membrane, then it is 
bound  to organic compounds and  lately it is released into the magnetosome without 
the transport of free iron through the cytoplasm.  The third mechanism proposes that 
iron is directly imported into vesicles from the periplasm of the cell envelope (Uebe 
& Schuler, 2016). The steps of biomineralization have been defined and are: 
nucleation, growth and morphological regulation (Tanaka et al., 2011).   
Nucleation is a well-orchestrated process that in the most of the cases ends up with 
the formation of a single iron crystal for each magnetosome. Nucleation occurs when 
inside the magnetosome there are the right conditions -pH should be ≥7, and the 





 (Uebe & Schuler, 2016). To date, two proposed models 





 precipitate, forming the magnetite straight away; while the second one 
suggests that the magnetite formation occurs by several discrete steps, involving the 
creation of precursor mineral phases that are transformed into magnetite (Faivre & 
Godec, 2015). The definition of the mechanisms which lead to the growth and to the 
morphological regulation of crystals are still obscure, and experiments conducted so 
far are based on the creation of mutants lacking the proteins believed to be involved 
in such process, but a complete picture is still missing (Uebe & Schuler, 2016). 
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The proteins involved in magnetosome biomineralization process so far discovered 
are: MamM, MamB, MamO, MamE, MamP, MamT, MamX, MamZ, MamH, 
MamN, MamS, MamR and the FtsZ-like proteins. 
MamM is an integral membrane protein localised to MM. MamM is believed to be 
involved in iron transport, magnetite nucleation, crystals growth and in other MM 
proteins localisation (Murat et al., 2010). The first function was attributed to MamM 
due to the protein homology with cation diffusion facilitator (CDF) protein family 
and because MamM single point mutation leads to magnetite biomineralization 
alterations (Murat et al., 2010). MamM seems to participate in many different 
activities, like accumulating iron in the magnetosome lumen and keeping high the 
magnetosome pH for magnetite/greigite biomineralization (Barber-Zucker et al., 
2016). It was found that MamM is responsible also for MamB stability, a protein 
taking part to both the iron accumulation and to the MM invagination processes. In 
MSR-1, the dependence of MamB stability from MamM suggests a possible 
interaction between the two proteins, maybe forming heterodimers (Uebe et al., 
2011).  
MamO is an integral membrane protein believed to be involved in crystal nucleation, 
as mutants lacking MamO possess magnetosomes without iron content and low 
magnetism (Guo et al., 2012; W. Yang et al., 2010).  
Besides being involved in protein sorting (Quinlan et al., 2011; W. Yang et al., 
2010), MamE takes part also in the biomineralization process. It was demonstrated 
that MamE deletion causes magnetosomes deprived of the iron content and without 
magnetite synthesis (Murat et al., 2010), so it is supposed that MamE could mediate 
biomineralization acting as a molecular switch together with other proteins, such as 
MamO (W. Yang et al., 2010). MamE, as well as MamP, T and X, possess the 
CXXCH motif, that is a c-type cytochrome motif which binds a haem, acting in iron 
reduction/oxidation (Quinlan et al., 2011; Raschdorf et al., 2013). The CXXCH motif 
seems to be unique of MTB, and so it was called "magnetochrome", defining a new 
class of cytochromes (Siponen et al., 2013). Since MamE, P, T and X are the only 
redox proteins, it was supposed that their role could be determinant in MTB crystal 
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shape and MTB evolution (Siponen et al., 2012). MamE is also expected to direct the 
synthesis and in the maturation of 20 nm iron-oxide crystals (Quinlan et al., 2011).  
MamP is an integral membrane protein believed to be involved in crystal size and 





, (Taoka et al., 2014). MamT is another integral protein 
believed to influence the magnetite crystal growth and electron-redox chain  (Jones 
et al., 2015; Murat et al., 2010; Siponen et al., 2013). Also MamX is believed to 
arrange crystal shape and maturation and to be involved in redox control (Barber-
Zucker et al., 2016; J. Yang et al., 2013). 
MamH is suggested to act in the magnetite biomineralization and magnetosomal iron 
transport (Uebe et al., 2011; Zeytuni et al., 2011). MamZ is believed to take part in 
iron transport (Zeytuni et al., 2011) and in electron shutting and redox reactions ions 
(Brokx et al., 2005). Mutants lacking both MamH and MamZ show more severe 
phenotypes than mutants for only one protein, suggesting a redundant function of the 
two proteins (Zeytuni et al., 2011). MamN is a TM protein suspected to be an 
antiporter, which extrudes protons released from magnetosome precipitation, and 
increases the pH inside the magnetosome- a necessary condition for in vitro 
magnetite synthesis (Komeili, 2012; Nudelman & Zarivach, 2014). Indeed, MamN 
deletion causes mutants containing empty magnetosomes and no magnetic response 
(Murat et al., 2010). 
FtsZ-like proteins are a copy of FtsZ, defined as bacterial tubulin-like cell division 
proteins found in three Magnetospirillum species (Ding et al., 2010; Richter et al., 
2007). FtsZ-like proteins genes are localised into the MAI region, in MamXY operon, 
a feature that suggests a possible involvement of these proteins in magnetosome 
chains assembly or in Magnetospirillum cells division (Jogler & Schuler, 2009; 
Müller et al., 2014).  
MamS and MamR are MTB specific proteins: MamS is thought to regulate 
magnetosome size and morphology, while MamR is believed to be involved in the 




1.6.8. Proteins involved in arrangement of magnetosome 
crystal size and morphology 
Some proteins, even if not directly involved in magnetosomes biomineralization 
process, play a role in the determination of magnetosomes size and morphology 
(Barber-Zucker et al., 2016). The protein discovered so far associated with magnetite 
in AMB-1 are: MamC, MamD, MamG (that in this strain are respectively named 
Mms13, Mms7 and Mms5) and protein Mms6. These proteins are supposed to 
localise in MM and to tightly interact with magnetite surface (Arakaki et al., 2014; 
Tanaka et al., 2011). As these genes are present only in AMB-1 strain, which 
synthesise octahedral shaped magnetite, it was supposed that their function is linked 
to this particular feature (Arakaki et al., 2014). 
MamC (Mms13) protein structure is predicted to be composed of two TM helices 
and one acidic alpha-helical loop present in magnetosome lumen, which is believed 
to bind iron and to participate to iron accumulation, creating the proper conditions 
for the magnetite nucleation (Valverde-Tercedor et al., 2015). Moreover, MamC is 
the most abundant protein exclusively found in MM (Arakaki et al., 2003; Grunberg 
et al., 2004; Grunberg et al., 2001; Lang & Schüler, 2008). MamD, also called 
Mms7, is also abundant in MM and his function is believed to be associated with the 
crystal morphology, as AMB-1 mutants for MamD show crystals reduced in size and 
with different faces respect to wild-type (Arakaki et al., 2014; Grunberg et al., 2001). 
MamG (also called Mms5) is another abundant protein localised in MM, predicted to 
be formed by two TM helices and a charged connecting loop between them that 
contacts magnetite crystals. (Lang & Schüler, 2008; Nudelman & Zarivach, 2014). 
As MamG deletion causes crystals reductions, it is possible that the protein has a role 
in crystal growth control, maybe interacting with the crystal face (Arakaki et al., 
2014).  
MamF is similar to MmsF (61% amino acid identity between the products), and it is 
the second most abundant protein in MM after MamC (Lohsse et al., 2014; Richter et 
al., 2007). The magnetosomes number and size is more affected in double mutants 
for MamF and MmsF, respect to mutants with single MmsF deletion, suggesting that 
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MamF could influence these magnetosome features (Lohsse et al., 2014). The 
secondary structure of MamF is predicted to be formed by three TM helices, two of 
whom connected by a loop with charged residues that could interact with magnetite 
crystals (Nudelman & Zarivach, 2014). Also Mms6 and MmsF are involved in 
crystal size and morphology determination, however, due to the interest they have 
raised, they will be described in a separate section. The different steps of 
magnetosome formation to which the described proteins take part are shown Figure 
12. 
 
Figure 12. Hypothetical representation of magnetosome biogenesis with proteins which take 
part to the process in M. gryphiswaldense.  
OM stands for outer membrane, while IM stands for inner membrane and MP stands for magnetosome 




1.7. Mms6 and MmsF: two interesting 
proteins involved in  MNPs 
biosynthesis 
Rationale for using Mms6 and MmsF proteins:  
MHT is a promising tumour treatment, but it is still far from optimal, due to the use 
of synthetic MNPs, which display cell toxicity and poor tumour localisation. The 
need of finding an alternative to chemical MNPs in MHT is of primary importance to 
improve the whole treatment.  
A possible approach is to use MTB magnetosomes, which are characterised by high 
SAR and a better heat distribution, but this idea has raised concernings regarding the 
application of bacterial structures inside the human body. An alternative to the 
magnetosomes use is the creation of engineered human MSCs able to biosynthesise 
MNPs. MSCs, indeed, could be easily engineered and show an exceptional tumour 
homing ability.  
The final purpose of this study was to create MSCs able to biosynthesise MNPs, and 
to deliver them directly inside the tumour. Then, tumours will be exposed to AMF, 
determining the killing of  both the magnetic MSCs and of the tumour cells.   
Mms6 and MmsF are two proteins believed to play a paramount role in iron 
crystal morphology regulation in MTB (Amemiya et al.,2007; Murat et al.,2012).  
For this purpose, MTB mms6 and mmsF genes, alone or in combination, were 






The protein Mms6, firstly introduced to the scientific audience by Arakaki et al. in 
2003, was isolated from magnetosomes of  M. magneticum AMB-1 together with the 
others magnetosomes associated proteins, after lipid membranes stripping and 
treatments based on detergent and heat (Arakaki et al., 2003). The extracted proteins 
were named  "Mms", which stands for "magnetosome membrane specific", and were 
numbered according to their molecular mass (Arakaki et al., 2003). Among the four 
proteins discovered, named Mms5, 6, 7 and Mms13, Mms6 presents a negative 
charge at neutral pH, being different from all the other Mms proteins, that are 
positively charged (Arakaki et al., 2003). Mms6 gene sequence shows a high 
consensus among different MTB species  (Staniland & Rawlings, 2016), especially 
in the C-terminal region (Figure 13a). The mass of the protein codified by the mms6 
gene is 12-15 kDa, larger than the 6 kDa Mms6 protein identified by SDS/PAGE, 
suggesting that Mms6 undergoes in vivo protease cleavage  (Arakaki et al., 2003; 
Grunberg et al., 2004). Mms6 has a predicted secondary structure formed by an 
unstructured N-terminal domain, a transmembrane helix and a C-terminal, which 
may form a α-helix structure (Nudelman & Zarivach, 2014), (Figure 13b). The 
presence of the helix is supported by protein model structure and sequence analysis, 
while 3D models show a negative patch on its carboxy-terminal domain (CTD) that 













Figure 13. Mms6 protein description. 
a) Mms6 truncated protein sequence alignment from different MTB species.  Residues conserved  are 
highlighted in red boxes, and similar residues are in red font. The first 98 residues are not shown, but 
are less conserved. The glycine-leucine repeated sequences are indicated by blue bar, and the C-
terminal amino-acid region are highlighted in yellow. Original picture taken from (Staniland & 
Rawlings, 2016). b) Ribbon  representation of  Mms6 protein structure among other proteins involved 
in magnetosomes size and shape control. TM helix are represented in grey and protein size is 
indicated in Angstroms, by black bar. c) 3D prediction of Mms6 protein structure among other 
proteins involved in magnetosomes size and shape control. Negative charges are in red and positive 
charges are in blue. Protein size is indicated in Angstroms, by black bar. Original pictures taken from 





1.7.1. Mms6 protein and its function  
The debate regarding the function of Mms6 -nucleating or shape control protein- is 
still open (Staniland & Rawlings, 2016). To better understand the role of Mms6 in 
M.magneticum AMB-1, Tanaka et al. performed mms6 gene knockout experiments, 
generating a Δmms6 mutant strain. Although the loss of mms6 gene did not affect the 
bacteria growth and the number of crystals, it was observed that crystals in Δmms6 
mutants are: 1) smaller respect to the wild-type, 2) show indefinite shapes instead of 
the cubo-octaedral structure observed for the wild-type, 3)  present a (110) face on 
the magnetic face surface, characterized by an higher energy and instability that is 
generally noticed in not matured crystals (Tanaka et al., 2010); (Figure 14). 
Moreover, SDS-PAGE experiments in Δmms6 strains point out a decrease of Mms5, 
7 and Mms13 proteins expression, suggesting that Mms6 could be involved not only 
in crystal shape and definition processes, but also in other Mms proteins recruitment. 
These results confirmed that Mms6 regulates crystals formation, as already proposed 
by  Amemiya and further reported by  Murat et al. (Amemiya et al., 2007; Lohsse et 
al., 2014; Murat et al., 2012). Nevertheless, other findings theorise a role for Mms6 
in magnetite crystal nucleation (Arakaki et al., 2003; Arakaki et al., 2014; Galloway 
J.M. et al., 2012). Magnetite (Fe3O4), is formed by ferric (Fe3
+
),  and ferrous iron 
(Fe2
+
),  at the 2:1  stoichiometric ratio. One way of producing magnetite in vitro 
relies on mixing these two valence irons that are subsequently precipitated by raising 
the pH (Staniland & Rawlings, 2016). Araki et al. found that by adding Mms6 (20 
ug/ml) at room temperature co-precipitation, the products of the reaction were 
mainly magnetite and an uncontrolled iron oxide precipitate respect to the wild-type 
crystals (Arakaki et al., 2003). The particles also showed a cuboidal shape, and a 
narrow size distribution, similar to the crystals observed in the magnetosomes. This 
experiment was repeated by other researchers, changing some reaction parameters 
(Amemiya et al., 2007; Bird et al., 2016; Galloway J.M. et al., 2012), and in all the 
cases it was demonstrated that the Mms6 addition increased the magnetite 
production. It was also observed that the crystal size is influenced by the protein 
surface curvature. Indeed when Mms6 is immobilised on the surface the crystals size 
is much bigger than when the protein is present in micelles (Bird et al., 2016). A 
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possible explanation provided for this behaviour is that by changing the protein 
curvature -flat or concave- also the angle of contact between Mms6 and the mineral 




1.7.2. Mms6 iron binding model 
Mms6 is an amphiphilic protein, which means that it possess both a hydrophilic (C-
terminal) and a hydrophobic (N-terminal) region, so in water Mms6 tends to form 
micelles, exposing the hydrophilic C-terminal outside and shielding the hydrophobic 
N-terminal within the core. Mms6 structure investigation by size-exclusion 
chromography, later confirmed by dynamic scattering experiments, suggest micelle 
dimensions of 200-400 kDa, formed of 20-40 protein subunits. Moreover, it was 
found that in presence of iron, the micelles tend to form highly ordered structures, 
such as discs, presumably interacting with iron  (L. Wang, Prozorov, et al., 2012; H. 
Zhang et al., 2015). 
Staniland et al. proposed that Mms6 self-assembles creating proteins rafts on the 
interior MM, exposing a C-terminal surface, similar to the surface of in vitro 
   a          b 
Figure 14. TEM of a) Δmms6 mutant  and b) wild-type M.magneticum AMB-1 strains. 
 In a), the loss of mms6 gene affects crystals size and shape, which appear smaller and of indefinite 
shape respect to the wild type (b). These results suggest that Mms6 could play a role in crystals 
formation. 
 Original picture taken from (Tanaka et al., 2011). 
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micelles, but with opposite curvature (Staniland & Rawlings, 2016), (Figure 15). 
They noticed that the Mms6 protein without the N-terminal (named C20Mms6) 
could self-assembly, but fails in controlling the magnetite formation. The Mms6 self-
assembly hypothesis was also guided by the observation that the 6 kDa Mms6 
protein sequence is rich of glycine-leucine repeated sequence (Figure 13a), a feature 
of self-assembly proteins, while the repeated sequences are missed in the C20Mms6. 
According to Staniland et al., the adjacent Mms6 molecules self-assemble through a 
"knob and hole arrangement", where hydrophobic residues interlock adjacent Mms6 
molecules creating "regularly packed structure" (Figure 15c). In this way, the acidic 
C-termini create a negatively-charged surface which binds iron. In addition to that, 
Staniland et al. studied the magnetite precipitation with or without Mms6 at different 
pH titrations, finding out that  the action of Mms6 below pH 4 is negligible and that 
Mms6 increases the magnetite production of the 20%  in "ferrous-rich ferric: ferrous 
ion ratios", acting as a "mineral/ferrous ion buffer". At pH<4, the acidic groups of 
Mms6 are protonated, a condition that reduces Mms6 iron binding ability, while at 
pH=7, deprotonation occurs forming negatively charged micelles with negative-
charged surface that binds iron, with a more accurate binding activity of ferrous iron 
(Rawlings et al., 2016; Zhang et al., 2015). All together, Staniland et al. proposed 
model suggests that: a) Mms6 self-assembles in the internal MM in a regulated way 
with a "knob and hole" mechanism, exposing the negatively charged carboxylate-rich 
surfaces; b) Mms6 binds iron on such surfaces when pH is near to 7, with a more 
specific binding activity for ferrous iron; c) it is possible to tune the MNPs size by 




1.7.3. MmsF protein and its function 
MmsF is an integral MM protein (Murat et al., 2012; Nudelman & Zarivach, 2014) 
encoded by mmsF gene, which belongs to the mms6 gene cluster of MAI (Figure 
16a). In M. Magneticum AMB-1, mmsF is located directly downstream to mms6, 
separated from it by only 17 nucleotides. No promoter was identified upstream of 
mmsF, so mms6 and mmsF are supposed to be co-transcribed (Murat et al., 2012). 
Figure 15. Mms6 self-assembly models. 
 a) Schematic representation of the Mms6 micellar assembly model (H. Zhang et al., 2015) in 
(Staniland & Rawlings, 2016). b) iron oxide MNPs (indicated by bright spots) nucleate and precipitate 
on the surface of Mms6 micelles, scale bar =20 nm (Kashyap et al., 2014) in (Staniland & Rawlings, 
2016); c) schematic model illustrating Mms6 self-assembly in negatively charged rafts, containing C-
terminal binding sites for regular iron ions binding to nucleate magnetite formation in (Staniland & 
Rawlings, 2016); d) schematic representation of how the crystal size is influenced by Mms6 protein 
surface curvature: i) Mms6 is in solution, forming micelles, ii) Mms6 is on a surface, iii) Mms6 is on 





MmsF predicted structure is formed of three transmembrane spanning (TMS) helices, 
with the C-terminus located inside the MM, and the N-terminus protruding in the 
magnetosomes cytoplasm (Murat et al., 2012), (Figure 16b). MmsF was firstly 
discovered as an abundant MM protein in Magnetospirillum Magneticum MS-1, but 
other homologs were also found in other species of MTB. Rawlings et al. identified 
two homologs of MmsF (amb0957) in M. magneticum AMB-1, denoted as mamF 
(amb0953) and mmxF (am1026), (Figure 16c). TMS helices and loops that connect 
them are highly conserved in all the proteins studied, as indicated in Figure 16c. 
Studies on  MmsF homologs show that even if they share more than 65% of identity 
with mmsF, there is not redundancy between functions of these genes. Indeed, it was 
demonstrated that the deletion of the mmsF gene causes deficient magnetosomes 
crystallisation that is not recovered by mamF and mmxF (Rawlings et al., 2016). 
When MmsF, MamF and MmxF are in the water, they solubilise and aggregate to 
protect their hydrophobic region from the aqueous environment (Rawlings et al., 
2016). This unusual soluble behaviour was analysed in water by TEM and 
cryoelectron microscopy, confirming that in presence of water, MmsF and its 
homologs self-assemble into precise vesicles-like structures, called "proteinosomes" 
by Rawlings et al. In their model, helices participate to protein assembly, while the 
loop connecting helices 1 and 2 is involved in magnetite formation process. 
Moreover, MmsF, MamF and MmxF create a protein island inside the MM, directing 
their acidic termini towards the inner part of magnetosome, so that they can take part 
in the crystal nucleation. However, despite their homology and their tendency to 
form ordered vesicles-like structures in water, only MmsF can improve the 
uniformity and the magnetisation of particles in vitro when added to magnetite 
precipitation reactions, while MamF and MmxF give origin only to mixed irons. 
MmsF is also the only protein among the three investigated to share the same "acid 
acid-acid-X-acid" motif with Mms6, adding weight to the hypothesis that MmsF is 
involved in magnetite oxides formation. Murat et al., trying to clarify the MmsF 
function in biomineralization, discovered that ΔmmsF mutants show misshapen 
crystals, carrying severe defects. These findings define a pivotal role for MmsF in 
biomineralization. Murat et al. also discovered that, when Mms6 is deleted, 
MamFDC proteins inhibit the action of MmsF. Indeed, MmsF recovers the wild 
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phenotype in ΔR3 mutants, lacking both mms6 and mamFDC clusters, but fails to 
recreate the wild-type features in Δmms6c1 mutants, which still contain mamFDC 
genes. These findings suggest that the magnetite synthesis is a complex phenomenon, 
to which many players take part. To further explore the MmsF role in magnetite 
formation, Murat et al. created mutants expressing only mamAB gene cluster, called 
miniMAI strain. The miniMAI strain is still able to form magnetosomes chains, even 
if the magnetosomes are fewer and of smaller dimension compared to the wild-type. 
In vivo MmsF can ameliorate the phenotype of miniMAI strain, enhancing the 
magnetite production and the answer to a magnetic field; however, it fails in 
completely recovering the wild-type phenotype. This behaviour suggests that other 
MAI regions, such as R6 combined with R14, could orchestrate the 
biomineralization, that is a result of many complexes, discrete steps  (Murat et al., 
2012). Overall, mmsF functions could be summarised as follow:  
1) mmsF restores wild-type phenotype in Δmms6c1 mutants for magnetisation but 
not for crystals shape (mms6 indeed is not present); 
2) mmsF restores wild-type phenotype in ΔR3 mutants;  
3) mmsF determinates crystals size and shape, as ΔmmsF mutants grow smaller 
nanoparticles with different geometry respect to wild-type and fail to mature in the 
cubo-octaedral shape. 
The complete list of Mam and Mms proteins and their suggested role are summarised 



















Figure 16. MmsF description. 
a) Schematic representation of the mms6 gene cluster to which mmsF gene belongs. The genes and 
ORFs comprised are represented by grey arrows, indicating  the orientation of transcription. The gene 
name, or gene number, is indicated below each gene or ORF. The black lines show the groups of 
genes identified as gene clusters. b) Schematic representation of the MmsF protein membrane 
spanning. c) The Sequences of MmsF, MamF, and MmxF were aligned in ESPript. Conserved 
residues are highlighted in red, similar residue types are shown in blue boxes, and TMS helices are 
indicated. d) Electron micrographs of  wild-type AMB-1, ΔR3, Δmms6cl, Δmms6, ΔmmsF mutants 
and the ΔR3 mutant complemented with mmsF. The insets are showing a higher magnification of the 
region boxed in the micrograph. Scale bars: 100 nm, insets 50 nm.  Pictures a) and d) are original 
images taken from Murat (Murat et al., 2012). Pictures b) and c) are original images taken from 
(Rawlings et al., 2014).  
Table 4. List of Mam and Mms proteins and they suggested function.  
Table adapted from (Barber‐Zucker et al., 2016). 
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1.8. MSCs in tumour therapy 
1.8.1. MSCs distinctive characteristics 
Adult mesenchymal stem cells (MSCs), are non-haematopoietic cells described for 
the first time by Friedenstein et al.(Nancarrow-Lei et al., 2017). MSCs can be 
detected as an heterogeneous subgroup of stromal stem cells also in adult brain 
tissue, heart, lung, adipose tissue, umbilical cord, fetal tissue and bone marrow  
(Norozi et al., 2016). 
It was reported that MSCs, in particular the ones isolated from bone marrow, adipose 
tissue, dental pulp, and other organs of the body, originate from blood vessel wall, 
and were found in the so-called perivascular "niche", that is the microenvironment 
responsible for the regulation of stem cells fate (da Silva Meirelles et al., 2008). The 
niche provides a plethora of signals to activate and/or repress genes and transcription 
programs. Accordingly to the stimuli received, stem cells are maintained in a 
dormant state (undifferentiated), or undertake the self-renewal or the differentiation 
pathway respectively, entering in different cell cycles, to fulfil the changing tissue 
demand during the life (Ferraro et al., 2010).  From their perivascular location, MSCs 
can maintain the surrounding tissue, taking part to the blood vessels stabilization, 
tissue and immune system homeostasis regulation and focal tissue injuries repair 







Figure 17. MSCs localise in perivascular niche.  
From there, MSCs undergo self-renewal and maintain the surrounding cells/tissue. When specific 
signals are given, they could differentiate into the osteoblastic (osteocytic), endothelial, chondrocytic, 




MSCs are defined by the following features (De Becker & Riet, 2016; Norozi, 
Ahmadzadeh, Shahrabi, et al., 2016): 
- they show a fibroblastic morphology and they adhere to plastic when cultivated 
in vitro; 
- they have the ability to differentiate in different cell lineage, such as 
chondrocytes, osteoblasts, adipocytes; 
- they are able to self renewal and to support haematopoiesis;  
- they must express CD105, CD73 and CD90, and lack expression of CD34, 
CD45, CD14, CD19, HLA-DR surface molecules. 
Among these qualities, MSCs possess also specific characteristics: 1) they are 
multipotent; 2) they tend to migrate to sites of tissue injury/inflammation; 3) they 
show immunomodulatory capacities; 4) they could escape immune recognition; 5) 
even if they do not express naturally MHC class II antigens, they can upregulate the 
expression of these molecules after being exposed to inflammatory cytokines or 
during MSCs differentiation (Le Blanc & Ringden, 2005). 
All these characteristic, especially the ability to engraft in the site of injury and their 
multipotency, make MSCs the suitable effectors in a wide variety of clinical fields, 
such as orthopaedics, where they have been employed for bone repair (Bashir et al., 
2014), haematology, where they have been employed to support the engraftment of 
hematopoietic stem cells (Bashir et al., 2014; De Becker & Van Riet, 2015; Fouillard 
et al., 2007),  or as a deliver in anticancer treatments (Durinikova et al., 2014; 
Hammer et al., 2015; Park et al., 2015; B. Qiao et al., 2015). 
Tumour-homing is a discussed MSCs property. The list of tumours to which MSCs 
can home specifically comprises gliomas (Nakamizo et al., 2005), breast (Goldstein 
et al., 2010; Karnoub et al., 2007; Liu et al., 2011), colon (Hung et al., 2005), ovarian 
(Komarova et al., 2010), and lung carcinomas, among many other primary and 
metastatic tumours (Loebinger et al., 2009; Xin et al., 2009). However, MSCs tissue 
migration and homing is a complex process, guided by a multitude of molecules and 




As stated above, MSCs are characterized by self-renewal and multipotency 
properties. 
Self-renewal refers to the ability to proliferate maintaining the undifferentiated state: 
the cell divides symmetrically creating two identical copies of itself for long periods 
of time. Depending on the stem cell, self-renewal is a well-modulated process, 
involving complex signalling networks. MSCs fate is regulated both by the niche 
signalling than by the circulation factors, which could enhance MSCs tropism or 
maintain the cells in their state (He et al., 2009).  
Multipotency is defined as the ability of a  progenitor cell to differentiate into a 
limited number of cell types with specific functions. The MSCs plasticity to 
differentiate in different cell lineages (osteogenic, adipogenic, and chondrogenic), 
together with their immunomodulatory and anti-inflammatory properties, make of 
these cells the best candidate for regenerative medicine, for the cancer therapy and 
for the treatment of autoimmune diseases such as type 1 diabetes (Murphy et al., 
2013; Rohban & Pieber, 2017b). 
Despite their interesting role in many clinical applications, MSCs origin in situ is still 
uncertain. Recent scientific works by Bruno Péault and others were aimed to disclose 
MSCs origin, finding out that MSCs originate from two progenitors cells, the 
pericytes and the adventitial cells (Corselli et al., 2012; Crisan et al., 2012). 
These two different cell populations were found associated with the blood vessels, 
depending on their size. The outside of the small blood vessels, such as capillaries 
and microvessels, is encircled by pericytes, while largest vessels such as arteries and 
veins are surrounded by adventitial cells (Rohban & Pieber, 2017a). Pericytes are 
contractile cells, embedded in the basement membrane, characterized by a prominent 
nucleus, a poor cytoplasm, and finger-like projections. Through their projecting 
processes, pericytes wrap around small vessels giving structural integrity to the 
vessel wall. Moreover, pericytes support the stem cell self-renewal and proliferation 
and are involved in the tissue regeneration and repair (Birbrair et al., 2014; Kunisaki 
et al., 2013). 
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Adventitial cells were found on the tunica adventitia, one of the three layers of which 
all the blood vessels wall, with the exception of capillaries, are formed (the others 
two are named tunica intima and tunica media).  For a long time, scientists have 
described the tunica adventitia as an unorganized layer made of fibroblasts and 
perivascular nerves, enclosed in a collagen-rich connective tissue (Majesky et al., 
2011).  
Only recently, it was found that the tunica adventitia is far more complex, and it is 
actively involved in the communication between vascular endothelial cells and 
smooth muscle cells, in the control of lumen size and in the immune response. The 
tunica adventitia contains different populations of cells, such as fibroblasts, 
macrophages, T-cells, B-cells, mast cells, and dendritic cells, which play a role in the 
vessel homeostasis and repair (Swedenborg et al., 2011). 
 
Recent scientific works by Bruno Péault and others found that actually adventitial 
cells and pericytes could have other properties in addition to the ones already 
discovered. These cells, indeed,  not only express MSC markers (e.g., CD10, CD13, 
CD44, CD73, CD90, CD105) but have also the ability to commit to osteogenic, 
adipogenic and chondrogenic cell lineages. Under inductive conditions in vitro, 
adventitial cells are able to differentiate into pericyte-like cells, which can then 
differentiate into mesoderm lineage cells, giving rise in culture to genuine MSC 
(Corselli et al., 2012; Crisan et al., 2012).  
These findings define the pericytes and adventitial cells as the MSCs progenitors and  






1.8.2. MSCs Homing in injury site 
The full mechanism by which the MSCs migrate and home to the tissue is still object 
of study. However, it is accepted that MSCs follow the same process followed by 
leucocytes, which is described in Figure 18 and could be sum up in four steps: 
 
1. In the blood stream, the cell contacts the endothelium; 
2. G-protein-coupled receptors activate the MSCs cells; 
3. an integrin-mediated, activation-dependent arrest happens; 
4. the cells transmigrate through endothelium and underlying  basement 
membrane (Butcher, 1996). 
 
Different factors play a distinctive role in MSCs migration and engraftment to the 
site of injury. Some of them are: the specialized glyoform of CD44, called 
hematopoietic cell E-/L-selectin ligand (HCELL), the chemokine G-protein coupled 
receptor, called CXCR4-stromal derived factor-1(SDF-1), and Integrins α4 and β1, 
which combine to the antigen 4 (VLA-4), determining its interaction with vascular 
cell adhesion molecule 1 (VCAM-1) (Moll & Ransohoff, 2010; Ruster et al., 2006; 
Sackstein, 2004; Segers et al., 2006). 
In the fourth and last step, MSCs transmigrate through the endothelial cell layer and 
the underlying basement membrane, composed of collagen and gelatin. These 
components of the basement membrane are degraded by lytic enzymes called 
metalloproteinase (MMP). An example of MMP involved in the degradation process 
is given by  MMP-2 and MMP-9, that are two gelatinases participating in the 
collagen and gelatin degradation (Nagase & Woessner, 1999; Steingen et al., 2008). 
To improve the MSCs homing efficiency, the CXCR4 expression has been enhanced 
both directly- by designed transfection or transduction experiments in which a 
plasmid was introduced into the cells virally (Bobis-Wozowicz et al., 2011) or not 
virally (Otani et al., 2009; Wiehe et al., 2013) or indirectly,  by using molecules or 
process that could favour CXCR4 expression. To improve the CXCR4 expression on 
MSCs membrane, many strategies have been proposed, such as treating the MSCs 
culture before of the injection with a cocktails of cytokines (Shi et al., 2007) like flt3 
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ligand stem cell factor (SCF), IL3, IL6 and hepatocyte growing factor (HGF), 
insulin-like growing factor 1 (IGF-1), tumour necrosis factor α (TNF α), IL 1β, 
interferon γ (IFN γ).  
Recombinant CXCR4 was bound to the cell surface of MSCs also using lipid-PEG 
(Won et al., 2014). MSCs migration is stimulated by Valproic acid and hypoxia, 
which increase expression of CXCR4 and MMP-2 in MSCs in culture, while MSCs 
motility and MMP-2 expression are enhanced by erythropoietin (EPO) and 
granulocyte colony stimulating factor (G-CSF).  MSCs homing efficiency is 
improved by irradiation and by expression of P-selectin glycoprotein ligand-1 
(PSGL-1) and HCELL, two E-selectin ligands that are required for HSC bone 
marrow homing (Fouillard et al., 2007; Mouiseddine et al., 2007; Ponomaryov et al., 
2000). Indeed, the MSCs homing capability was improved when the active site of 
PSGL-1, called Sialyl Lewis X (SLEX), was introduced into the MSCs cell 
membrane using biotinylated vesicles (Sarkar et al., 2010). Also, high cell 
confluence influences MSCs migration behaviour, decreased by TIMP-3 which at 











Figure 18. MSC migration to bone marrow.   
Four steps describing the MSCs migration and homing to bone marrow (Thethering+rolling, 
Activation, Arrest, Transmigration) with the main strategies used to enhance MSC homing (Cytokine 
cocktails, Hypoxia, Transduction, Transfection, Valproic acid, Irradiation, SDF-1 and CXCR4 
expression stimulation). 
CD: Cluster of differentiation; EC: Endothelial cell; BM: Basement membrane; HCELL: 
Hematopoietic cell E-/L-selectin ligand; PSGL-1: P-selectin glycoprotein ligand-1; SLEX: Sialyl 
Lewis X; SDF-1: Stromal cell derived factor 1; VLA-4: Very late antigen 4; VCAM-1: Vascular cell 
adhesion molecule 1; Ab: Antibody; TIMP:Tissue inhibitor of metalloproteinases; MMP: Matrix 
metalloproteinase; EPO: Erythropoietin; G-CSF: Granulocyte colony stimulating factor; MSC: 
Mesenchymal stromal cell. Original picture taken from (De Becker & Riet, 2016). 
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1.8.3. MSCs clinical administration 
MSCs could be clinically applied by two principal routes: systemic administration 
and local administration. In systemic administration, the cells are injected by 
intravenous (IV) or intra-arterial injection (IA); in local administration, they are 
injected by intracoronary injection (IC) or directly in the tissue of interest  (De 
Becker & Riet, 2016). In animal models, MSCs are usually injected into circulation 
by intravenous injection (IV): this method is considered the safest and repeatable, but 
the downsides are that cells could be trapped in lungs, not reaching the tumour site 
immediately. IV injections can be subcutaneous (Reagan & Kaplan, 2011; N. Wang 
et al., 2009), intratracheal (Xin et al., 2009), through the tail vein (Wang et al., 2009), 
through the internal carotid artery (Nakamizo et al., 2005), or intraperitoneal 
(Komarova et al., 2010). 
1.8.4. MSCs and their double-edge role in tumour  
The natural predisposition of MSCs to reach sites of injury, especially tumour, is 
today well established (Hong et al., 2014; Loebinger, Kyrtatos, et al., 2009; Mathieu 
et al., 2012; Menon et al., 2007). However, it is still difficult to define the role that  
MSCs play in the tumour growth, as it appears dual (Figure 19). According to some 
researches, MSCs favour the tumour growth and spreading, acting as tumour 
progression factors, while others claim that MSCs have a role in tumour suppression, 
inhibiting tumour growth by direct/indirect interaction with tumour cells (Norozi et 
al., 2016). This "double edge" behaviour of MSCs in tumour growth will be 
discussed below. 
1.8.5. MSCs support tumour growth 
Solid tumours are composed of two main components: tumour cells and tumour 
stroma, which comprises tumour vasculature, cells of the immune system, 
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extracellular matrix (ECM), carcinoma-associated fibroblasts (CAF) and tumour-
associated fibroblasts (TAF), that are fibroblastic stroma cells and MSCs (Goel & 
Mercurio, 2013; Huang et al., 2012; Caplan &Dennis, 2006; Locatelli &Bianchi, 
2014). All the components of tumour stroma are actively involved in the ECM 
signals release. The concern in MSCs application in tumour arises from the fact that 
MSCs can differentiate in TAFs and CAFs and form the vascular network of the 
tumour (Dominici et al., 2006; Hong et al., 2014). Furthermore, MSCs seem able to 
secrete growth factors and to suppress the immune response by inhibiting the 
proliferation of CD4 and CD8 T-cells while increasing the T-regulatory cells (T-reg) 
(Lysko et al., 2011; Xiao et al., 2009). In addition to that, MSCs could lead to 
metastasis by the epithelial-to-mesenchymal transition (EMT) program, which is a 
process for invasiveness and metastasis of cancer cells associated with a poor clinical 
prognosis (Erta et al., 2012; Kuai et al., 2012; Norozi, Ahmadzadeh, Shahjahani, et 
al., 2016). This process is activated by factors like collagen, cytokines, TGF-β, FGF, 
HGF and epidermal growth factor  (EGF), that are also secreted by MSCs (Caplan & 
Dennis, 2006). In addition to that, MSCs could also inhibit the production of pro-
inflammatory cytokines (TNFα and IFN-γ) while increasing the expression of 
suppressing cytokines as IL-10 (Perron & Dodd, 2012). In damaged sites, activated 
ECM proteases favour the recruitment of MSCs (Bergfeld & DeClerck, 2010). MSCs 
can actively interfere with cancer stem cells (CSC), supporting their self-renewal and 
enhancing their invasive properties. CSC, indeed,  produce IL-6, which can support 
MSCs chemotaxis and homing in primary tumour growth site. (Arango-Rodriguez et 
al., 2015). Additionally, IL-6 binds to  IL6R/gp130 on MSCs, stimulating  CXCL7. 
The molecule CXCL7 binds to the CXCR2 receptor on CSCs, favouring the 
synthesis of cytokines IL-8, IL-6, CXCL6 and CXCL5, which lead to CSCs self-
renewal and invasiveness (Buschmann et al., 2001; Luheshi et al., 2009). 
1.8.6. MSCs suppress tumour growth 
Despite many studies underline the promoting effect of MSCs on tumour growth and 
expansion, many others found that MSCs are actively involved in tumour 
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suppression (Figure 19). Indeed, MSCs seem to discourage tumour growth by 
promoting: angiogenesis inhibition, inflammatory cells infiltration and Wnt and AKT 
signal suppression, cell cycle arrest and cell apoptosis (Cousin et al., 2009; Dasari, 
Kaur, et al., 2010; Dasari, Velpula, et al., 2010; Khakoo et al., 2006; Lu et al., 2008; 
Ohlsson et al., 2003; Olaso et al., 1997; L. Qiao, Xu, Zhao, Zhao, et al., 2008; L. 
Qiao, Xu, Zhao, Ye, et al., 2008; Rhee et al., 2015). Studeny and al. and Ryu et al. 
demonstrate that MSCs can synthesise IFN-β, inhibiting the tumour growth (Ryu et 
al., 2014; Studeny et al., 2004a). When cultured in 3D systems, MSCs express 
TRAIL, which lead to tumour-cell specific apoptosis (Du et al., 2012; Madrigal et 
al., 2014). MSCs exert tumour inhibition by increasing p21 expression and favouring 
caspase 3 pathway, which blocks the cell cycle in phase G0/G1 leading to apoptosis 
of cancer cells (Lu et al., 2008). MSCs injected into mice bearing non-Hodgkin's 
lymphoma, increase animals' survival. MSCs were also seen to play an anti-
angiogenic role when co-cultured with endothelial cells (Secchiero et al., 2010). The 
immunocompatibility of MSCs make them a suitable universal donor for allogeneic 
transplantation (Chiu, 2005). 
MSCs can stop tumour cells growth by arresting the cell cycle in G1 phase by 
expressing factors as CyclinA, CyclinE, CyclinD2, and p27KIP1 (Aggarwal & 
Pittenger, 2005; Corcione et al., 2006; Cousin et al., 2009; Glennie et al., 2005; Lu et 
al., 2008; Ramasamy et al., 2007; Sotiropoulou et al., 2006). It was demonstrated that 
the addition of ADSC-conditioned cell culture medium in cancer cells stimulated 
necrosis after G1-phase arrest in the absence of apoptosis, and when ADSC was 
introduced into pancreatic adenocarcinoma, the tumour growth stopped (Lu et al., 
2008). In some cases, in vivo results do not reflect in vitro results: the growth of 
tumour cells cultivated with MSCs in vitro was arrested at the G1 phase, but when 
mice were injected with MSCs and tumour cells the effect was the opposite, and 
tumour growth augmented compared to tumour cell alone (Ramasamy et al., 2007; 
Rhee et al., 2015).  
MSCs can regulate the cellular signalling in the tumour. MSCs injected 
intravenously in a Kaposi’s sarcoma model migrated to the tumour and effectively 
inhibited tumour proliferation through inhibition of AKT (Khakoo et al., 2006), one 
of the most important players in the tumour migration and invasiveness process. 
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AKT, together with WNT creates the phosphoinositide 3-kinase (PI3K)/AKT and 
WNT/β-catenin signalling pathway, involved in the cell survival, proliferation, 
growth, migration, and metabolism (Engelman et al., 2006). 
MSCs can have a pro-inflammatory effect on the tumour.  Ohlsson et al. documented 
that MSCs were able to inhibit rat colon carcinoma by stimulating the infiltration of 
both granulocytes and macrophages, even if MHC-class I expression was low and 
MHC class II was absent  (Ohlsson et al., 2003). 
Some studies found that MSCs are not detrimental when applied to the tumour site, 
and exploited the MSCs ability of homing to the tumour to deliver pro-apoptotic 
agents directly to the tumour site. The most employed anti-cancer drugs that MSCs 
carry are type I interferon (IFNα- and IFN-β), IL-2, IL-12, CXCL1, cytokine 
deaminase, TRAIL (Komarova et al., 2006; Loebinger, Eddaoudi, et al., 2009; 
Menon et al., 2009; Nakamizo et al., 2005; Studeny et al., 2002; Studeny et al., 
2004b). IL-2overexpressing MSCs were effective against different types of tumour 
(X. Chen et al., 2008; Nakamura et al., 2004; Stagg et al., 2004), whereas CXCL1 
and IL-12, activating both T cells and NK cells, can reduce breast tumour, lung 
tumour and melanoma (X. Chen et al., 2008; X. C. Chen et al., 2006; Eliopoulos et 
al., 2008; Gao et al., 2010; Xin et al., 2007). Beside these treatments, the effect of the 
former drugs could be amplified by using MSCs specifically engineered to express 
them (Nakamizo et al., 2005; Ren et al., 2008; Studeny et al., 2002; Studeny et al., 
2004a). Tumour cells can be specifically targeted by oncolytic viruses- expressing 
MSCs (Dembinski et al., 2010; Hakkarainen et al., 2007; Komarova et al., 2006; 
Stoff-Khalili et al., 2007), or by MSCs carrying nanoparticles in drug delivery (L. Li 
et al., 2011), or again by MSCs converting enzymes in cancer therapies (Hamada et 
al., 2005; Kucerova et al., 2008a, 2008b; Matuskova et al., 2010; Uchibori et al., 
2009; Zischek et al., 2009).  
In summary, these contrasting findings on MSCs action on tumour growth and 
microenvironment, suggest that MSCs regulation in tumour is determined by a 
complex plethora of factors which take part in the process, such as timing of MSCs 
injection, type of tumour cells, MSCs origin and degree of differentiation (Norozi, 
Ahmadzadeh, Shahrabi, et al., 2016). Therefore, caution and evaluation of the 







Figure 19. MSC "double edge" behaviour in tumour growth. 
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1.9. Bacterial magnetosomes in MHT 
1.9.1. Magnetosomes show features that are indicated for 
magnetic hyperthermia experiments 
Recently, MTB magnetosomes have attracted scientific interest in the MHT of 
tumours. MHT treats tumours by the use of MNPs localised in the tumour site that is 
exposed to the AMF: the MNPs,  heated by the AMF,  exert an anti-tumour activity 
(Alphandery et al., 2013). Nowadays, the nanoparticles employed in the clinical 
application are Superparamagnetic Iron Oxide Nanoparticles (SPIONS), that are 
chemically synthesised. However, SPIONS do not fulfil all the requirements to be 
successfully employed in MHT. Indeed, due to their small size, SPIONS are unable 
to deliver the necessary amount of heat when subjected to an AMF, but form 
aggregates which cause toxicity in vivo. Moreover, they show thermally unstable 
magnetic moment (Alphandery et al., 2013).  
Magnetosomes, on the other hand, show peculiar characteristics that make them, to 
date, the most feasible nanoparticles for MHT. Their ferrimagnetic behaviour, 
together with their large size, allow the release of a significant amount of heat when 
they are subjected to an AMF. In addition to that, magnetosomes can provide a 
uniform amount of heat in the cell without any agglomeration,  due to their 
arrangement into chains (Alphandery et al., 2013). Magnetosomes can be isolated by 
MTB by different ways, such as sodium hydroxide, sonication, French press, and a 
pressure homogenizer to lyse the bacteria cells. After extraction, magnetosomes are 
subjected to the purification step, lyophilisation and sterilization with gamma rays, 
and in the end, the suspension of magnetosomes is characterised before therapeutic 




1.9.2. Magnetosomes toxicity: are they safe for the body? 
In vitro, magnetosomes are not toxic for H22, HL60 and EMT-6 cells at the dose of 9 
µl/ml, as well as they are not toxic for mouse fibroblasts at the concentration of 1.3 
mg/ml. In vivo experiments on mice and rats, reveal that animal death is reached 
when they are injected intravenously with 480 mg/kg of bacterial magnetosomes for 
mice and less than 82 mg/kg for rats (Sun J. et al., 2010). However, it was necessary 
a far lower dose of SPIONS (135 mg/kg) to kill the mice (Liu R-T et al., 2012), 
suggesting that magnetosomes are less toxic to the body than SPIONS. Organs of 
rats treated with less than 82 mg/kg were investigated by histological analysis, and 
no haemorrhage nor inflammation or hyperaemia were found.  
Moreover, another point in favour of magnetosomes is that they contain magnetite 
(Fe3O4),  a relative insoluble iron oxide, that is unable to trigger any Fenton reaction, 
which typically occurs when iron ions are dissolved, creating hydroxyl radicals, 
strong oxidants (Alphandery et al., 2013). On the contrary, magnetosomes have been 
reported to scavenge ROS (Guo et al., 2012). The toxic effect ascribed to 
magnetosomes could derive from their nanometric size, which favours their 
clogging, leading to embolism, blood clot, and cell toxicity (Alphandery et al., 2013). 
Magnetosomes immunotoxicity could also depend on other biological components, 
such as nucleic acids and proteins which remain in impure magnetosomes. Despite 
studies regarding magnetosomes immunotoxicity have been carried out, it is still not 
clear if magnetosomes contain antigens or pyrogens (Sun J. et al., 2010). 
Magnetosomes injected in mice and rats are degraded by lysosomes after 28 days 
(Liu R-T et al., 2012). In one study, magnetosomes administrated to mice and rats 
were tracked by fluorescence microscopy (T. Tang et al., 2012), whereas in another 
study organs of animals injected with magnetosomes were subjected to histological 
analysis (Liu R-T et al., 2012; Sun et al., 2009). Magnetosomes appear to migrate in 
liver (Liu R-T et al., 2012; Sun et al., 2009), spleen (Liu R-T et al., 2012), lungs (T. 
Tang et al., 2012), where they were found located inside lysosomes, partially 
degraded. In addition to that, the presence of magnetosomes was not detected by the 
analysis of urine and faeces of mice and rats subjected to intravenous injection of 
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magnetosomes, suggesting that the magnetosomes have been totally degraded by 
animals (Sun et al., 2009). However, magnetosomes were detected in faeces of mice 
after both intra-tumoral and intravenous administration by another study (Alphandery 
et al., 2011). Understanding how magnetosomes are degraded inside the body is 
challenging, but the most accredited hypothesis suggests principally two routes: the 
reticuloendothelial system and urine/faeces (Alphandery et al., 2013). Not many 
studies have compared magnetosomes and chemically synthesised MNPs body 
degradation; however, experiments on MNPs degradation inside the body reveal that 
MNPs are metabolised by organ's parenchyma with metal ions, leaking from the core 
material up to 6 months after the intravenous injection (Lacava et al., 2004). 
Although it is still too early to indicate the magnetosomes as the safest SPION, these 
findings suggest a possible use of magnetosomes as therapeutic agents in MHT. 
1.9.3. Physic properties of  magnetosomes 
Magnetosomes are the nanoparticles which provide the most powerful source of heat 
when applied in MH (Alphandery et al., 2013). This quality is given by specific 
features, such as ferrimagnetic behaviour, cubic shape, large shape and thermally 
stable magnetic moment, that are all factors leading to a high loss per cycle. Loss per 
cycle is defined as the SAR divided by the frequency of oscillations of the AMF, and 
it is useful for the comparison of magnetosomes SAR in different AMF. Moreover, it 
was demonstrated that magnetosome loss per cycle increases by increasing the 
magnetic field strength (Dutz et al., 2007; Rudolf Hergt et al., 2005; Sun et al., 2009; 
Timko et al., 2009) and, above 10 mT, magnetosome losses are either equivalent or 
larger than the losses of chemically synthesised MNPs  (Alphandéry et al., 2011; 
Dutz et al., 2007). Alphandery et al. investigated in which way the magnetosomes 
should be administrated to led to the higher heat efficiency, if whole AMB-1 MTB, 
chains of magnetosomes, or single magnetosomes (Alphandery et al., 2011); (Figure 
20). In an applied magnetic field of 108 kHz and strength of 22 to 88 mT to whole 
AMB-1 bacteria, they found that the losses per cycle were due to the magnetosomes 
viscosity and not to the whole bacteria, whose contribute was very low (Alphandéry 
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et al., 2011). Instead, magnetosomes extracted as a chain or as a single component 
produced a heat given both by the inversion of magnetosome than by the 
magnetosome rotation, with an increasing in the magnetic losses. However, the study 
was not able to define which was the best arrangement -magnetosome or chains of 





1.9.4. Magnetosomes as anti-tumour treatment 
There are only a few studies conducted to determine the magnetosomes effect as 
anti-tumour treatment. In one study in which MCF-7 tumour cells were mixed 
together with magnetosomes, 80% of cell population died following AMF 
application and reaching a temperature of 47 °C. The treatment, which resulted more 
harsh for the cancer cells respect to the healthy ones, was considered safe also if 
applied to the healthy tissue. Cell death was directly proportional to the increasing 
Figure 20. TEM investigation of MTB. 
Pictures of whole AMB-1 MTB (A), chains of magnetosomes from AMB-1 MTB (B), and single  
magnetosomes from AMB-1 MTB (C). Images taken from (Alphandery et al., 2013). 
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incubation time, the concentration of magnetosomes, the magnetic field strength and 
the number of times that the experiment was repeated (Liu R-T et al., 2012). 
Alphandéry et al. performed an experiment in which whole MTB, chains of 
magnetosomes, individual magnetosomes, and SPIONS were tested applying a 
magnetic field strength of 40 mT at a frequency of 198 kHz, in xenografted breast 
tumours mice. Results revealed that only chains of magnetosomes made the tumour 
to disappear, also after 30 days from treatment. The temperature reached during the 
treatment with chains of magnetosomes was 45-46 °C, demonstrating that is the 
particular arrangement of chains to make magnetosomes efficient in MHT. The 
chains prevent agglomerations, and the resulting toxic effect, while the heating is 
distributed more uniformly inside the cell (E. Alphandery et al., 2011). Chains of 
magnetosomes have a different coating, made of proteins and lipids  respect to single 
magnetosomes, that have only a lipidic coating (E. Alphandery et al., 2012), a feature 
that is believed responsible for their different z potential
3
 (–22mV at pH 7), respect 
to the  one of the individual magnetosomes (+10mV at pH 7) while their alignment 
into chains give them  larger magnetic anisotropy and a faster elimination from the 
body. 
These results were partially contradicted by a study conducted by (Mannucci et al., 
2014). In the study it was investigated the effect of chains of magnetosomes 
extracted from M. gryphiswaldense on colon cancer cells  HT-29  in HT experiments. 
The findings revealed that the magnetosomes enter the cells not as chains but as 
single nanoparticles or short chains. Mannucci et al. described the internalisation of 
magnetosomes inside the cells as a multistep process, in which: 1) magnetosomes 
adhere to the cellular membrane, 2) magnetosomes are internalised in vesicles, 3) 
magnetosomes are carried to the Golgi apparatus, 4) magnetosomes are included in 
double layer membrane-like vesicles. In this study, it was observed no tumour 
remission in mice treated, but tumour tissue necrosis both by histology and MRI. The 
low tumour cell death, compared to other studies in which magnetosomes were 
successfully employed to kill tumour cells (Alphandery, 2014) was imputed to the 
                                                 
3
 Zeta potential is the potential difference between the surface of a solid particle immersed in a 
conducting liquid and the bulk of the liquid https://en.oxforddictionaries.com/ 
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lower AMF strength and frequency applied, to the different strain of MTB used and 
to the different tumour model investigated. However, in mice exposed to the 
treatment, it was observed a temperature increase of  2-3 °C, and it was also found 
that temperature increased linearly with the increasing of the AMF. Mannucci et al. 
also proposed a model of MNPs migration, based both on a passive transport carried 
on by the reticuloendothelial system and by active transport, operated by 
macrophages, similar to what happen for iron. In addition to that, the success in 
tracking magnetosomes in living tissue, due to their iron content, also opens more 








Magnetic Hyperthermia Therapy (MHT) is a promising tumour treatment. However,  
the MNPs used as a mediator in the treatment until now are still far from optimal 
(Alphandery et al., 2013). To overcome the use of synthetic MNPs, the research 
moved toward the use of bacterial magnetosomes found in MTB and characterised 
by high SAR and a better heat distribution (Alphandery et al., 2013). Still, the 
concern regarding the use of  these bacterial organelles in the human body could 
cause reluctance in the medical community.  
Among all the MTB proteins, Mms6 and MmsF had been suggested as determinant 
players in iron crystal morphology regulation (Amemiya et al., 2007) (Murat et al., 
2012). A new prospect for MHT is provided by MSCs. These cells not only show 
exceptional qualities of tumour homing, but could also be engineered, making them 
able to express the required gene and, consequently,  the features derived from that 
gene expression. With these qualities, MSCs become the "Trojan horse of biology", 
making possible to deliver the engineered MSCs directly inside the tumour.  
The goal of this study was to create engineered MSCs, able to express mms6 and 
mmsF genes, alone or in combination, in the attempt to create MNPs bearing MSCs. 
The main aims to prove that were: 
1. To transfect MSCs with the MTB genes mms6 and mmsF, alone or in 
combination; 
2. To determine if the expression of mms6 and mmsF genes inside MSCs leads 
to the  production of MNPs, as seen for the MTB; 
3. To estabilish if the expression of the mms6 gene inside MSCs affects MSCs 
functionality; 
4. To determine if the MNPs created inside the mms6-expressing MSCs could 
















2.1.1. List of reagents: 
Table 5. Cell culture reagents 
Reagents Company 
DMEM (Dulbecco’s Modified Eagle 
Medium) 
Life Technologies, UK 
 
FBS (Fetal Bovine Serum) Life Technologies, UK 
Trypsin with 0.25% EDTA 
(Ethylenediaminetetraacetic acid) 
 
Life Technologies, UK 
100x PenStrep 
(Penicilin/Streptomycin) 
Life Technologies, UK 
PBS (Phosphate Buffered Saline) SigmaAldrich, UK 
HBSS (Hanks’ Balanced Salt 
Solution) 
Sigma Aldrich, UK 





Table 6. RNA isolation/DNA synthesis/agarose gel electrophoresis/PCR reactions 
reagents/Sanger Sequencing 
Reagent Company 
Qiazol Qiagen, UK 







DNA/RNA-se free water 
SigmaAldrich, UK 
 
RNA Denaturating Loading 
Buffer 






Agarose SigmaAldrich, UK 
Tris-borate-EDTA (TBE) 
buffer 
Thermo Fisher Scientific, UK 
RNeasy Mini Kit Qiagen, UK 






qScript cDNA Synthesis Kit Quanta Biosciences/VWR, UK 
SYBRStain Life Technologies, UK 
DNA ladder 
 
New England BioLabs, UK 
Q5High-Fidelity DNA 
Polymerase 
New England BioLabs, UK 
 
dNTPs Thermo Fisher Scientific, UK 




Table 7. Gene purification from agarose gel/restriction enzymes digestion/vector 










Table 8. Bacteria transformation/plasmid amplification/ plasmid purification 
Reagent Company 
Subcloning Efficiency™ 
DH5α™ Competent Cells 
Invitrogen, UK 




Ampicillin 1000x SigmaAldrich, UK 
LB Broth (Luria-Bertani 
medium) 
SigmaAldrich, UK 
Plasmid Maxi Kit Qiagen, UK 
Isopropanol SigmaAldrich, UK 
Ethanol SigmaAldrich, UK 
 
Reagent Company 





New England Biolabs, UK 
NotI enzyme 
 
New England Biolabs, UK 
NEBuffer 3.1(10x 
concentrated) 
New England Biolabs, UK 
BSA (Bovine serum 
Albumin) 
SigmaAldrich, UK 









3% Glutaraldehyde SigmaAldrich, UK 
1% Osmium tetroxide SigmaAldrich, UK 
Resin TAAB,UK 
Cleaved Caspase-3 antibody 
(Asp175)-(NEB9661S) 
Cell Signaling Technology,  
UK 
Anti-Nuclei Antibody, clone 
3E1.3(MAB4383) 
Merck Millipore, UK 
MOM Blocking reagent Vector Laboratories, UK 
Bond Polymer Refine 
Detection kit 
Leica,UK 
Harris Hematoxylin solution SigmaAldrich, UK 
HistoChoice SigmaAldrich, UK 
DPX mounting medium Fluka,UK 
Rabbit anti-osteocalcin 
antibody  (ab13420) 
Abcam, UK 
Blocking serum (X0907) DAKO,UK 
Alexa Fluor 488-conjugated 
goat anti-rabbit lgG (green) 
secondary antibody (A32731) 
ThermoFisher Scientific, UK 
Antifade Mounting Medium 
with DAPI (H1200) 
Vector Laboratories, UK 
Formaldehyde SigmaAldrich,UK 

























Alizarin Red SigmaAldrich,UK 
Alcian Blue Fluka,UK 
Oil Red Solution Sigma Aldrich, UK 
Isopropanol Fisher Scientific, UK 
 
Table 11. In vitro/in vivo AMF exposure 
Reagent Company 
Pierce LDH Cytotoxicity 
Assay 
ThermoScientific, UK 
AlamarBlue Cell Viability 
Assay 
ThermoScientific, UK 
CellTracker CM-DiI Red Dye 
Molecular 
Probes, Invitrogen, UK. 
CellTracker CM-DiI Green 
CMFDA Dye 
Molecular Probes, Invitrogen, 
UK. 
DMSO Sigma-Aldrich,UK 




2.1.2. List of Solutions 
Table 12. List and recipes of solutions 
Solution Recipe 
Ferric quinate solution (0.01M) 
0.27 g of FeCl3 and 0.19 g of quinic acid 
were added to 100.0 ml of distilled water. 
The pH of the solution has been adjusted to 
6.7 (human cell pH) by adding some drops 
of 
NaOH before to autoclave it at 121°C for 15 
minutes 
3% glutaraldehyde solution 
glutaraldehyde diluted in 0.1M sodium 
cacodylate buffer 
Flow cytometry buffer 
0.5 % BSA and 0.05 % sodium azide (NaN3)  
were dissolved  in 1xPBS 
CellTrackerTM CM-Dil Red dye 
stock 
 
50µl of  DMSO were added to one vial 
containing 50µg dried powder, to the final 
concentration of 1M 
CellTracker Green CMFDA dye 
stock solution 
11µl of DMSO were added to one vial of 50 
mg CellTracker Green CMFDA Dye dried 
powder, to the final concentration of 10mM 
2% Alizarin Red S solution (pH 
4.2) 
2 g of  Alizarin Red S were dissolved in 100 
ml of ddH2O, mixing and adjusting pH to 4.2 
with 0.1% NH4OH 
4% PFA 10 ml of PFA diluted in 30 ml of 1x PBS 
3.7% paraformaldehyde for 
Immunofluorescence 
for 100 ml: 10 ml of 10x PBS, 33.4 ml of 
11.1% formaldehyde (freshly prepared), 0.6 
ml of 30% Triton X-100, 56 ml of distilled 
water. 
Washing Buffer 0.1% Tween 20 in 1x PBS 
Alcian Blue staining solution 
60 ml of ethanol 100% were mixed with 40 
ml acetic acid 100%. Then, 100 mg of 
Alcian Blue were dissolved in this solution 
and mixed in magnetic stirrer. 
Alcian Blue destaining solution 
120 ml of 100% ethanol were mixed with 80 
ml of 100% acetic acid 
Oil Red O solution 
 
300 mg of Oil Red O powder were dissolved 
in 100 ml of 99% Isopropanol 
Oil Red O solution 3:2 
3 parts of Oil Red O solution were diluted in 
2 parts of ddH2O and sterile filtered with a 
0.22 µm filter. 
60% Isopropanol 
60 ml of 100% isopropanol were mixed with 




2.2.1. Cell culture media 
MG63 Homo sapiens bone osteosarcoma cells and A431 Ecad-GFP expressing 
human epidermoid carcinoma cell line culture medium: DMEM medium, high 
glucose, supplemented with 10% FBS and 1% of 100U/ml/100μg/ml Penicillin-
Streptomycin (P/S). The complete medium was prepared by adding to 450 ml of 
DMEM medium 50 ml of FBS and 5 ml of P/S. 
MG63 Homo sapiens bone osteosarcoma cells FeQ doped medium: MG63 Homo 
sapiens bone osteosarcoma cells medium described above with the addition of 3.4 
µl/ml of FeQ solution, to a final concentration of 34 µM. 
Human Mesenchymal Stem Cells (MSCs) culture  standard  medium: DMEM 
medium, high glucose supplemented with 20% of FBS and 1% of 100 U/ml/100μg/ml 
P/S. The complete medium was prepared adding to 400 ml of DMEM medium 100 
ml of FBS and 5 ml of  P/S. 
Human Mesenchymal Stem Cells (MSCs) FeQ doped  medium: Human 
Mesenchymal Stem Cells (MSCs) culture  standard  medium with the addition of 3.4 
µl/ml of FeQ solution to a final concentration of 34 µM. 
MSC osteogenesis differentiation medium: StemPro Osteogenesis Supplement was 
added to the StemPro Osteocyte/Differentiation Basal Medium, from the StemPro 
Osteogenesis Differentiation Kit (Gibco). 
MSC chondrogenesis differentiation medium: StemPro Chondrogenesis Supplement 
was added to the StemPro Osteocyte/Differentiation Basal Medium, from the 
StemPro Chondrogenesis Differentiation Kit (Gibco). 
MSC adipogenesis differentiation medium: StemPro  Adipocyte Supplement was 
added to the StemPro Adipocyte Differentiation Basal Medium, from the StemPro 
Adipogenesis Differentiation Kit (Gibco). 
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Resuscitation of the cells: 
A cryogenic vial containing an aliquot of cells was removed from liquid nitrogen, 
and thawed in a water bath at 37°C for 2 minutes. The cells were then immediately 
mixed with 10 ml of complete pre-warmed medium and centrifuged at 177 x g for 5 
minutes. The supernatant was discarded, and cells were resuspended in 10 ml of 
complete medium and seeded in a 75 cm
2 
flask. Cells were cultivated in the 




2.2.2. Cell culture  
All the cell culture procedures were performed in laminar flow hoods. Cells were 
cultured in their specific medium and cultured in the incubator, at 37 °C with 5% 
CO2. 
A431 ecad-GFP expressing human epidermoid carcinoma cell line was kindly 
provided by Professor Val Brunton, MRC Institute of Genetics & Molecular 
Medicine, University of Edinburgh.  
Human mesenchymal stem cells (MSCs) were kindly provided by B.Péault 
laboratory, MRC Centre for Regenerative Medicine (CRM), Royal Infirmary, 
Edinburgh. Cells were isolated from human fetal bone marrow with informed 
consent from Edinburgh Royal Infirmary, propagated and used at low passage 
(p<10). 
2.2.3. Passaging of cells  
Cells were passaged when they reached the 80% of confluence (2 times a week). 
Cells were washed with 4 ml of 1x PBS and then incubated with 1 ml of Trypsin-
EDTA 0.25% for 2 minutes in the incubator at 37 °C with 5% CO2. Cells were then 
resuspended and collected in 10 ml of complete medium. The cell suspension was 
then centrifuged at 177 x g for 5 minutes, the supernatant was discarded, and the cell 
pellet was resuspended in 10 ml of complete medium. Then 2 ml of cell suspension 
were put into a T75 flask containing 8 ml of complete medium (1:5 ratio).  
2.2.4. Cells transfection 
MG63 cells and MSCs were transfected with plasmid pcDNA3.1 containing the gene 
mms6 and with the plasmid pcDNA4/TO containing the gene mmsF, alone or in 
combination, using the X-tremeGENE HP Transfection Reagent (Roche), 
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accordingly with the manufacture's protocol. The details about the gene mms6 and  
the insertion of the gene mmsF into the plasmid pcDNA4/TO can be found in the 
appendix 8.1 and in appendix 8.2 respectively. 
A detailed transfection protocol could be found in appendix 8.3.Transfection 
efficiency was estimated around 70% (appendix 8.4).  
Briefly, cells were grown in T25 flasks. When the cells reached 80% confluence, 6 
µl of each plasmid (1000 ng/µl), alone or in combination, were  added to a sterile 
vial (1.5 ml) containing 600 µl of pre-warmed Optimem Medium (Gibco). Then, 18 
µl of Transfection Reagent were added to the vial directly in the middle of the 
medium without touching the vial's walls. The solution was gently mixed and it was 
left at RT for 20 minutes. In the meanwhile, the medium of the T25 flasks was 
changed with 6 ml of DMEM 20% FBS without P/S. 
After 20 minutes, the mix was spin down for 3 seconds and then it was gently added 
to the cells in the flask, trying to cover all the flask surface, drop by drop. The flask 
was gently swirled for 30 seconds and then incubated O/N in incubator. The day 
after, the medium was changed with fresh medium doped with Ferric Quinate (FeQ) 
solution (0.01 M,  3.4 µl/ml).  
After transfection of cells, drug selection was not used.  
The control wild-type cells that were doped with FeQ were not exposed to the 
transfection reagent. 
2.2.5. Storage of cells 
The freezing medium was made by adding 1 part of DMSO to nine parts of FBS. 
5x10
6
 cells were added to each vial. Cells were stored to -80°C freezer for one day 




2.3. Molecular Techniques 
2.3.1. Isolation of total RNA from cells 
RNA was isolated from cells using the standard Qiazol method. Confluent cells were 
washed with 4 ml of sterile 1x PBS twice. 1 ml of Qiazol was added in each 75 cm
2
 
flask, gently covering all the surface; the flask was then incubated at RT for 5 
minutes. The cells were homogenised by pipetting and transferred in a fresh 1.5 ml 
DEPC treated microcentrifuge tube. Then 200 µl of chloroform were added to the 
cells, in the chemical hood.  Then, cells were mixed by vortex and incubated at RT 
for 3 minutes. The cells were subsequently centrifuged at 13,000xg in a bench 
ultracentrifuge at 4
o
C for 20 minutes. In the tube appeared three aqueous phases: a 
transparent phase, containing the RNA, a white ring, and a pink phase, containing the 
proteins. Carefully, only the transparent phase was aspirated with a filtered tip and 
transferred in a fresh DEPC treated microcentrifuge tube. 500 µl of isopropanol were 
added to the tube, mixing its content by slow inversion for 15 times and then it was 
incubated at RT for 10 minutes, followed by centrifugation at 13,000xg at 4
o
C for 10 
minutes. The supernatant was discarded, and the pellet was washed twice adding 500 
µl of 75% ethanol, followed by centrifugation at 13,000xg at 4
o
C for 10 minutes. The 
supernatant was discarded and the excess of ethanol was removed by a 200 µl 
filtered tip. The pellet was air-dried at RT for 10 minutes. Then, the pellet was 
resuspended in 30 µl of RNAse free water and then it was kept on ice. RNA yield 




2.3.2. RNA yield and purity determination by 
spectrophotometry 
Yield and purity of RNA samples were determined using a NanoDrop 
spectrophotometer (Labtech, UK). The absorbance was measured at wavelength 260, 
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280 and 230 nm. The absorbance ratio of RNA samples at 260/280nm of ~2.0 and 
absorbance ratio at 260/230nm in a range of 2.0 - 2.2 were considered as highly pure. 
2.3.3.  RNA integrity assessment 
RNA integrity was assessed by electrophoresis on denaturing agarose gel. Briefly, 5 
μg of RNA were dissolved in 2x RNA Denaturing Loading Buffer and incubated at 
65
 o
C  for  5 minutes. For denaturing agarose gel preparation, 0.5 g of agarose were 
added to 36 ml of ddH2O, and the solution was microwaved for 2-3 minutes, to 
dissolve the agarose. Then, 14ml of MOPS Running Buffer were added to the 
agarose under the fume hood together with 1μl of 10,000x concentrated SyberSafe, 
to visualise the RNA under the ultra-violet (UV) image analyser. The gel was left at 
RT to cool down. Electrophoresis was performed in 1x MOPS Buffer using a 
horizontal gel electrophoresis system (Bio-Rad). An example of RNA stability test is 
in appendix  8.5, showing the two main bands of RNA: 28S rRNA and 18S rRNA. 
RNA was stored at -80
o
C for future use. 
2.3.4. cDNA synthesis and DNAse I treatment  
cDNA was synthesised by reverse-transcribing 1μg of RNA. The genomic DNA 
contamination was removed by incubating 1μg of RNA with 1 μl of DNAse I and 1μl 
of 10x DNAse I buffer for 15 minutes at room temperature (RT). DNAse I activity 
was inactivated by adding 1μl of 200 μM EDTA followed by samples incubation at  
65 ºC for 10 min. cDNA was synthesised following qScript™cDNA Synthesis Kit 
(Quanta Biosciences) protocol: 1μg of RNA was added to 1μl of qScript Reverse 
Transcriptase enzyme and  4 μl of 5x qScript Reaction Mix (which contained random 
oligo-dT), and then water was added up to 20 μl of final total volume. The reaction 
was vortexed gently and then centrifuged for 10 seconds to collect contents. 
Then, the reaction was incubated in a thermal cycler (Tetrad2 DNA Engine, Bio-
Rad) programmed as follows: 
91 
 
 1 cycle: 22ºC, 5 min 
 1 cycle: 42ºC, 30 min 
 1 cycle: 85ºC, 5 min 
 4ºC hold 
Then, 1/10
th
 of the reaction (2 μl) were used for RT-PCR amplification. Samples of 
cDNA were stored in -20 ºC. 
2.3.5. Reverse Transcription Polymerase Chain Reaction (RT-
PCR) 
The nucleotide sequences of the primers used in this study were designed using 
Primer3 software. Primers were bought from Sigma Aldrich. Amplification of 
fragment was performed in a thermal cycler (Tetrad2 DNA Engine, Bio-Rad). 
RT-PCR was prepared according to the protocol provided by Quiagen: 
 12.5 μl of TopTaq Buffer (2x),  
 2.5 μl of TopTaq Dye (10x),  
 2 μl of cDNA, 
 1μl of primer Forward (10μM), 
 1μl of primer Reverse (10μM),  
 6 μl of RNAse free water.  
The PCR reaction was conducted as follows: 
 Initial Denaturation Temperature: 95 ºC - 3 min 
 Denaturation Temperature: 95 ºC - 30sec 
 Annealing Temperature: 55-62 ºC - 30-45 sec        35 cycles 
 Extension Temperature: 72 ºC - 1 min 
 Final Extension Temperature: 72 ºC - 1 min 
 Hold: 4 ºC - ∞ 
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The human Glyceroaldehyde-3-Phosphate Dehydrogenase (GAPDH) was chosen as 
housekeeping gene. To determine the mmsF gene expression in the MG63 cells, two 
couples of primers were designed using Primer3 software, named MmsFA and 
MmsFB. Both of them matched the theoretical requirements to detect the mmsF gene 
expression in MG63 cells, so it was chosen to work with both the couples of primers 
to determine the best one to detect the mmsF expression in cells. Primers sequences 
are shown in appendix 8.6. 
2.3.6. DNA agarose gel electrophoresis 
The PCR amplified products were resolved in 2% agarose gel. Briefly, 2 g of agarose 
were mixed with 100 ml of 0.5x TBE, and dissolved using microwave. Then, 
10,000x diluted SyberSafe stain (Invitrogen) was added to the gel to visualise the 
DNA under UV image analyser. The gel was cooled at RT, and then 12-20 μl of the 
sample were loaded into the gel and run in running buffer made of 0.5xTBE in 
horizontal gel electrophoresis system (Bio-Rad) at a constant voltage of 110V for 40-
50 min. The molecular weight (MW) of the PCR product was determined by loading 
1 μl of DNA ladder onto the gel (100bp DNA Ladder, New England BioLabs). Then, 
the gel was exposed to UV light to image the DNA bands. Gene expression was 
normalised using GAPDH as housekeeping gene. 
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2.4. Physical techniques 




 cells were resuspended in 1ml of cell culture medium. The cells were 
centrifuged at 200xg for 5 minutes, and the pellet was resuspended in 50µl of cell 
culture medium and transferred to a 1,5 ml microcentrifuge tube. Then, 1% agarose 
solution was prepared by dissolving in a glass beaker 0,5 g of agarose powder in 50 
ml of 1x PBS. The solution was put in microwave at 800 W for 3 minutes, checking 
every 30 seconds that the solution did not flow out of the beacker. In the meantime, 
the bottom of a PCR tube (volume 0.5 ml) was cut with scissors and it was put 
upside down with the lid closed in an ice bucket. The 1% agarose solution was left to 
cool down for 30 seconds at room temperature; then cell pellet was carefully 
resuspended in 100 µl of agarose solution avoiding air bubbles. The cell solution was 
immediately transferred to the PCR tube with the cut bottom. 
The cell solution was left to solidify for 10 minutes, then with the help of a pipette 
tip, the solidified cell sample was transferred in a 5 ml bijoux filled with 3% 
glutaraldehyde solution, under the chemical hood. 
The samples were then processed in the Electron Microscopy facility (Western 
General Hospital), Edinburgh. Briefly, samples were included in resin according to 
the following procedure: incubation in 1% Osmium tetroxide overnight at 4 °C, 
followed by samples dehydratation with increasing concentration of Ethanol (10%, 
50%, absolute ethanol). Then, samples were incubated with propylene oxide for  20 
minutes at RT twice and then incubated with propylene oxide/resin mix (50/50) for 1 
hour. Samples were then included in resin (TAAB)  for 2 hours at room temperature 
and then incubated in the same resin for 24 hours at 60°C.  
Ultrathin sections, 60 nm thick, were cut on a Leica EM UC7 Ultratome and picked 
up on copper grids. The grids were stained with uranyl acetate and lead citrate and 
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viewed on a Jeol 1200EX2 transmission electron microscope. The digital images 
were viewed with a Deben AMT XR41 camera system. 
ImageJ analysis of TEM pictures 
TEM pictures of mms6-pcDNA3.1 transfected MSCs at day 0, 15 and 21 were 
analysed using a custom-made plugin of the ImageJ software. Ten TEM pictures 
were analysed for each time-point. For each picture, it was determined the total 
number of vesicles filled with the electron-dense content, then their average at each 
time point was calculated using Excel software. It was also calculated, for each 
analysed cell, the percentage of  electron-dense filling of vesicles; then the average 
was calculated using Excel software. Statistical analysis and graphs were performed 
using GraphPad Prism  (Prism 5.0, USA). 
2.4.2. SQUID (Superconducting Quantum Interference Device) 
samples preparation 
SQUID magnetometer is an instrument which measures the total magnetic moment 
of a sample, including all atomic and molecular magnetic contributions. To perform 
SQUID measurements, cells were centrifuged at 5000 x g for 5 minutes, the 
supernatant was removed, and the pellet was washed with 1 ml of 1x PBS and 
centrifuged again at 5000 x g for 5 minutes. The supernatant was discarded and the 
pellet was transferred in a non-magnetic plastic capsule  inside a 1.5 ml 
microcentrifuge tube sealed with parafilm. The pellet was desiccated at 60 °C for 30 
minutes in a vacuum-pump centrifuge (RVC 2-18, CHRIST). The parafilm that 
sealed each Eppendorf was punctured to avoid sample damage by vacuum. The 
sample material was weighed using a Sartorius Micro M3P balance to derive mass-
specific values. Then, the capsule was closed and inserted in a plastic straw inside 
the SQUID magnetometer, following the protocol described in the appendix 8.7. 
Magnetisation data were taken at temperatures 5 K < T < 350 K, using a liquid-He-
cooled variable-temperature insert installed in the commercial SQUID-magnetometer 
apparatus (MPMS, Quantum Design Inc., San Diego, USA). For MG63 cells, two 
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different measurement modes were applied. In the first mode, the temperature-
dependent magnetisation was determined in a small, fixed field (μ0H = 0.01T) 
between body temperature, T = 310 K, and T = 5 K. In the second mode, it was 
determined the field dependence of the magnetisation at body temperature in 
magnetic fields up to μ0H = 7T. MSCs were analysed only in the first mode.  
The measurements were performed at varying temperatures moving the samples 
through a pick-up coil system connected to the SQUID via a flux transformer in a 
constant magnetic field, generated by a superconducting coil. The diamagnetic 
contribution of the pure-protein component to magnetisation given by controls 
sample of transfected cells grown in non-iron containing media was subtracted from 
the measured properties of the other sample materials, to obtain the magnetisation 
component originating from the nanoparticles.  
The SQUID measurements on MG63 cells were kindly carried out by Dr. Marc 
Uhlarz in Dresden High Magnetic Field Laboratory (HLD-EMFL), Helmholtz-
Zentrum Dresden-Rossendorf (Germany), while the SQUID measurements on MSCs 
were performed at King's Building, in Edinburgh (Scotland). 
2.4.3. Hyperthermia samples preparation 
The cellular hyperthermia was kindly measured by Dr Franca Albertini's group, 
Magnetic Materials Group IMEM-CNR in Parma, Italy. 
The cells were investigated using the magnetic hyperthermia device from NanoScale 
Biomagnetics, DM1 and DM2 applicators (0-300G, up to 430kHz) for colloidal 
solutions and cell cultures. 
The cells were firstly  collected in 1,5 Eppendorf tubes and  then washed twice with 
1x PBS.  Following cells centrifugation at 5000 x g for 5 minutes, a pellet formed 
and the supernatant was removed. The cell material was dried at room temperature 
for 12 hours and then preserved in -80 °C freezer until shipment. 
In Parma, the cells were then resuspended in 0.2 ml of distilled water  in a vial 
connected to a thermocouple whose ends were in contact with the cell solution. The 
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vial was put in a calorimeter totally isolated from the external environment. Around 
the calorimeter, there was a coil which generated an AMF. When the system reached 
the thermal equilibrium, the magnetic field was switched on, and only the 
temperature variation due to the magnetic component of the cells was measured, 
making possible to determine which gene was responsible for the cells 
magnetisation. Results were analysed using Origin Software. 
2.4.4. AFM (Atomic Force Microscopy) and MFM (Magnetic 
Force Microscopy) experiments 
AFM (Atomic Force Microscopy) and MFM (Magnetic Force Microscopy) 
measurements were kindly performed by Dr. Alek Dediu research group, Consiglio 
Nazionale delle Ricerche (CNR), Bologna, Italy. 
 
AFM/MFM Samples Preparation  
For the AFM/MFM  investigations, paraffin blocks of cells used for TEM 
measurements were cut on a Leica EM UC7 Ultratome in slices of a thickness of 80 
nm, and put on circular glass coverslips used as support. Each section was put on a 
different glass coverslip for AFM-MFM imaging, considering 4 sections for each 
sample. Slices were fixed on glass coverslips with a drop of water and they were left 
to dry at room temperature, then the glass coverslips were put into a 24 wells plate, 
considering one glass for each well. Then, the plates were sent to Bologna for 
AFM/MFM measurement. 
AFM (Atomic Force Microscopy) experiments 
Semi-contact mode AFM was performed at ambient conditions using the AFM 
device Stand-Alone SMENA AFM, (NT-MDT). The AFM was equipped with a 
SFC050 head mounting silicon probes with a guaranteed curvature radius of < 10 nm 
and resonance frequencies of 190 – 330 kHz (NSG series probes, NT-MDT). Image 




MFM (Magnetic Force Microscopy) experiments 
Magnetic Force Microscopy was performed on a Bruker Multimode 8 AFM (Bruker 
Nano Surface) equipped with a Nanoscope V Controller, a JV type scanner and 
magnetic probes NT-MDT. The microscope was operated in double-pass lift mode 
with lift heights ranging from 30 to 600 nm. The images shown were acquired at 512 
x 512 pixel resolution. The noise-level corresponding to ad-hoc non-magnetic 
samples was also evaluated around 0.1-0.3 degrees, hence at least one order of 




2.5. MSCs functionality assessment 
2.5.1. Immunofluorescent flow cytometry staining of MSCs 
A suspension of 1×10
6
 MSCs was stained with APC-conjugated CD34, VioBlue-
conjugated CD45, PE-conjugated CD73, PE-c 
onjugated Vio770 CD90 and FITC-conjugated CD105. Experiments were performed 
using BD FACSARIA II (BD Biosciences), and results were analysed by BD FACS 
Diva Software version 6.1.3 (BD Biosciences). The complete list of antibodies could 
be found in appendix 8.8. The experiments were repeated in triplicate.  
Optimisation of fluorescence compensation settings for multicolour flow 
cytometric analyses 
The fluorescence spillover from fluorochrome-conjugated antibodies was 
compensated using Compbeads (BD Biosciences). Briefly, 5 µl of each prediluted 
antibody stock to be tested  were incubated with 60 µl of CompBeads Anti-Mouse 
Ig, κ particles and 60 µl of CompBeads Negative Control for 30 minutes at RT in the 
dark. Then, 200 µl of  1x PBS were added to each tube and pelleted by centrifugation 
at 200xg for 10 minutes. The supernatant was aspirated with a Pasteur pipette, and 
the bead pellet was resuspended adding 200 µl of 1x PBS in each tube, and mixed 
thoroughly. Samples were then analysed by flow cytometry.  
Flow Cytometry fluorescent antibody staining 
1×10
6
  MSCs were resuspended in 100 µl of flow cytometry buffer and incubated for 
10 minutes in the dark at 4°C with 5 µl of each antibody: APC-conjugated CD34, 
VioBlue-conjugated CD45, PE-conjugated CD73, PE-conjugated Vio770 CD90 and 
FITC-conjugated CD105. Then, cells were washed by adding 2 ml of flow cytometry 
buffer and centrifuged at 300xg for 10 minutes. The supernatant was aspirated 




2.6. MSCs differentiation experiments 
2.6.1. Osteogenesis 
Wild-type and mms6-expressing MSCs were differentiated in cell culture medium for 
osteogenesis for 10 or 21 days, using StemPro Osteogenesis Differentiation Kit 
(Gibco). Cells not induced in osteogenic medium were considered as a negative 
control (0 Day).  
The differentiation experiments were performed in the absence of FeQ doping. 
To perform the osteogenic differentiation, cells were seeded in 3 different 24 wells 
plates for each cell group, at a density of 2x10
4 
cells/well cultured in standard culture 
medium. After 48 hours, at confluence, cells grown in one plate for each group were 
considered as time point 0 Day, the medium was removed, cells were washed twice 
with 1x PBS and fixed in 4% PFA for 30 minutes at RT in the fume hood. After 
fixation, cells were washed twice with 1 ml of ddH2O/well and stained with 2% 
Alizarin Red S solution (pH 4.2) for 30 minutes. The cells were then washed three 
times with 1ml of ddH2O/well and observed under light microscope and 
photographed at 100X magnification. 
In cells considered as time point 10 Days and 21 Days, the standard culture medium 
was removed, cells were washed once with 1x PBS  and it was added 1 ml/well of 
pre-warmed MSCs osteogenesis differentiation medium. Cells were then cultured in 
the incubator at 37 °C, 5% CO2, and were refeeded every 3 days. After 10 and 21 
days, the MSCs osteogenesis differentiation medium was removed, cells were 
washed twice with 1 ml of 1xPBS and fixed in 4% PFA for 30 minutes at RT in fume 
hood. After fixation, cells were washed twice with 1 ml of ddH2O /well and stained 
with 2% Alizarin Red S solution (pH4.2) for 30 minutes. The cells were then washed 
three times with 1ml of ddH2O/well and observed under light microscope and 
photographed at 100X magnification. 
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2.6.2. Immunofluorescent Osteocalcin staining 
To perform the Immunofluorescent staining (IF), MSCs (passage<10) were seeded 
on coverslips in 3 different 24 wells plates for each cell group, at a density of 2x10
4
 
cells/well, cultured in the standard medium, at 37°C and 5% CO2. The cells were 
then induced for osteogenesis and, after 10 or 21 days of incubation with the 
differentiation medium, cells were subjected to IF. 
The medium was aspirated, then cells were washed three times with 1 ml of  1x PBS 
and fixed with 1 ml of 4% PFA diluted in 1x PBS for 15 min at RT. The fixative was 
aspirated, and cells were rinsed three times in 1x PBS for 5 min each and 
permeabilized in 0.1% Triton X-100 in 1x PBS for 10 min and washed three times in 
1x PBS before blocking in normal goat serum (20% in 0.1% BSA-PBS ) for 60 min 
at RT. The blocking solution was then aspirated and cells were incubated with rabbit 
anti-human osteocalcin IgG (AbD Serotec 7060-1515; 1:40 in 0.1% BSA-PBS) 
overnight at 4°C, followed by three washings in 1x PBS and incubation with Alexa-
Fluor 488-conjugated goat anti-rabbit IgG diluted 1:100 in 0.1% BSA-PBS for 1hour 
at RT in the dark. Coverslips were washed three times with 1x PBS then incubated in 
DAPI solution (1:5000 in distilled water) for 10 minutes at RT and imaged using a 
Fluorescent Microscope (Nikon E800). Experiments were performed in triplicate and 
repeated three times.  
2.6.3. Chondrogenesis 
Wild-type and mms6-expressing MSCs were differentiated in cell culture medium for 
chondrogenesis for 21 days using StemPro Chondrogenesis Differentiation Kit 
(Gibco). Cells not induced in chondrogenic media were considered as a negative 
control (0 Day). 
To perform the chondrogenic differentiation, cells were seeded in 2 different 24 
wells plates for each cell group, at a density of 2*10
4
 cells/ well in standard culture 
medium. After 48 hours, when the cells reached the confluence, cells grown in one 
plate for each group were considered as time point 0 Day, medium was removed and 
101 
 
cells were washed twice with 1X PBS, then fixed in 4% PFA for 30 minutes at RT in 
a fume hood, washed twice with ddH2O, and stained with Alcian Blue staining 
solution, as explained below. 
In cells considered as time point 21 Days, the medium was removed, and it was 
added 1 ml/well of pre-warmed chondrogenic differentiation medium in the dark. 
The cells were then cultured in the incubator, at 37°C and 5% CO2 until day 21. 
Culture were refed every 3 days. 
After 21 days, the cartilage spheroids were well visible. The differentiation medium 
was removed, and spheroids were carefully washed with 1x PBS twice, paying 
attention to do not aspirate them, and then they were fixed in 4% PFA for 30 minutes 
at RT. Then, the fixative was removed and  spheroids were washed twice with 
ddH2O. Immediately before use, the required amount of Alcian Blue staining 
solution was filtered through a 0.22 µm syringe filter equipped with a PES-
membrane. The ddH2O was carefully aspirated, and 2 ml of filtered Alcian Blue 
staining solution were added in each well. Then, spheroids were incubated in the 
dark for 45 minutes at RT. At the end of the incubation time, the Alcian Blue 
staining solution was carefully aspirated and the cartilage spheroids were washed 
with 1 ml of Alcian Blue destaining solution for 10 min, for three times. The 
destaining solution  was removed and spheroids were covered with 1 ml of 1x PBS. 
The intense dark blue cartilage spheroids were then pictured using an IPhone 6 
camera.  
2.6.4. Adipogenesis  
Wild-type and mms6-expressing MSCs were differentiated in cell culture medium  
for adipogenesis for 10 or 21 days using StemPro Adipogenesis Differentiation Kit 
(Gibco). Cells not induced in the adipogenic medium were considered as a negative 
control (0 Day). 
To perform the adipogenic differentiation, cells were seeded in 3 different 24 wells 
plates for each cell group, at a density of 2x10
4 
cells/well in standard culture 
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medium. After 48 hours, when the cells reached the confluence, cells grown in one 
plate for each group were considered as time point 0 Day, medium was removed 
from the wells and cells were washed twice with 1x PBS, then fixed in 4% PFA and 
stained with Oil Red O solution, as explained below.  
In cells considered as time point 10 Days or 21 Days, the medium was removed and 
it was added 1 ml/well of pre-warmed complete Adipogenesis differentiation 
medium in the dark. The cells were then put in the incubator, at 37°C and 5% CO2  
for the required time. Culture were refed every 3 days. After 10 and 21 days of 
incubation with the complete differentiation media, the medium was removed and 
plates were carefully washed twice with 1 ml of 1x PBS, to not disrupt the cells 
monolayer. The cells were fixated in 4% PFA under the chemical hood, then they 
were incubated for 1 hour at 37°C, paying attention to do not perturb the lipids 
droplets. After fixation, cells were washed twice with 1ml of 1x PBS, then incubated 
with 1 ml of 60% isopropanol for 1 minute. Then, the isopropanol was disposed and 
the cells were let dry under the chemical hood. At this point, it was added the Oil 
Red O solution diluted 3:2 in distilled water for 20 minutes. When the incubation 
time  passed, cells were washed with 1x PBS for three times and imaged immediately 
at light microscope at 200x magnification. Cells were pictured using a coloured 
camera (Micropublisher camera, QIMAGING). The pictures of cells incubated with 
complete differentiation media for 10 and 21 days were compared to the 0 Day 
plates.  
2.6.5. Cell proliferation assessment by Incucyte ZOOM System 
Software 
Incucyte ZOOM System Software was used to study the cell proliferation by both 
qualitative and quantitative analysis. Cell proliferation was qualitatively monitored 
by pictures, and quantitatively assessed as the percentage rate of MSCs plate 
coverage, in a real-time quantitative live-cell analysis.  
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To perform the cell proliferation study, MSCs cells (passage<10) were seeded in 3 
different 24 wells plates for each cell group, at a density of 2x10
4 
cells/well in 
standard culture medium. The cells were seeded in each plate according to the 
following layout: 
- Lane 1- Wild-type MSCs  
- Lane 2- Wild-type MSCs in FeQ doped medium for 21 days 
- Lane 3 - mms6-expressing MSCs (21 days post transfection, cultured in FeQ 
doped medium) 
After 1 hour from seeding, the cells were moved from cell culture incubator in the 
Incucyte machine incubator, where the proliferation monitoring started. Cells were 




2.7. In vitro AMF exposure  
2.7.1. Media used in the experiments 
 Standard medium: DMEM supplemented with 20% FBS + 
Penicillin/streptomycin (100 U/ml/100μg/ml), without FeQ. 
 Exposure medium: DMEM supplemented with 10% FBS, without Penicillin 
streptomycin and without FeQ. 
2.7.2. mms6-expressing MSCs monolayers creation and cell 
exposure procedures 
MSCs seeding in Petri dishes for cell monolayer arrangements  
Wild-type MSCs and mms6-expressing MSCs were seeded in sterile 35 mm Petri 
dishes at the density of 3x10
5
 cells each Petri dish, using 2 ml of standard medium. 
Cells were incubated at 37°C, 5% CO2 overnight. The following day, the standard 
medium was changed with the exposure medium, immediately before the AMF 
exposure. 
AMF exposure of cell monolayers: 
Six sterile 35 mm Petri dishes, each containing a single monolayer of mms6-
expressing MSCs, were created as explained above. Then, three Petri dishes were 
exposed one by one to an AMF of 565.3 kHz frequency for 1 hour, in the 
magneTherm device, using 40°C recirculating water from water bath, while the other 
three Petri dishes were inserted in the magneTherm system under the same 
conditions, but with AMF switched off,  as a control. After exposure, unless 
otherwise specified, Petri dishes were incubated overnight in the incubator at 37°C 





Bright field microscopy investigation of  the effect of the exposure for one hour  
to an AMF of 565.3 kHz frequency on Plain MSCs and mms6-expressing MSCs, 
arranged in a monolayer. 
Wild-type MSCs and mms6-expressing MSCs, grown in a monolayer arrangement as 
previously explained, exposed and not exposed to AMF, were imaged in bright field 
microscopy at 40x magnification with an inverted microscope. 
2.7.3. MSCs seeding in tubes for 3D cell pellets arrangements 
Creation of  3D pellets composed only of MSCs cells 
To create 3D pellets of mms6-expressing MSCs, cells were seeded in 35 mm Petri 
dishes at the concentration of 3x10
5
 cells for each Petri dish and cultivated in the 
incubator at 37°C and 5% CO2 in standard medium, until confluence. From each 
Petri dish, a 3D pellet was created as follows: the cells were trypsinized and 
resuspended in 150 µl of the standard medium, in a 15 ml sterile plastic tube. The 
cells were then centrifuged at 113xg for 2 minutes, to create a pellet, and incubated 
overnight in the incubator at 37°C, 5% CO2 before AMF exposure. 
Creation of  3D co-cultures of mms6-expressing MSCs and cancer cells pellets 
Two types of 3D co-cultures cell pellets were created, one composed of mms6-
expressing MSCs mixed with MG63 cells and one composed of mms6-expressing 
MSCs mixed with A431 ecad-GFP expressing cells respectively. To create a 3D co-
culture composed of mms6-expressing MSCs and MG63 cells, at 1:2 ratio,  2x10
5
 
mms6-expressing MSCs and 4x10
5 
MG63 cells were mixed and resuspended in 
200µl of medium; to create the 1:4 ratio, 1.2x10
5
 mms6-expressing MSCs and  
4.8x10
5
 MG63 cells were mixed and resuspended in 200µl of medium. To create a 
3D co-culture composed of mms6-expressing MSCs and A431 ecad-GFP expressing 
cells, at 1:2 ratio, 2x10
5 
mms6-expressing MSCs and 4x10
5
 A431 ecad-GFP 
expressing cells were mixed and resuspended in 200 µl of medium. The cells were 
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then centrifuged at 113xg for 2 minutes, to create a pellet, and incubated overnight in 
the incubator at 37°C, 5% CO2 before AMF exposure. 
2.7.4. Description of the assays used in the experiments: 
Pierce LDH Cytotoxicity Assay, AlamarBlue Cell Viability 
Assay, Trypan Blue Exclusion Assay. 
Pierce LDH Cytotoxicity Assay description 
The kit quantifies lactate dehydrogenase (LDH), an enzyme involved in the energy 
production, found in cell cytosol. In glycolysis,  LDH enzyme converts pyruvate to 
lactate via reduction of NAD
+
 to NADH, while inside the liver LDH performs the 
opposite reaction in the Cori cycle. When cells are damaged, and their plasma 
membrane breaks, LDH is released in the medium. The kit used in the experiments 
exploits the reaction between a diaphorase (an enzyme that catalyses the reduction of 
various dyes) and the NADH formed by LDH reaction. The NADH is used by the 
diaphorase to reduce a tetrazolium salt to a red formazan product. In this way, it is 
possible to quantify the extracellular LDH presence, which is directly proportional to 
the formazan production. To measure the LDH release, cell culture media is 
transferred in a fresh microplate with the addition of the kit reagents. Following an 
incubation time of 30 minutes at RT, the reaction is stopped, and the LDH activity is 
determined  by spectrophotometric absorbance at 490 nm. 
Pierce LDH Cytotoxicity Assay experimental procedure 
After the exposure, the AMF exposed and the unexposed controls cells were 
immediately seeded in a 96 wells sterile plastic plate at the concentration of 5.5x10
3
 
cells/well, in triplicate, considering three wells for the Maximum LDH activity 
(Lysis buffer) and three wells for the Spontaneous LDH activity (water), as 
suggested by manufacture's protocol. Then, the cells were incubated overnight in the 
incubator at 37°C, 5% CO2. The day after, the Lysis buffer (10 µl each well) was 
added to the three wells considered for the Maximum LDH activity, while water (10 
µl each well) was added in the three wells considered for the Spontaneous LDH 
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activity. The plates were then incubated in the incubator for 45 minutes. After that, 
50 µl of medium taken from each well were transferred in a fresh 96 well plate, flat 
bottom. Then, 50 µl of Reaction Mixture were added to each well, and the plate was 
incubated at RT for 30 minutes in the dark. At the end of the incubation time, 50 µl 
of Stop Solution were added to each well, and the solution absorbance was 
immediately read at the plate reader (FLUOstar Omega, BMG LABTECH).  
 
The percentage of cytotoxicity was calculated according to the formula suggested by 
the  protocol: 
                
                                             
                                             
     
2.7.5. Cell viability investigation by AlamarBlue Cell Viability 
Assay 
AlamarBlue Cell Viability Assay description 
Cytosol of viable and healthy cells is a reducing environment. The kit employed for 
these experiments relies on the reduction capacity that living cells have. AlamarBlue 
Cell Viability Assay contains resazurin, which is a cell permeable, non-fluorescent  
and non-toxic blue dye. Resazurin enters inside the cells, and it is reduced by the 
viable ones in resorufin, a red fluorescent dye, that can be monitored on a plate 
reader or a fluorescence spectrophotometer. Comparing the fluorescence of two or 
more cell populations, it is possible to establish which one is the more viable. 
AlamarBlue Cell Viability Assay experimental procedure 
After the exposure, Alamar Blue reagent was added to the cells medium in the 
proportion of 1/10
th
 of cell medium volume. Then, the cells were incubated in the 
incubator at 37°C, 5% CO2. Medium fluorescence was read after 3 hours of 
incubation with Alamar Blue reagent in the plate reader (FLUOstar Omega, BMG 
LABTECH) by excitation at 544 nm and emission at 590 nm. Results are presented 
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both as relative fluorescence units (RFU) than as the percentage of cell viability, 
against controls considered as 100% viable. This percentage was calculated 
according to (Zachari et al., 2014; Duzgunes, 2003): 
%Viability =
                              
                                   
     
Negative controls are represented by exposure medium without cells and with the 
addition of 10% Alamar Blue reagent.  
2.7.6. Cell death determination by Trypan Blue Exclusion Assay  
Trypan Blue Exclusion Assay description 
Trypan Blue solution is routinely employed to count the cells in the haemocytometer 
during subculturing and in experiments that require an accurate determination of the 
cell viability using bright field microscopy. Trypan Blue dye is excluded from viable 
cells, which possess a selective membrane. Dead cells, instead, are permeable to the 
dye and do uptake it. Observing the cells in bright field microscopy, it is possible to 
differentiate the dead cells, which appear blue, from the living cells, which remain 
translucent. 
Trypan Blue Exclusion Assay experimental procedure 
To count the viable cells number by Trypan Blue Exclusion Assay, 100 µl of 0.4% 
Trypan Blue Solution were added to 100 µl of cells suspension (1:1 dilution) and 
incubated at RT for 5 minutes. Then, 10 µl of the suspension were loaded into a 
haemocytometer. Blue stained cells and the number of total cells were counted using 
bright field microscopy, at 100x magnification. 
Percentage of living cells were calculated as: 
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2.7.7. Description of the MSCs staining procedures with 
CellTracker CM-Dil Red 
CellTracker
 
CM-Dil Red description 
CellTracker CM-DiI Red is a nontoxic red fluorescent dye employed for cell tracking 
that could be viewed in fluorescent microscopy. It is a nonspecific lipophilic 
compound that labels the plasma membrane of cells in culture. This dye is well 
retained by the cell, allowing for multigenerational tracking of cellular movements. 
The CellTracker CM-DiI Red excitation/emission spectra (553/570 nm maxima)  do 
not overlap with green fluorescent dyes and proteins. 
MSCs staining with CellTracker CM-Dil Red  
The CellTracker
 
CM-Dil Red dye stock solution was reconstituted at the 
concentration of 1 mg/ml according to manufacturer's protocol, by adding 50µl of  
DMSO to one vial containing 50µg of dried powder, to the final concentration of 
1M. For the mms6-expressing MSCs labelling, cells were cultivated in standard 
medium supplemented with FeQ 3.4µl/ml in a T75 cell culture flask. When cells 
reached confluence, the exhausted medium was removed, and the cells were rinsed 
with 5 ml of HBSS. Next, 30 µL of the CellTracker CM-Dil Red dye stock solution 
were added in 10 ml of HBSS inside a sterile plastic tube and the solution was added 
to the cells in the flask, in the dark. The cells were then incubated in the incubator at 
37
o
C  and 5% CO2  for 5 minutes followed by 15 minutes of incubation in ice, in the 
dark. Then, the solution was removed, and the cells were washed with 4 ml of HBSS. 
The cells were trypsinized and resuspended in 10 ml of HBSS in a sterile 15 ml 
plastic tube. Then, the cells were centrifuged  at 177xg for 5 minutes. Supernatant 




2.7.8. Description of the MG63 cells staining procedures with 
CellTracker Green CMFDA Dye 
CellTracker Green CMFDA Dye description 
CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) is a green, stable, 
nontoxic fluorescent dye used for cell tracking. As for CellTracker CM-DiI, this dye 
passes through cell membrane,  it is well retained by cells and it is passed to the next 
generation of daughter cells. CellTracker Green CMFDA dye fluorescence lasts for 
at least 72 hours and its green excitation/emission spectra (492/517 nm maxima) 
does not overlap with GFP (green fluorescent protein) and RFP (red fluorescent 
protein) excitation/emission spectra. 
CellTracker  Green CMFDA Dye MG63 staining experimental procedure   
The CellTracker Green CMFDA Dye stock solution was reconstituted at the 
concentration of 10 mM according to manufacturer's protocols by adding 11µl of 
DMSO to one vial containing 50 mg CellTracker Green CMFDA Dye  dried powder.  
For the MG63 cells labelling, cells were cultivated in standard medium in a T75 cell 
culture flask. When cells reached confluence, the exhausted medium was removed 
and the cells were rinsed with 5 ml of HBSS. Next, 10 µL of the CellTracker™ 
Green CMFDA Dye stock solution were added in 10 ml of HBSS in a sterile plastic 
tube, and the solution was added to the cells in the flask, in the dark. The cells were 
then incubated in incubator at 37°C, 5% CO2 for 30 minutes. At the end of the 
incubation time, the staining solution was removed and cells were rinsed with 4 ml of 
HBSS after the labelling. The cells were harvested by trypsinization, resuspended in 
10 ml of HBSS in a sterile 15 ml plastic tube and then centrifuged at 177xg for 5 





2.7.9. Description of the experimental procedures used for AMF 
exposure of mms6-expressing MSCs cultivated in a 
monolayer 
The effect of one hour 565.3 kHz AMF on mms6-expressing MSCs arranged in a 
monolayer. Determination of cell cytotoxicity by LDH cytotoxicity assay  
The effect of AMF exposure at 565.3 kHz on mms6-expressing MSCs was 
established by the Pierce LDH Cytotoxicity Assay Kit. In these experiments, the cells 
were grown in monolayers in Petri dishes, as explained in section 2.7.2. Three Petri 
dishes were exposed to AMF at 565.3 kHz frequency for 1 hour, in the magneTherm 
system, using 40 °C recirculating water from the water bath, while three Petri dishes 
were inserted in the magneTherm system under the same conditions, but with AMF 
switched off, as a control. The controls and the exposed cells were tripsinised 
immediately after the exposure and seeded in a 96 wells plate at the concentration of 
5.5x10
3
 cells/well, in triplicate. The cells were incubated O/N in the incubator. The 
following day, the Pierce LDH Cytotoxicity Assay was carried out as explained in 
section 2.7.4. 
The effect of one hour 565.3 kHz AMF on mms6-expressing MSCs arranged in a 
monolayer. Determination of cell viability by AlamarBlue Cell Viability Assay. 
The effect of one hour of AMF exposure at 565.3 kHz on mms6-expressing MSCs 
viability was established by the AlamarBlue Cell Viability Assay. In these 
experiments, the cells were grown in a monolayer in Petri dishes, as explained in 
section 2.7.2. Three Petri dishes were exposed to AMF at 565.3 kHz frequency for 1 
hour, in the magneTherm system, using 40°C recirculating water from the water 
bath, while three Petri dishes were inserted in the magneTherm system under the 
same conditions, but with the AMF switched off,  as a control. 
After the exposure, the Petri dishes were put in the incubator. The next day, the cell 
viability was assessed by AlamarBlue Cell Viability Assay as suggested by 
manufacture's protocol, as explained in section 2.7.5, and fluorescence intensity was 
read after 3h of incubation with AlamarBlue reagent.   
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2.7.10. Description of the experimental procedures used for AMF 
exposure of 3D cultures: 
The effect of one hour 565.3 kHz AMF on 3D cultures of mms6-expressing 
MSCs. Treatment was repeated twice and followed by cell death assessment by 
Trypan Blue Exclusion Assay. 
Six tubes containing 3D pellets of mms6-expressing MSCs were created as explained 
in section 2.7.3. Then, three tubes were exposed one by one to AMF of 565.3 kHz 
frequency for 1 hour, in the magneTherm system, using 40 °C recirculating water 
from water bath, while the other three tubes were inserted in the magneTherm system 
under the same conditions, but with AMF switched off, as a control. After exposure, 
tubes were incubated overnight in the incubator at 37°C and 5% CO2. In this 
experiment, due to the 3D arrangement of cells that formed a thick pellet, it was 
chosen to duplicate the AMF exposure, so the following day, the exposed tubes were 
exposed again at 565.3 kHz for 1 hour (double exposure). Cell viability was assessed 
by Trypan Blue Exclusion Assay, as explained in section 2.7.6. 
The effect of one hour 565.3 kHz AMF on 3D cultures of mms6-expressing 
MSCs and MG63 cells. Treatment was repeated three times and followed by cell 
viability assessment by Trypan Blue Exclusion Assay. 
The formation of 3D pellets was obtained by co-culturing mms6-expressing MSCs 
and MG63 cells in 15 ml tubes, at 1:2 and at 1:4 ratio, as explained in section  2.7.3. 
For each ratio, six tubes were made, three were inserted one by one in the 
magneTherm system and exposed to an AMF at 565.3 kHz frequency for one hour, 
while the other three tubes were inserted in the magneTherm system under the same 
conditions, but with the AMF switched off, as a control. After the exposure, the tubes 
were put in incubator at 37°C and 5% CO2. The following day, the tubes that had 
been exposed the previous day to the AMF, were exposed again twice, for one hour 
at the same 565.3 kHz frequency, with a 2 hours pause between each exposure. The 
cells of each tube were then counted by Trypan Blue Exclusion Assay, as explained 
in section 2.7.6. 
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The effect of one hour 565.3 kHz AMF on 3D co-cultures of mms6-expressing 
MSCs and A431 ecad-GFP expressing cells. Treatment was repeated three times 
and followed by AlamarBlue Cell Viability Assay. 
The formation of 3D pellets was obtained by co-culturing mms6-expressing MSCs 
and A431 ecad-GFP expressing cells in 15 ml tubes, as explained in section 2.7.3. 
For these experiments, the chosen ratio was 1:2, counting 2x10
5 
mms6-expressing 
MSCs, stained by CellTracker CM-Dil Red, and  4x10
5
 A431 ecad-GFP expressing 
cells. For each experiment, three pellets were exposed one by one to AMF at the 
frequency of 565.3 kHz for 1 hour, while three pellets were kept in the machine 
under the same conditions but not exposed at AMF, serving as controls. The 
following day, the exposed pellets were exposed again twice, for one hour at the 
same 565.3 kHz frequency, with a 2 hours pause between each exposure. Then the 
cells were seeded in triplicate in a 96 multiwells plate at a density of 5.5 x10
3
 
cells/well in 100 µl of exposure medium and incubated overnight in the incubator at 
37°C and 5% CO2. The following day, AlamarBlue Cell Viability Assay was 
performed as described in section 2.7.5, using 10 µl of Alamar Blue reagent per well, 





2.7.11. Fluorescent microscopy on 3D co-cultures of CellTracker 
CM-Dil Red stained mms6-expressing MSCs and 
CellTracker Green CMFDA Dye stained MG63 cells, at 1:2 
ratio. 
mms6-expressing MSCs were stained with CellTracker CM-Dil Red, while MG63 
cells were stained with CellTracker Green CMFDA Dye, as explained in sections 
2.7.7 and 2.7.8. The two cell populations were then mixed in plastic sterile tubes (15 
ml each) at the ratio of 2:1, counting 4x10
5
 MG63 green stained cells and 2x10
5
 CM-
Dil Red stained 21 days mms6-expressing MSCs. The cells were then centrifuged at 
177xg for 2 minutes, forming pellets. Three pellets were exposed to AMF for 1 hour, 
in the magneTherm system at 565.3 kHz frequency, using 40 °C recirculating water 
from the water bath, while the other three pellets were placed in the magneTherm 
system in the same conditions, but with the AMF switched off, as a control. Then, 
pellets were  incubated at 37°C, 5% CO2. The day after, the exposed pellets were 
exposed again twice, with a pause of 2 hours between the two exposures. Then the 
cells (control and exposed) were seeded in quadruplicate in 24 wells plate (2 x10
4 
cells/well). The next day, the nuclei of the cells were stained with DAPI, by adding  
25 µl of VECTASHIELD mounting medium with DAPI on cells. Cells were covered 
with a glass coverslip, and then they were immediately imaged by fluorescence 
microscopy, at 100x magnification. The pictures were analysed using ImageJ 
software, and for each picture, the number of green cells (MG63 cells) and the 





2.7.12. MagneTherm system device description 
The AMF was applied using the magneTherm system device from Nanotherics, a 
commercial device designed to study magnetic fluid and nanoparticles hyperthermia 
(Figure 21). In this work, the device was used to investigate the AMF effects on the 
MNPs created inside the MSCs by mms6 gene expression, 21 days post transfection.  
The physical principle that underlies the magneTherm system device function is that 
a current applied through a conductor determines the creation of a circular magnetic 
field around it, as described by Ampere's law:  
  
   
   
 
where B is the magnetic field, µ0 the permeability of the free space, I is the current in 
the wire, and r the radius from the wire.  
If the conductor is a coil (as for the magneTherm system), the magnetic field strength 
is enhanced, and a strong field is created at the centre of the coil, where all the 
magnetic field generated by each turn of the coil pass. The physical concept that 
drives the experiments is that MNPs subjected to an AC magnetic field:  
 lose energy as a consequence of their magnetisation reversal process, 
producing  heat;  
 tend to vibrate, causing the cell membrane breaking.   
The magneTherm system device was used in this case to determine if MNPs 
expressed by  mms6-expressing MSCs could support MH when an AMF is applied. 
For all the experiments it was used the 17-turning coil provided with the instrument, 
with the capacitor array type B6.2. The oscilloscope Volts/Div was set at 50 mV, the 
DC power supply voltage was set at 23.1 V and the AMF frequency chosen was 
565.3 kHz. The device was integrated with a water jacket to keep the cells at a 
constant temperature of 37°C. In all the experiments performed, the Petri dishes and 
the tubes in which the cells were seeded were inserted in the magneTherm device 














Figure 21. Nanotherics magneTherm system device used in the experiments.  
Components of the system are: a) Function Generator, b) DC Power Supply, c) Oscilloscope, 
d) magneTherm system, e) Water jacket, f) Cooling water connecting tubes, g) Waterbath. 
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2.8. In vivo AMF exposure 
2.8.1. Delivery of an AMF by magneTherm device: experiment 
layout 
"All experiments were carried out in accordance with the United Kingdom Animal 
Scientific Procedures Act (1986) and UK Home Office regulations under project 
licence number (PPL No.) 70/7926.  
All the implantation and the culling were undertaken by Morwenna Muir". 
 
16  female CD-1 nude mice, two-months old, were implanted  subcutaneously 
bilaterally, with 1x10
6
 A431 Ecad-GFP cells per implant, diluted in  0.1ml of HBSS. 
Tumours were measured twice weekly by plastic callipers (Camlab, UK) and animals 
were weighed daily post-intracardiac injection. The volume of mice tumours was 
calculated as an ideal ellipsoid following the formula:  
0.5 x lenght of tumour x square of tumour breadth 
Tumours were randomised before to start, and 4 groups of 4 mice each were created 
by grouping tumours of the same volume together, so that the total volume of each 
group was the same as each other.  
Then, groups of mice were treated as follow:  
Group A - A431 Ecad-GFP cells s/c + Anaesthesia Only 
Group B - A431 Ecad-GFP cells s/c + magneTherm treatment, 565.3kHz Daily, x 
3 days 
Group C - A431 Ecad-GFP cells s/c + red mms6-expressing MSCs + Anaesthesia 
Only 
Group D - A431 Ecad-GFP cells s/c + red mms6-expressing MSCs + 
magneTherm treatment, 565.3kHz Daily, x 3 days 
One week later, Group C and Group D were intracardiac injected with 1x10
6
  red 
mms6-expressing MSCs. Animals were culled after the final magneTherm treatment 
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(treatment am, cull pm). On cull, tumours were split and stored in HBSS, formal 
saline and snap frozen; liver, lung and spleen were removed and halved and half 
stored in formal saline for immunohistochemistry investigation, half snap frozen for 
fluorescent microscopy imaging.  
Due to the busy laboratory schedule, Group A and B were implanted one week later 
than Group C and D. 
2.8.2. Description of AMF treatment by magneTherm device 
The MagneTherm water bath was set to 40
o
C to keep the instrument coil at the same 
temperature during all the treatment, as suggested by the manufacture. Mice exposed 
to magneTherm were anesthetised by isofluorane, their eyes were cover with 
Lacrilube (Allergan) to avoid eyes drying, and then they were positioned on a ruler 
with the face mask on to provide anesthetisation during all the duration of the 
treatment. The ruler was carefully inlaid through the magneTherm to allow a rectal 
probe to be inserted with the help of soft paraffin on. The ruler was then pushed back 
into the magneTherm machine so that the tumours were centrally placed and the 
reading on the ruler was kept in consideration to ensure that further treatments were 
all placed the same. magneTherm was plug in and frequency was set at 565.3 kHz 
following the protocol described in the appendix 8.9. Mice were treated in the 
magneTherm for 30 minutes. The mice skin temperature was read every 5 minutes 
respectively by an infrared thermometer gun, while mice core temperature was read 
by a rectal thermocouple. At the end of the treatment, the ruler was slightly moved 
through the magneTherm to allow rectal probe or thermocouple wire to be removed, 
then back through the magneTherm to remove the mouse. At the end of the AMF 
treatment, mice were placed into the recovery box and monitored until their full 




2.8.3. RNA extraction from mice tissues 
RNA was extracted from mice organs and tumours using the RNeasy Mini Kit 
(Quiagen) and following the manufacture's instructions. Briefly, the tissue samples 
from the animals were disrupted, and the lysate was homogenised in Buffer RLT and 
centrifuged for 3 minutes at full speed. Then, the supernatant was carefully removed 
by pipetting and transferred into a new microcentrifuge tube. A volume of 70% 
ethanol  was added to the cleared lysate, and mixed immediately by pipetting. The 
samples were transferred to an RNeasy spin column placed in a 2 ml collection tube 
and centrifuged for 15 seconds at 8000xg. The flow-through was discarded. Then, 
700 μl Buffer RW1 were added to the RNeasy spin column and samples were 
centrifuged for 15 seconds at 8000xg  to wash the spin column membrane. The flow-
through was discarded. Then, 500 μl Buffer RPE were added to the RNeasy spin 
column, and samples were centrifuged for 15 seconds at 8000xg to wash the spin 
column membrane. The flow-through was discarded. This step was repeated twice. 
The RNeasy spin column was placed in a new 1.5 ml collection tube and 30–50 μl 
RNase-free water were added directly to the spin column membrane. Samples were 
centrifuged for 1 min at 8000xg  to elute the RNA. Yield and purity of RNA samples 
were determined using a NanoDrop spectrophotometer and cDNA was synthesised to 
perform the RT-PCR,  as previously explained. 
2.8.4. Prussian Blue staining 
For each mouse, sections of liver, spleen, lung and tumours were stained with PBR 
solution. Sections were washed in water and then incubated in the PBR solution for 
20 minutes. Then, sections were washed well in running water and counterstained 
with 1% neutral red. Then, section were washed again in running water, cleared and 
mounted. Ferric iron was blue and nuclei were stained in red. Sections were imaged 
in bright field at 400x magnification, in NanoZoomer Digital Slide Scanner 
(Hamamatsu), using NanoZoomer Digital Pathology software (Hamamatsu) and 
considering 5 fields for each section. 
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2.8.5. Fluorescent microscopy 
Following mice sacrifice, spleen, liver, lung and tumours were retrieved and snap 
frozen, to be subsequently sectioned at 5 µm thickness at the cryostat. Cell nuclei 
were stained with DAPI (Vectashield) and then sections were imaged by 
fluorescence microscopy at 200x magnification (Zeiss Axioskop 2). 
2.8.6. Cells Fixable Viability Dye eFluor 450 staining 
Tumour tissues were analysed for dead cells  by Fixable Viability Dye eFluor® 450 
(ThermoFisher). The dye was thawed at room temperature for 10 minutes, then 
diluted 1:1000 in 1X PBS (20 µl of dye were diluted in 20 ml of  1x PBS). Fresh 
tumours tissues were cut into small pieces by scalpel and immediately placed in a 24 
wells sterile plate. Tumour tissues were washed twice with 1 ml of 1x PBS, then they 
were covered with 2 ml of diluted Fixable Viability Dye eFluor® 450 and incubated 
on ice in the dark for 30 minutes. After incubation, the dye was removed from each 
well, and tumour tissues were washed with  1x PBS  twice. To avoid samples drying, 
2 ml of 1x PBS  were added to each well. Tumour tissues were kept on ice in the 
dark and immediately imaged at Multiphoton microscope. Image analysis was 
carried out using Imaris software (8.0.1). 
2.8.7. Multiphoton Imaging setup 
After mice culling, slices of fresh tumours were analysed for dead cells  by Fixable 
Viability Dye eFluor 450 (ThermoFisher) and for the red MSCs presence (Group C 
and Group D). 
Briefly, a picoEmerald (APE) laser provided both a tunable pump laser (720–
990 nm, 7 ps, 80 MHz repetition rate) and a spatially overlapped second beam termed 
the Stokes laser (1064 nm, 5–6 ps and 80 MHz repetition rate). The laser was 
inserted into an Olympus FV1000 microscope coupled to an Olympus 
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XLPL25XWMP N.A. 1.05 objective lens using a short-pass 690 nm dichroic mirror 
(Olympus).  GFP protein fluorescence detection: two-photon fluorescence signals 
were filtered using the following series of filters: FF520-Di02, FF483/639-Di01 and 
ET525/50m. CellTracker CM-DiI Dye red fluorescence detection: two-photon 
fluorescence signals were filtered using FF520-Di02, FF757-Di01 and FF01-
609/181. Fixable Viability Dye eFluor signals were filtered using FF520-Di02, 
FF483/639-Di01 and FF01-466/40. The pump laser was tuned to 860 nm and used 50 
mW power as measured at the objective, whilst the Stokes laser used 20 mW power 
as measured at the objective. 
2.8.8. Immunohistochemistry (IHC) of paraffin embedded 
sections  
Following mouse sacrifice, the organs were washed extensively in 1xPBS, collected in  
HBSS and then fixed in 4% formaldehyde for 24 hours at RT. They were then washed 
three times in 1xPBS before sending to the Division of Pathology Histology services 
laboratories for processing and paraffin embedding. 4µm sections were cut from the 
paraffin blocks and put on positive charged glass slides. IHC staining was performed on 
an automated Leica Bond III stainer using Bond Polymer Refine Detection kit (Leica). 
Slides were subjected to dewaxing, epitope retrieval and then antibody staining 
processes. The following protocols for Caspase 3 and E3.1 were followed. 
For Caspase3 antibody staining, the sections were incubated with the primary 
antibody diluted 1:100 for 1 hour, followed by three washes in BOND wash. The 
sections were then incubated with Post Primary antibody solution to enhance 
antibody penetration for 8 minutes, followed by a further three washes in BOND 
wash. Ready to use Dako EnVision-HRP labelled anti-rabbit labelled polymer (Dako) 
secondary antibody was then applied for 30 minutes at RT, followed by three washes in 
BOND wash before adding two washes of Mixed DAB Refine solution-substrate 
chromogen, 3.3’- diaminobenzidine (DAB) to allow visualization of the complex 
with a brown precipitate. The sections were washed three times in deionised water 
and counterstained using Harris Hematoxylin solution for 5 minutes, followed by 
deionised water wash, BOND wash and one final deionised water wash. 
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For E3.1  antibody staining, the sections were incubated with MOM Blocking 
reagent (Mouse on Mouse, Vector Laboratories) for 60 minutes,  followed by  three 
washes in BOND wash. The Blocking Reagent is used to block any non-specific 
binding of  mouse antibodies.  
Slides were then incubated with primary antibody diluted 1:500 for 15 minutes,  
followed by three washes in BOND wash. The sections were then incubated with anti 
Mouse IgG-HRP secondary antibody (SigmaAldrich) diluted 1:300 for 15 minutes, 
followed by three washes in BOND wash before adding Mixed DAB Refine Solution 
to visualise. Then, a further 3 washes in deionised water were applied after DAB 
incubation. 
The sections were then counterstained with Harris Hematoxylin solution for 5 minutes, 
followed by deionised water wash, BOND wash and final deionised water wash. 
All IHC Slides were then dehydrated and cleared in graded alcohols and Xylene as 
follows: 50% ethanol for 30 sec, 80% ethanol for 2 mins, 2x 100% ethanol for 2 min and 
2x Xylene for 5min. Sections were then mounted in a DPX mounting medium. 
2.8.9. Haematoxylin and Eosin (H/E) staining of paraffin 
embedded sections  
Sections were washed in distilled water, dewaxed in xylene and rehydrated in 
increasing concentration of ethanol (100%- 80%- 50% ethanol, 2 minutes each). 
Then, sections were washed in running water for 2 minutes and stained with ready-
made Harris Haematoxylin (Shandon) for 4 minutes, transferred to a dish of Scott’s 
tap water substitute (SigmaAldrich)  until the tissue sections turned blue, then 
washed in running water and stained with EosinY solution (Shandon) for 5 minutes. 
Slides were washed in running water, dehydrated and cleared in graded alcohols, and 





2.8.10. Statistical Analysis 
The results were analysed using Excel software and GraphPad Prism  (Prism 5.0, 
USA). 
Statistical analysis of TEM pictures and flow cytometry results was performed using 
one-way ANOVA, followed by post hoc Tukey test  between groups when a 
statistical difference was found. A value of p< 0.05 was considered statistically 
significant. 
Proliferation statistical analysis was performed using two-way ANOVA test, 
followed by Bonferroni post test to perform multiple pairwise comparisons when the 
two-way ANOVA confirmed statistical significance. A value of p<0.05 was 
considered statistically significant. 
For the in vitro AMF exposure results, statistic analysis was carried out using 
Student's t-test to compare the two cell populations -exposed and not exposed- to 
AMF. A value of p < 0.05 was considered statistically significant. 
Statistical analysis on tumours volume and growth was carried out using two-ways 
ANOVA. A value of p < 0.05 was considered statistically significant. 
Statistical analysis on red MSCs inside the tumours of exposed and not exposed mice 
was calculated using Student's t-test to compare the two cell populations -exposed 
and not exposed- to AMF. A  p-value that was equal or less than 0.01 was considered 
statistically significant. 
For Caspase-3 stained tumour cells, five different regions of each tumour were 
considered, and the percentage of caspase-3 stained cells on the total cell nuclei was 
determined.  Statistical analysis was performed using one-way ANOVA. A value of 









3.  Expression of MTB genes 
mms6 and mmsF, alone or in 
combination, in human 
osteosarcoma MG63 cells. 
Study of the created 
intracytoplasmic structures 









3.1. Introduction  
In this chapter,  it was determined whether the MTB genes mms6 and  mmsF could 
be expressed or co-expressed in human osteosarcoma MG63 cells. It was also 
investigated if the expression of these genes in human cells leads to the creation of 
vesicles similar to magnetosomes, as for MTB. To ascertain that, the human 
osteosarcoma MG63 cells were transfected with plasmids pcDNA 3.1 containing the 
mms6 gene, the plasmid pcDNA 4/TO containing the mmsF gene, and co-transfected 
with both of them. The cells were then cultured in a ferric quinate (FeQ) doped 
medium (3.4 µl FeQ/ml), following the same protocol for the culture of MTB, to 
provide non-magnetic iron necessary to create magnetosomes. The expression of the 
MTB genes in MG63 cells was determined at the transcript level by RT-PCR. The 
creation of intracytoplasmic structures, due to the translation of the  mms6, mmsF 
and mms6+mmsF genes respectively into Mms6, MmsF and Mms6+MmsF proteins, 
was assessed by Transmission Electron Microscopy (TEM). The magnetic properties 
of the created structures were evaluated by Superconducting Quantum Interference 
Device (SQUID).  The response of the created intracytoplasmic structures to an AMF  





The hypothesis of the presented study was that it is possible to express MTB genes 
mms6 and  mmsF, alone or in combination, in human osteosarcoma MG63 cells. 
The goal of the study was to confirm the former hypothesis and to evaluate the 
intracytoplasmic particles formed by the MTB genes expression inside the cells, 
according to different techniques: 
1. The mms6 and mmsF gene expression, alone or in combination,  inside the 
MG63 cells, was assessed by Reverse Transcription Polymerase Chain 
Reaction (RT-PCR). 
2. The morphology of the intracytoplasmic particles created in the MG63 cells 
by mms6 and mmsF gene expression, alone or in combination, was analysed 
by Transmission Electron Microscopy (TEM). 
3. The magnetisation of MG63 cells expressing mms6 and mmsF genes, alone or 
in combination, was analysed by Superconducting Quantum Interference 
Device (SQUID). 
4. It was determined if the intracytoplasmic particles created inside the MG63 
cells by mms6 and  mmsF gene expression, alone or in combination, could 






3.3. mms6, mmsF and mms6+mmsF 
co-expression in MG63 cells 
assessment by RT-PCR 
MG63 cells were transfected with plasmids pcDNA 3.1 containing the mms6 gene, 
with plasmid pcDNA4/TO containing the mmsF gene, and co-transfected with both 
of them and cultured in a FeQ doped medium (34 µM). Ten days after the 
transfection, RNA was extracted from transfected MG63 cells, and cDNA was 
synthesised. The expression of these genes in MG63 transfected cells  was evaluated 
by RT-PCR. Wild-type MG63 cells cultured for 10 days in a FeQ doped medium (34 
µM) were considered as a control. 
mms6, mmsF and mms6+mmsF co-expression were normalized to the housekeeping 
gene GAPDH. To test the mmsF gene expression in MG63 cells, it was chosen to 
design two different pairs of primers, named MmsFA and MmFB, to obtain two 
different amplicons length of 122 bp for MmsFA and 205 bp for MmsFB 
respectively.  
The RT-PCR results show the expression of  both genes, mms6 and mmsF, in the 
MG63 cell line, confirming the validity of the transfection (Figure 22). mms6 gene 
was present in mms6-pcDNA 3.1 transfected and in mms6-pcDNA3.1+mmsF-
pcDNA4/TO co-transfected MG63, as indicated by the band of 108 bp present in 
wells 2 and 3, while it was absent in the control cells (well 1). Both the couples of 
primers designed to test the mmsF gene expression inside the MG63 cells worked. 
MmsF was present in mmsF-pcDNA4/TO transfected and in mms6-
pcDNA3.1+mmsF-pcDNA4/TO co-transfected MG63, as indicated respectively by 
the expected band of 122 bp for the couple of primers MmsFA (wells 5 and 6), and 
by the expected band of 205 bp for the couple of primers MmsFB (wells 8 and 9), 
while it was absent in the wild-type (control) cells (wells 4 and 7). The mixes Mms6, 
MmsFA, MmsFB and GAPDH, containing all the reagents for RT-PCR except the 
cDNA, were considered as a negative control for RT-PCR reaction. The light band in 
the MmsFA mix (negative control-well 15), shows a light contamination in the 
couple of primers MmsFA: for this reason the couple of primers MmsFA was 
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discarded and the couple of primers MmsFB was kept for the subsequent 
experiments and called for simplicity MmsF. As a control, the GAPDH expression 
levels were found to be constant for all the samples (wells 10-13), as shown by the 
expected  band of 210 bp,  indicating that the gel lanes have been evenly loaded with 
sample material. Except the mix MmsFA, all the negative controls show no bands, 
indicating no contamination in the RT- PCR mixes (wells 14, 16, 17). 
The co-transfection of MG63 cells with mms6-pcDNA 3.1 and mmsF-pcDNA4/TO 
resulted in less expression of each transcript than the single transfections alone, as 








Figure 22 Representative image for RT-PCR reaction for mms6 and mmsF genes expression in 
MG63 cells.  
A) Mix Mms6: 1) Control cells; 2) mms6-pcDNA3.1 transfected cells; 3) mms6-pcDNA3.1+mmsF-
pcDNA4/TO co-transfected cells.  Mix MmsFA: 4) Control cells; 5) mmsF-pcDNA4/TO transfected 
cells; 6) mms6-pcDNA3.1+mmsF-pcDNA4/TO co-transfected cells. Mix MmsFB: 7) Control cells; 8) 
mmsF-pcDNA4/TO transfected  cells; 9) mms6-pcDNA3.1+ mmsF-pcDNA4/TO co-transfected cells. 
Mix GAPDH: 10) Control cells; 11) mms6-pcDNA3.1 transfected cells; 12) mmsF-pcDNA4/TO 
transfected cells; 13) mms6-pcDNA3.1+mmsF-pcDNA4/TO co-transfected cells. M=marker. 14) 
Mms6 mix negative control; 15) MmsF mixA negative control; 16) MmsF mixB negative control; 17) 





3.4. Analysis of the intracytoplasmic 
particles formation in mms6-
pcDNA3.1, mmsF pcDNA/4TO and 
mms6-pcDNA3.1+ mmsF pcDNA/4TO 
co-transfected MG63 cells using 
Transmission Electron Microscopy 
(TEM)  
Having confirmed by RT-PCR that MTB genes mms6, mmsF and mms6+mmsF are 
expressed in MG63 transfected cells, the effect of these genes product on the inner 
morphology of MG63 cells was investigated by TEM. This technique was employed 
to determine if these genes, alone or in combination, can create in MG63 cells the 
magnetosomes observed in MTB. mms6-pcDNA3.1, mmsF-pcDNA/4TO and mms6-
pcDNA3.1+mmsF-pcDNA/4TO co-transfected MG63 cells were cultured in medium 
doped with FeQ (34 µM) for 10 days after transfection. Wild-type MG63 cells 
cultured in medium doped with FeQ (34 µM ) for 10 days were considered as a 
control.  
From TEM investigation, it could be noticed that the cytoplasm of the wild-type cells 
incubated only with FeQ solution appears clear, without the presence of inner 
vesicles or intracytoplasmic particles (Figure 24 a-c). 
However, two different kinds of structures were identified in the cytoplasm of MG63 
cells expressing the gene mms6, mmsF or both of them: 
1) vesicles containing dispersed content, with the tendency to form clusters 
(Figure 24 e, i); 
2) vesicles containing electron dense material, present in mms6, mmsF and 
mms6+mmsF expressing MG63 cells (Figure 24 f, h, n). 
The vesicles size varies from 300 nm to more than 1 μm, and at higher magnification 
they appear filled with groups of clustered granules, with a diameter smaller than 100 
nm. It is not clear if the larger nanoparticles are aggregates of the smaller particles.  
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Electron-dense structures were found in most, but not all mms6/F expressing cells, 
which agrees with the fact that not all cells will be transfected (Figure 23).  
No differences were noticed between vesicles formed by the gene mms6, mmsF or 
both of them: the size of the granules embedded in the membrane is comparable for 
both the genes. The electron dense structures observed in the transfected cells, did 
not show visible difference among the different transfections: the vesicles content 
seems to be neatly separated and completely different from the ordered 





Figure 23. TEM investigation of Mms6/F transfected MG63 cells. 
Not all MG63 cells co-transfected with mms6-pcDNA3.1+mmsF-pcDNA/4TO  showed electron-
dense structures. In some cases, only a few structures were found in cells, pointed by yellow circles 
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Figure 24. TEM investigation of MG63 cells. 
a-c) MG63 cells incubated with FeQ (34 µM FeQ) for 10 days, single cell and cytoplasm. The black 
area of the nucleus contains densely packed DNAd-f) mms6-pcDNA3.1 transfected MG63, single 
cells and cytoplasm. g-i) mmsF-pcDNA/4TO  transfected MG63, single cells and cytoplasm. l-n) 
mms6-pcDNA3.1+ mmsF-pcDNA/4TO co-transfected MG63, single cells and cytoplasm. Scale bars 
are: 2 µm for figures a, d, g, l; 500 nm for figures b, c, h, m, n and 100 nm for figures e, f, i. 
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3.5. SQUID measurements on mms6-
pcDNA3.1, mmsF-pcDNA/4TO and 
mms6-pcDNA3.1 + mmsF pcDNA/4TO 
co-transfected MG63 cells. 
The magnetisation of mms6-pcDNA3.1, mmsF-pcDNA/4TO and mms6-pcDNA3.1+ 
mmsF pcDNA/4TO co-transfected MG63 cells was analysed by Superconducting 
Quantum Interference Device magnetometer (SQUID). In these experiments it was 
measured the magnetisation of 10x10
6
 MG63 cells for each sample, 10 days after the 
transfection, incubated with FeQ (3.4 µl FeQ/ml). Wild-type  MG63 cells incubated 
with FeQ (3.4 µl FeQ/ml) for 10 days were considered as a control. The FeCl3 
powder used in the FeQ solution was firstly investigated alone under the same 
conditions used later for the other samples, resulting non-magnetic (Figure 25).It 
was measured the FeCl3 powder and not the FeQ solution as the SQUID used in this 
experiment could measure only dry samples. 
The samples magnetisation was first investigated in a temperature-dependent 
experiment (Figure 26, panel a). The resulting plot shows a lower branch and an 
upper branch, both of them equal approximately at 20 K. Firstly, the samples were 
cooled down to the lowest temperature (5K), so that the nanoparticles were randomly 
oriented. Then, at 5K, a very low field was applied (100 Oersted, or in other 
measurement 100 millitesla) and the recording started. The samples were then heated 
very slowly up to 320 K, (lower branch of the curve). The temperature raising makes 
the nanoparticles more mobile, so they tend to orient themselves in the field, 
increasing the magnetisation of the sample. However, above a certain temperature 
(here 20 K), the Brownian motion brings so much disorder that the  nanoparticles 
start to move randomly and they disorient again, causing the magnetisation 
decreasing. In the upper branch of the curve, samples were cooled down again. In the 
beginning, the magnetisation matched very well with that of the heating curve, but a 
little above 20 K the magnetisation increased, where the heating curve dropped. 
MmsF-pcDNA/4TO transfected MG63 cells showed the higher magnetisation 
(10.5*10
-5
 emu) while mms6-pcDNA3.1 transfected MG63 cells  showed only a 
magnetisation of 7*10
-5
 emu and mms6-pcDNA3.1+ MmsF-pcDNA/4TO co-
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transfected MG63 showed a very poor magnetisation (2.2*10
-5
 emu), very similar to 
that registered for the negative controls (2.6*10
-5
emu). 
The magnetisation of the samples was then measured in a magnetic field dependent 
experiment at the fixed temperature of 310 K, corresponding to 36.85 °C, the human 
body temperature (Figure 26, panel b). Due to the cost of the experiment, in terms 
of money and time, it was chosen to investigate, for this second part of the 
experiment, only the mms6-pcDNA3.1 transfected MG63 cells and the mmsF-
pcDNA/4TO transfected MG63, which showed the higher magnetisation, 
considering the MG63 cells incubated with FeQ solution for 10 days as a control. 
The magnetic field was varied  up to 7T, maintaining constant the temperature at 
310K. The obtained magnetisation curve, although "square-shaped",  describes a 
superparamagnetic behaviour. No hysteresis was detected, therefore it can be 





Figure 25. SQUID measurement of FeCl3 powder. 
Powder was bought from Sigma Aldrich (product number 157740) and shows a paramagnetic 



















Figure 26. SQUID measurement of MG63 cells. 
Panel a: representative picture of SQUID measurements on mms6-pcDNA3.1, mmsF-pcDNA/4TO 
and mms6-pcDNA3.1+ mmsF pcDNA/4TO co-transfected MG63 cells, incubated with FeQ (3.4 µl 
FeQ/ml) for 10 days. Lower branch: zero field cooling, then the samples were heated in 100 Oe. 
Upper branch: samples were then cooled again in 100 Oe. MG63 cells cultured in a medium doped 
with FeQ (3.4 µl FeQ/ml) for 10 days were used as a control. 
 Panel b: Representative picture of field-dependent curves at fixed temperature (310 K, equal to 36.85 
ºC) on mms6-pcDNA3.1 and mmsF-pcDNA/4TO transfected MG63 cells, incubated with FeQ (3.4 µl 
FeQ/ml) for 10 days. No hysteresis loop around (0,0) point was noticed, so the samples show 
superparamagnetism. MG63 cells cultured in a medium doped with FeQ (3.4 µl FeQ/ml) for 10 days 
were used as a control. 
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3.6. Hyperthermia measurements on 
mms6-pcDNA3.1, mmsF-pcDNA/4TO 
and mms6-pcDNA3.1+ mmsF 
pcDNA/4TO co-transfected MG63 
cells. 
It was investigated if the transfection of MG63 cells with mms6-pcDNA3.1 and  
mmsF-pcDNA/4TO plasmids, alone or in combination, results in intracytoplasmic 
structures that produce HT response following application of AMF. For this reason, 
the transfected MG63 cells, 10 days after transfection and cultured in the presence of 
FeQ (3.4 µl FeQ/ml), were subjected to HT experiments. Wild-type (Plain) MG63 
and  wild-type (Plain) MG63 cultured in the presence of FeQ (3.4 µl FeQ/ml) for 10 
days were considered as negative controls. Samples were investigated under a 
magnetic field of 250 Oe and 429 kHz, using 18*10
6
 MG63 cells for each sample. 
The temperature values were recorded for 20 minutes  from the beginning of the 
measurements (Figure 27).  
In the first 300 seconds, samples temperature raised of 0.1 °C for all the transfected 
cells, which seem to have all the same magnetic behaviour. However, increasing the 
magnetic exposure time, it was noticed a different behaviour for each gene: after 
1000 seconds of exposure to the magnetic field, mmsF was the gene which conferred 
the higher magnetisation to the MG63 cells, showing a temperature rising of  1.1 °C 
compared with mms6 (+0.8°C) and mms6+mmsF genes (+0.7°C). Surprisingly, 
MG63 transfected with both the plasmids were the less magnetised cells, indicating 
that the co-transfection of MG63 cells with both the genes, does not lead to a 
summative effect of the single magnetisations. MG63 Plain and MG63+FeQ, both 








Figure 27. Hyperthermia on MG63 cells. 
Effect of AMF on the temperature of mms6-pcDNA3.1, mmsF-pcDNA/4TO and mms6-pcDNA3.1+ 
mmsF pcDNA/4TO co-transfected MG63 cells.  
Cells were cultivated in a FeQ doped medium (3.4 µl FeQ/ml) for 10 days after transfection and then 
investigated under a magnetic field of 250 Oe and 429 kHz in a time of 1200 seconds. A number of 
18*10
6 
cells was considered for each sample. Wild-type (Plain) MG63 and wild-type (Plain) MG63 





The RT-PCR results indicate that the MTB genes mms6 and  mmsF could be 
successfully expressed or co-expressed in the MG63 cells and that their translation 
into proteins leads to the creation of electro-dense structures, which are visible at 
TEM.  
When transfected MG63 cells were observed at TEM, it was noticed the presence of 
two different types of vesicles, respectively filled with dispersed and electron dense 
content. The latter ones bear resemblance to magnetosomes, but without their 
characteristic geometrical shape. The most probable inner-membrane typology these 
vesicles resemble are endosomes (appendix 8.10), possibly transformed by genes 
mms6 and mmsF in structures able to accept FeQ solution and to convert it in iron-
like crystals. TEM images of transfected cells reflect what found elsewhere (Zurkiya 
et al., 2008). Zurkiya et al. studied the effects of the expression of the MTB gene 
MagA, involved with iron transport, into the monoclonal cell line 2B5, derived from 
the human cell line 293FT and which expresses the magA gene under the control of 
the doxycycline-inducible promoter.  
The 2B5 cell line was induced and incubated with 200 μM Fe for 4 days, then 
imaged at TEM. Electron micrographs revealed the presence of vesicles very similar 
to endosomes, filled with particles and with the typical compartmentalization of the 
multivesicular bodies of the cellular degradation pathway. The particles were present 
also outside the vesicles, which were found individually or grouped and not aligned 
into chains, as seen for magnetosomes. As stated by Zurkiya et al., the lack of 
organization of the vesicles into a chain-like structure could be due to the lack of the 
presence of the other MTB genes involved in the chains organization process.  
Overall, TEM pictures from Zurkiya show cells with the same characteristics 
observed also in the  MTB gene expressing cells of this study, adding weight to the 
findings. 
There was no difference in the vesicles appearances between the different groups of 
transfected cells.  
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The investigation of the magnetism of transfected MG63 cells assessed by SQUID 
reveals a superparamagnetic behaviour, demonstrating that the expression of the 
MTB genes mms6, mmsF in MG63 cells create magnetic electro-dense structures, 
similar to the MTB observed magnetosomes. The registered SQUID magnetization 
was of the order of 10
-5
 emu, which is consistent with the measurements performed 
on natural MTB magnetosmes (Schüler, 2006)  
The Hyperthermia experiments conducted  to evaluate the response to an AMF field 
of the intracytoplasmic structures created by mms6 and mmsF gene expression inside 
MG63 cells, alone or in combination,  shown only  a  mild temperature rising for 
transfected cells compared to the negative controls. The observed rising of 
temperature is very far from the one normally observed in magnetic HT (HT is 
achieved when the temperature is  ≥42 °C), therefore it is difficult to define this 
behaviour a real "hyperthermia response" of the transfected MG63 cells to an applied 
AMF. The SQUID and the HT experiments would have benefited from a positive 
control of synthetic MNPs, i.e. SPIONS. This could have helped in defining the 
magnetic behaviour of the magnetic electron-dense structures observed in the 
transfected cells, comparing their response to the magnetic field with the chemical 








4. Evaluation of the effect of 
the transfection on MSCs 
stemness, proliferation and 
pluripotency. Expression of 
MTB genes mms6 and mmsF, 
alone or in combination, in 
human MSCs and study of the 
created intracellular 
structures by TEM, SQUID, 





The results obtained expressing the genes mms6, mmsF and co-expressing both of 
them in the MG63 cells show that it is possible to transfect a human cancer cell line 
with MTB genes, and that these genes are able to create magnetic structures inside 
the cells. 
However, the final aim of the research was to create magnetic human MSCs, so the 
subsequent step of the research was to transfect human fetal bone marrow derived  
MSCs with plasmid pcDNA 3.1 containing mms6 gene, with the plasmid 
pcDNA4/TO containing mmsF gene, and co-transfect MSCs with both the plasmids.  
To determine if the transfection of MSCs with mms6-pcDNA3.1 plasmid does lead to 
any detrimental effect on the cells, a number of experiments were carried out to 
determine if, after 21 days from transfection, the MSCs could still be considered 
stem cells and so could be employed in MHT medical experiments.  
Flow cytometry experiments and differentiation experiments were respectively 
carried out to confirm MSCs stemness and their ability to differentiate into the 
osteogenic, chondrogenic and adipogenic lineage. Incucyte ZOOM System was used 
to assess that MSCs proliferation is unchanged after transfection. Wild-type MSCs 
cultivated for 21 days in normal medium conditions and MSCs cultivated for 21 days 
in medium doped with FeQ (3.4 µM) were considered as controls. 
The expression of the mms6, mmsF and mms6+mmsF genes in MSCs was 
determined at transcript level by RT-PCR. The creation of magnetic structures, due 
to the translation of the genes into proteins, was assessed by TEM. The magnetism of 
the created structures was evaluated by Superconducting Quantum Interference 
Device (SQUID), Hyperthermia and Atomic Force Microscopy (AFM)/ Magnetic 





The aim of this chapter was to demonstrate the hypothesis that the transfection with 
plasmid mms6-pcDNA3.1 could be performed on MSCs without any adverse effect 
on MSCs stemness, proliferation and ability to differentiate into the osteogenic, 
chondrogenic ad adipogenic lineage.  
The effects of the transfection on MSCs were investigated up to 21 days post-
transfection, to determine if the MSCs properties remain unaltered, also after several 
days from transfection.  
Then, it was demonstrated that it is possible to express MTB genes mms6 and  mmsF, 
alone or in combination, in human MSCs. 
The transfected MSCs were subjected to different experiments: 
1. The MTB mms6 and mmsF gene expression, alone or in combination,  inside 
the MSCs, was confirmed by Reverse Transcription Polymerase Chain 
Reaction (RT-PCR). 
2. The morphology of the intracytoplasmic particles created in the MSCs by 
MTB mms6 and mmsF gene expression, alone or in combination, was 
analysed by Transmission Electron Microscopy (TEM). 
3. The magnetisation of MSCs expressing MTB mms6 and  mmsF genes, alone 
or in combination, was analysed by Superconducting Quantum Interference 
Device (SQUID). 
4. It was analysed if the intracytoplasmic particles created in the MSCs by MTB  
mms6 and  mmsF gene expression, alone or in combination, could produce an 









4.3.1. Flow cytometry on MSCs  
Flow cytometry was used to evaluate if MSCs are still able to express the typical 
mesenchymal stem cell surface markers 21 days after the transfection. All the cells 
analysed were at low passage (passage<10). Cell surface markers for undifferentiated 
MSCs are: ecto-5-prime-nucleotidase CD73, Thy1-antigen CD90, CD105 or 
endoglin; while negative markers for MSC are hematopoietic progenitor cell antigen 
CD34 and CD45 (common leukocyte antigen).  
It was counted the percentage of  mms6-pcDNA3.1 transfected MSCs expressing the 
surface markers CD34, CD45, CD73, CD90 and CD105, 21 days after the 
transfection and after being cultivated in medium doped with FeQ solution (34 µM). 
Wild-type MSCs cultivated for 21 days in normal medium (Plain cells) and Wild-
type MSCs cultivated in medium doped with FeQ solution (34 µM) for  21 days  
were used as controls. 
Figure 28,Figure 29 and Figure 30 show a representative picture of flow cytometry 
experiments and Figure 31 illustrates the percentage of positive cells for the 
investigated surface markers. 
Results show that 21 days after mms6-pcDNA3.1 plasmid transfection, MSCs are 
positive for CD73, CD90, CD105 (>95%) and negative for CD34 (<5%). In 
particular, there is no difference between the groups of cells in the average of the 
percentage of positive cells for surface markers CD34, CD73,CD90 and CD105, 
while the percentage of CD45 positive cells for MSCs transfected with mms6-
pcDNA3.1 plasmid for 21 days is slightly higher than 5% (7.6%).  All the groups are 






Figure 28. Representative image for flow cytometry experiment for wild-type MSCs cultured for 
21 days in standard medium (Plain cells). 
Percentage of positive cells for CD34, CD45, CD73, CD90 and CD105 markers are indicated by the 







Figure 29. Representative image for flow cytometry experiment for MSCs cultured in medium 
doped with FeQ (3.4 µl FeQ/ml) for 21 days. 
Percentage of positive cells for markers CD34, CD45, CD73, CD90 and CD105 are indicated by the 






Figure 30. Representative image for flow cytometry experiment for 21 days mms6-pcDNA3.1 
transfected MSCs. 
Percentage of positive cells for markers CD34, CD45, CD73, CD90 and CD105 are indicated by the 





Figure 31. Flow cytometry analysis on MSCs. 
a)Table and b) graph of percentages of positive cells for CD34, CD45, CD73, CD90 and CD105 
markers in wild-type MSCs cultured for 21 days (Plain), MSCs cultured in medium doped with FeQ 
solution (3.4 µl FeQ/ml) for 21 days and 21 days mms6-pcDNA3.1 transfected MSCs, cultured in 
medium doped with FeQ solution (3.4 µl FeQ/ml). Values were obtained by flow cytometry analysis. 
All the cells are negative for CD34 and CD45 (positive cells <5%), while only 21 days  mms6-
pcDNA3.1 transfected MSCs are slightly positive for CD45 (positive cells >5%). All the groups of 
cells are statistically different for CD45 marker. All the cells are positive for CD73, CD90 and CD105 
markers (cell percentage> 95%). Results are shown ± standard deviation. Statistically significant  





4.3.2. MSCs proliferation analysis 
Cells proliferation was another parameter taken into consideration to determine if the 
transfection of MSCs with mms6-pcDNA 3.1 plasmid could affect the health and the 
function of the transfected cells. Three different groups of cells were considered: 
wild-type MSCs cultured in standard medium for 21 days (Plain), wild-type MSCs 
cultivated in medium doped with FeQ  solution (34 µM)  for  21 days  and 21 days 
mms6-pcDNA3.1 MSCs transfected cultivated in medium doped with FeQ  solution 
(34 µM) for 21 days.  
The experiment was carried on for a period longer than 6 days. Figure 33 shows that 
at day number 5 (corresponding to time point 120 hours) all the cell groups reached  
>90% confluence and after this time point it was almost impossible to notice any 
difference in the cells plate coverage by visual inspection only. The mms6-
pcDNA3.1 transfected MSCs seemed to adhere to the plate surface in a smaller 
number than the other two groups at investigation time point 0, corresponding to 2 
hours after the cells seeding (Figure 32, time 0). However, in the pictures taken later, 
the transfected cells covered the plate surface in the same way than the other two 
groups (Figure 32, day 2). 
The quantitative analysis of the cells plate coverage reveals that there is no difference 
in cell proliferation of the three groups until day 3 and 4, where it was noticed a 
statistical difference (p<0.01) between mms6-pcDNA3.1 transfected MSCs and 
MSCs grown in the medium doped with FeQ for 21 days (Figure 34a). However, the 
fact that no statistical difference was observed between wild-type and mms6-
pcDNA3.1 transfected MSCs, indicates that the transfection does not affect the 
proliferation of transfected MSCs significantly. No statistical difference was noticed 
at day 5 and 6, when the plate coverage is more than  95% for all the groups. 
The results indicate that the MSCs proliferation, 21 days after transfection,  is not 
affected immediately after the cells seeding, but instead 3-4 days later, and only if 
compared to MSCs grown in the medium doped with FeQ for 21 days. Moreover, 
even if this data is not statistically relevant, it was observed that in some cases the 
transfected cells require more hours to fully cover the plate, compared to the other 
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two groups (Transfected MSCs reach >95% of confluence on day 6, one day later 
than the other two groups). Figure 34b shows a representative picture of the cell 





Figure 32. Representative image of qualitative analysis of MSCs proliferation. 
The cells investigated were wild-type MSCs cultivated in standard condition for 21 days (Plain), 
MSCs incubated with FeQ doped medium for 21 days and 21 days mms6-pcDNA 3.1 MSCs 
transfected incubated with FeQ doped medium for 21 days.  Cells were imaged at different time points 






Figure 33. Representative image of qualitative analysis of MSCs proliferation. 
The cells investigated were wild-type MSCs cultivated in standard condition for 21 days (Plain), 
MSCs incubated with FeQ doped medium for 21 days and 21 days mms6-pcDNA 3.1  MSCs 
transfected incubated with FeQ doped medium for 21 days. Cells were imaged at different time points 









Figure 34.  Incucyte ZOOM System cell proliferation analysis. 
 a) Quantitative evaluation of proliferation rate (expressed as plate coverage percentage average) of 
wild-type MSCs cultivated in standard condition for 21 days, MSCs incubated with FeQ doped 
medium (3.4 µl/ml) for 21 days, and 21 days mms6-pcDNA3.1 transfected MSCs incubated with FeQ 
doped medium (3.4 µl/ml). Cell proliferation was monitored for a time longer than 6 days. Results are 
shown as proliferation rate average with standard deviation bars. Statistically significant results are 
indicated by asterisks.  
b) Representative picture of Incucyte ZOOM System cell proliferation curve of wild-type MSCs 
cultivated in standard condition for 21 days (1), MSCs incubated with FeQ for 21 days (2) and 21 
days mms6-pcDNA 3.1 transfected MSCs incubated with FeQ for 21 days (3) over an incubation 




4.3.3. Differentiation of MSCs 
To evaluate if the transfection could cause any adverse effect on MSCs pluripotency, 
in vitro functional differentiation experiments were carried out on wild-type MSCs 
and mms6-pcDNA3.1 transfected MSCs. Both the cells groups were differentiated 
into the osteogenic, chondrogenic and adipogenic lineage using the appropriate 
medium for each lineage. The results were then compared,  using the wild-type 
MSCs as a positive control.  
4.3.4. Osteogenic Differentiation 
Wild-type and mms6-pcDNA3.1 transfected MSCs were incubated with osteogenic  
differentiation medium for 0, 10 and 21 days. After 3 weeks of incubation with the 
osteogenic differentiation medium, the successful differentiation of MSCs in 
osteoblasts was confirmed by free calcium deposits stained by the Alizarin Red dye 
(Figure 35). No difference was observed between the wild-type MSCs and the 
mms6-pcDNA3.1 transfected MSCs. 
MSCs incubated with osteogenic differentiation medium for 10 and 21 days were 
also investigated for osteocalcin (OCN) expression by immunofluorescence (Figure 
36). OCN is a protein secreted merely by osteoblasts and plays a role in bone 
mineralization and calcium ions homeostasis. For this reason, OCN is employed as a 
biochemical marker in bone formation. From Figure 36 it is possible to appreciate 
that OCN production is already detectable after 10 days of cells incubation with 
osteogenic medium, as indicated by green fluorescence.  Negative controls are shown 






Figure 35. Representative pictures of Alizarin Red staining. 
 a-c) Wild-type MSCs incubated with osteogenic differentiation medium for 0, 10 and 21 days. d-f) 
mms6-pcDNA3.1 transfected MSCs incubated with osteogenic differentiation medium for 0 days, 10 





Figure 36. Representative images of indirect immunofluorescence.  
OCN antibody staining in wild-type  and mms6-pcDNA3.1 transfected MSCs followed by Alexa 
Fluor 488-conjugated goat anti-rabbit lgG (green) secondary antibody. a) wild-type MSCs after 10 
days of incubation with the osteogenic medium; b) mms6-pcDNA3.1 transfected MSCs after 10 days 
of incubation with the osteogenic medium; c) wild-type MSCs after 21 days of incubation with the 
osteogenic medium d) mms6-pcDNA3.1 transfected MSCs after 21 days of incubation with the 
osteogenic medium. DAPI was used to stain the cell nuclei (blue). Images were taken using the 
confocal microscope. Scale bar is 50 µm. 
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4.3.5. Chondrogenic Differentiation 
Wild-type and mms6-pcDNA3.1 transfected MSCs were incubated with 
chondrogenic differentiation medium for 21 days. At day 21, the cells layers of both 
the cells groups were observed to shrink and to completely detach from the plate 
bottom, creating spheroids. Cells were then fixed in formalin 10% and stained with 
Alcian Blue to reveal any presence of aggrecan (Figure 37). Both the cells types 
showed the presence of aggrecan, indicating the correct differentiation into the 
chondrogenic lineage. No difference was observed between the wild-type MSCs and 
the mms6-pcDNA3.1 transfected MSCs. 
  
Figure 37.  Representative pictures of Alcian Blue staining. 
a) Wild-type MSCs and b) mms6-pcDNA3.1 transfected MSCs at day zero. c) Wild-type MSCs and d) 
mms6-pcDNA3.1 transfected MSCs incubated with chondrogenesis differentiation medium for 21 
days. After the staining, the plates were immediately pictured using a digital camera.  
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4.3.6. Adipogenic  Differentiation 
Wild-type and mms6-pcDNA3.1 transfected MSCs were incubated with adipogenic  
differentiation medium for  0, 10 and 21 days. At each time point, cells were fixed in 
4% paraformaldehyde and stained by Oil Red O. Pictures of cells were taken in light 
microscopy and photographed at 200x magnification in bright field, using a coloured 
camera (Figure 38). Wild-type MSCs grown in standard medium served as negative 
controls: no changes in morphology were noticed, and cells were negative for Oil 
Red O staining. In both the cell types induced for adipogenesis, at day 10, it was 
possible to appreciate the formation of lipid droplets, which became more evident at 
day 21, stained in bright red by Oil Red O. The lipid droplets size of wild-type MSCs 
appeared bigger than the mms6-pcDNA3.1 transfected, which showed an higher 
amount of tiny intracellular lipid vesicles. Overall these results confirm that wild-









Figure 38. Representative pictures of Oil Red O staining.  
a) Wild-type MSCs not induced in the adipogenesis differentiation medium (day 0); b) mms6-
pcDNA3.1 transfected MSCs not induced in the adipogenesis differentiation medium (day 0); c) wild-
type MSCs incubated with the adipogenesis differentiation medium for 10 days; d) mms6-pcDNA3.1 
transfected MSCs incubated with the adipogenesis differentiation medium for 10 days. e) wild-type 
MSCs incubated with the adipogenesis differentiation medium for 21 days, f) mms6-pcDNA3.1 
transfected  MSCs incubated with the adipogenesis differentiation medium for 21 days. After staining, 




4.4. mms6, mmsF and mms6+mmsF 
co-expression in MSCs assessment 
by RT-PCR 
It was determined whether mms6, mmsF and mms6+mmsF genes could be expressed 
in MSCs. MSCs were transfected with plasmids mms6-pcDNA 3.1, mmsF -pcDNA 
4/TO, and co-transfected with both of them. Then, the transfected MSCs were 
incubated for ten days in a FeQ doped medium (34 µM). Wild-type MSCs and wild-
type MSCs cultured for 10 days in a FeQ doped medium (34 µM) were considered as 
control. 
Ten days after the transfection, RNA was extracted from MSCs and cDNA was 
synthesised. The transfection and expression of these genes were evaluated by RT-
PCR experiments, which confirmed the mms6, mmsF and mms6+mmsF genes 
expression in transfected MSCs (Figure 39). mms6-pcDNA 3.1 and mms6-
pcDNA3.1+ mmsF-pcDNA4/TO co-transfected MSCs express the mms6 gene,  as 
indicated by the band of 108 bp (wells 3 and 5), while the wild-type MSCs, the wild-
type MSCs cultured in medium doped with the FeQ solution and the MSCs 
transfected only with mmsF-pcDNA4/TO do not express it (wells 1, 2, 4). 
The gene mmsF was present in mmsF-pcDNA4/TO transfected and in mms6-
pcDNA3.1+ mmsF-pcDNA4/TO co-transfected MSCs (wells 9 and 10), as indicated 
by the expected band of 205 bp for the pairs of primers MmsFB, called for simplicity 
MmsF, while the wild-type MSCs, the wild-type MSCs cultured in medium  doped 
with the FeQ solution and the MSCs transfected only with mms6-pcDNA3.1 do not 
express it (wells 6-8). The bands present at the bottom of the gel are due to primer 
dimer amplification and do not compromise the quality of the experiment. 
The mms6, mmsF and mms6+mmsF co-expression was normalized to the 
housekeeping gene GAPDH. The  GAPDH expression levels were found to be 
constant for all the samples (wells 13-17), as shown by the expected  band of 94 bp,  
indicating that the gel lanes have been evenly loaded with sample material.  
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Mixes Mms6, MmsF and GAPDH (wells 11,12,18) containing all the reagents for 
RT-PCR except the cDNA, were considered as negative controls for the RT-PCR 



















Figure 39. RT-PCR on MSCs. 
a) Representative image for expression of mms6, mmsF and mms6+mmsF genes in MSCs. mms6 gene 
expression was investigated for: 1) Wild-type (Plain) MSCs, 2) MSCs incubated with FeQ (34 µM) 
for 10 days, 3) mms6-pcDNA3.1 10 days transfected MSCs, 4) mmsF-pcDNA/4TO 10 days 
transfected MSCs, 5) mms6-pcDNA3.1+ mmsF-pcDNA/4TO 10 days transfected MSCs. mmsF  gene 
expression was investigated for: 6) Wild-type (Plain) MSCs, 7) MSCs incubated with FeQ (34 µM) 
for 10 days, 8) mms6-pcDNA3.1 10 days transfected MSCs, 9) mmsF-pcDNA/4TO 10 days 
transfected MSCs, 10) mms6-pcDNA3.1+mmsF-pcDNA/4TO 10 days transfected MSCs. 11) Mms6 
mix (negative control), 12) MmsF mix (negative control). 
b) GAPDH  gene expression was investigated for: 13) Wild-type (Plain) MSCs, 14) MSCs incubated 
with FeQ (34 µM) for 10 days,  15) mms6-pcDNA3.1 10 days transfected MSCs, 16) mmsF-
pcDNA/4TO 10 days transfected MSCs, 17) mms6-pcDNA3.1+mmsF-pcDNA/4TO 10 days 
transfected MSCs. 18) GAPDH mix (negative control). M= marker.  





4.5. Analysis of the intracytoplasmic 
structures formed in mms6-
pcDNA3.1, mmsF-pcDNA/4TO and 
mms6-pcDNA3.1+ mmsF-pcDNA/4TO 
co-transfected MSCs using 
Transmission Electron Microscopy 
(TEM)  
After having established that genes mms6, mmsF and mms6+mmsF were expressed 
respectively in mms6-pcDNA3.1, mmsF-pcDNA/4TO and mms6-pcDNA3.1+ mmsF-
pcDNA/4TO co-transfected MSCs, it was determined how the effect of these genes 
expression influenced the internal morphology of the MSCs using TEM. This 
technique was used to investigate if these genes are able, alone or in combination, to 
create in human MSCs the same vesicles observed for mms6, mmsF and 
mms6+mmsF expressing MG63 cells.  
mms6-pcDNA 3.1, mmsF-pcDNA 4/TO and mms6-pcDNA 3.1+ mmsF-pcDNA4/TO 
co-transfected MSCs were analysed at TEM after 10,15 and 21 days from 
transfection. The pictures were compared with the ones obtained for MSCs cultured 
in medium doped with FeQ (3.4 µl FeQ/ml) after 10 days, 15 days and 21 days of 
incubation with the solution, considered as controls.  
TEM pictures of MSCs cultured in medium doped with FeQ (34 µM) after 10 days, 
15 days and 21 days of incubation with the solution show a time-dependant 
increasing amount of vesicles containing disperse material, probably the FeQ 
solution (Figure 40).  
MSCs expressing MTB genes show vesicles filled with both dispersed (Figure 41c, 
Figure 41f, Figure 42h, Figure 42 i, Figure 43c) and electro-dense material (Figure 
41e, Figure 41h, Figure 42f, Figure 43i). The vesicles diameter could reach more 
than 1 µm in length (Figure 42 f) and each of them could encase more sub-vesicles 
filled within electron-dense content (Figure 41c, Figure 41e, Figure 41h, Figure 
42e-f, Figure 43b). No difference was noticed between the structures created in the 
mms6-pcDNA3.1 and the mmsF-pcDNA/4TO transfected MSCs. All the observed 
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vesicles are filled with the same electron-dense material and show similar shape and 
size.  mms6-pcDNA3.1+mmsF-pcDNA/4TO co-transfected MSCs vesicles, however, 








MSC+FeQ 10 days 
MSC+FeQ 15 days 
MSC+FeQ 21 days 
Figure 40. TEM pictures of MSCs cultured in medium doped with FeQ. 
Representative TEM pictures of MSCs doped with FeQ (34 µM) after 10 days, 15 days and 21 days of 
incubation with the solution.   
a-c) 10 days of incubation with the solution: single cell and particulars of the cytoplasm; d-f) 15 
days of incubation with the solution: single cell and particulars of the cytoplasm; g-i) 21 days of 
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Figure 41. TEM pictures of mms6-expressing MSCs. 
Representative TEM pictures of mms6-expressing  MSCs cultured in medium doped with FeQ 10 
days, 15 days and 21 days after the transfection.  
a-c) 10 days after the transfection: single cell and particulars of the cytoplasm; d-f) 15 days after the 
transfection: single cell and particulars of the cytoplasm; g-i) 21 days after the transfection: single cell 
and particulars of the cytoplasm. Scale bars: a) = 10 µm; b) and i) =100 nm; c), e), f), h) =500 nm; d) 








Figure 42. TEM pictures of mmsF-expressing MSCs. 
Representative TEM pictures of mmsF-expressing MSCs cultured in medium doped with FeQ 10 
days, 15 days and 21 days after  the transfection.  
a-c) 10 days after the transfection: single cell and particulars of the cytoplasm; d-f) 15 days after the 
transfection: single cell and particulars of the cytoplasm; g-i) 21 days after the transfection: single cell 
and particulars of the cytoplasm. Scale bars are: a), d), g) =2 µm; b), c), e), f), h), i)= 500 nm. 
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mms6+mmsF 
 10 days 
mms6+mmsF 
 15 days 
mms6+mmsF 
21 days 
Figure 43. TEM pictures of mms6+mmsF expressing MSCs. 
Representative TEM pictures of mms6+mmsF expressing MSCs cultured in medium doped with FeQ 
10 days, 15 days and 21 days after the co-transfection. 
a-c) 10 days after the co-transfection: single cell and particulars of the cytoplasm; d-f) 15 days after 
the co-transfection: single cells and particulars of the cytoplasm; g-i) 21 days after the co-transfection: 






4.6. SQUID measurements on mms6-
pcDNA3.1, mmsF-pcDNA/4TO and 
mms6-pcDNA3.1+mmsF pcDNA/4TO 
co-transfected MSCs  
The magnetisation of transfected MSCs was analysed by Superconducting Quantum 
Interference Device magnetometer (SQUID). The samples analysed were mms6-
pcDNA3.1, mmsF-pcDNA/4TO and mms6-pcDNA3.1+mmsF pcDNA/4TO co-





for each sample. MSCs incubated with FeQ (34 µM)  for 10 
days were used as a control. 
The time point chosen to analyse the MSCs (10 days) was the same chosen for the 
MG63 cells, to detect any consistency between the magnetic behaviour of the two 
cell types. 
The samples magnetisation was investigated in a temperature-dependent experiment 
(Figure 44). The lower branch and the upper branch of the graphs are equal 
approximately at 20 K. In order to obtain a random orientation of the nanoparticles,  
samples were cooled down to 5K and then it was applied a very low field (100 
Oersted, corresponding to 100 millitesla), beginning the magnetic recording. The 
samples were then heated very slowly up to 320 K, (lower branch of the curve). The 
magnetisation of the sample follows the temperature rising until 20 K. Above this 
temperature, magnetisation decreases, as previously seen for MG63 cells. As the 
temperature of samples was lowered again (upper branch of the curve), it was 
observed that both the magnetisation curve and the heating curve were aligned but 
then, around  20 K, the magnetisation of samples increases, while the heating curve 
decreases, according to the typical behaviour of superparamagnetic nanoparticles: the 
nanoparticles are oriented in the field, and lowering the temperature only makes the 
order stronger.  
The most magnetised cells appear to be mms6-pcDNA3.1 transfected MSCs, with  a 
magnetisation near to 6*10
-5
 emu, followed by mmsF-pcDNA/4TO transfected MSCs 
(5*10
-5





 emu). A very low magnetisation was found for MSCs incubated with FeQ 
(3.1*10
-6





Figure 44. Representative SQUID measurement of MSCs. 
 a) MSCs incubated with FeQ (3.4 µl FeQ/ml) for 10 days; b) mms6-pcDNA3.1, c) mmsF-
pcDNA/4TO and d) mms6-pcDNA3.1+ mmsF pcDNA/4TO co-transfected MSCs, all incubated with 
FeQ (34 µM) for 10 days. Lower branch: zero field cooling, then the samples were heated in 100 Oe. 








4.7. Hyperthermia measurements on 




transfected MSCs  
The magnetism of the intracytoplasmic vesicles created within MSCs transfected 
with plasmids mms6-pcDNA3.1, mmsF-pcDNA/4TO and mms6-pcDNA3.1+ mmsF-
pcDNA/4TO, 10 days after transfection, and incubated in medium doped with FeQ 
solution (34 µM)  was investigated by HT experiments.  Wild-type MSCs cultured in 
standard medium for 10 days and wild-type MSCs incubated in medium doped with 
FeQ solution (34 µM) for 10 days were considered as controls. Samples were 
investigated under a magnetic field of 250 Oe and 429 kHz, using 4.5x10
6
 cells for 
each sample. The rising of temperature was investigated until 750 seconds after the 
beginning of the experiment (Figure 45). 
It was noticed a modest temperature rising in the transfected MSCs. In the first 150 
seconds, samples temperature raises of 0.1 °C for all the transfected cells, which 
seem to have all the same magnetic behaviour. Increasing the magnetic exposure 
time, the higher temperature rising was determined in this case by the mms6 gene, 
which leads to a cell temperature rising of  +0.3 °C after 7 minutes, +0.5 °C after 8.5 
minutes and up to +0.6 °C after 10 minutes, proving to be the most magnetising 
gene. Results show that MSCs co-expressing both the mms6+mmsF genes are 
slightly more magnetised than mmsF expressing MSCs, but both the cell types show 
a temperature rising of less than +0.4 °C after 10 minutes from the exposure to the 









Figure 45. Representative picture of hyperthermia measurements on MSCs. 
Cells investigated were mms6-pcDNA3.1, mmsF-pcDNA/4TO and mms6-pcDNA3.1+mmsF-
pcDNA/4TO co-transfected MSCs in a magnetic field of 250 Oe and 429 kHz in a time of 750 






4.8. Transmission Electron Microscopy 
(TEM) analysis of the 
intracytoplasmic structures formed 
within mms6-pcDNA3.1 transfected 
MSCs  
Both the SQUID and the hyperthermia measurements confirmed that mms6 is the 
gene which confers the higher magnetisation to MSCs, and TEM pictures indicated 
that mms6 is also responsible for the creation of magnetic vesicles filled with 
electron-dense material inside the mms6-expressing MSCs. 
Following these findings, it was necessary to understand if the passing of time after 
transfection could influence the number of vesicles created inside the mms6-
pcDNA3.1 transfected MSCs as well as the percentage of electron-dense content 
found in each cell. 
The expression of mms6 gene in mms6-pcDNA3.1 transfected MSCs was confirmed 
by RT-PCR experiments at the different time points taken in consideration for TEM 
vesicles analysis (Figure 46). mms6 genes is expressed in MSCs after 10, 15 and 21 
days from transfection, as  indicated by the band of 108 bp present in wells 5-7, 
while it was absent in the wild-type MSCs and in the wild-type MSCs incubated with 
medium doped with FeQ solution for 10,15 and 21 days (wells 1-4). GAPDH 
expression levels were found to be constant for all the samples, as shown by the 
expected  band of 94 bp (wells 8-14),  indicating that the gel lanes have been evenly 
loaded with sample material.  
Mms6 and GAPDH mixes without cDNA (wells 15 and 16)  served as negative 
controls and show no bands, indicating no contamination in the RT- PCR mixes. 
The results of  the ImageJ analysis of TEM pictures of mms6-pcDNA transfected 
MSCs at 10, 15 and 21 days are shown in a time-dependent graph (Figure 47, Panel 
A). The average of the number of vesicles formed by the mms6 gene at day 21 
respect to day 15 is statistically significant (p<0.05). 
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For each vesicle, it was also calculated the percentage of  electron-dense filling 
respect to the vescicle area, then the average was calculated, considering 10 pictures 
for each time point. The results are shown in a time-dependent graph (Figure 47, 
Panel B), where the percentage of electron-dense material created at day 15 and at 
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Figure 46.  mms6 expression in MSCs at different time points. 
1. A) Mms6 mix: 1) Wild-type MSCs, 2) MSCs incubated with FeQ for 10 days, 3) MSCs incubated 
with FeQ for 15 days, 4) MSCs incubated with FeQ for 21 days, 5) 10 days mms6-pcDNA3.1 
transfected MSCs, 6) 15 days mms6-pcDNA3.1 transfected MSCs, 7) 21 days mms6-pcDNA3.1 
transfected MSCs. B) GAPDH mix: 8) Wild-type MSCs, 9) MSCs incubated with FeQ for 10 days, 
10) MSCs incubated with FeQ for 15 days, 11) MSCs incubated with FeQ for 21 days,  12) 10 days 
mms6-pcDNA3.1 transfected MSCs, 13) 15 days mms6-pcDNA3.1 transfected MSCs, 14) 21 days 
mms6-pcDNA3.1 transfected MSCs. 15) Mms6 mix (negative control), 16) GAPDH mix (negative 
control). M= marker. 




Figure 47. Analysis of vesicles investigated at TEM. 
 Panel a. Average of the vesicles number at different time points (10, 15 and 21 days) after MSCs 
transfection with mms6-pcDNA3.1 plasmid. Panel b: Average of the percentage of electron-dense 
material found in vesicles at different time points (10, 15 and 21 days) after MSCs transfection with 
mms6-pcDNA3.1 plasmid. Results are indicated as average with standard deviation error bars. One-
way ANOVA test was used for statistical significance, followed by post hoc Tukey test between 
groups when a statstical difference was found; a value of p<0.05 was considered statistically 
significant; n=10. Asterisks indicate statistical significance. 
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4.9. Magnetic Force Microscopy (MFM)  
on mms6-pcDNA3.1 transfected  
MSCs 
SQUID measurements revealed that mms6 is the gene able to confer the highest 
magnetism to MSCs. To have a further confirmation of the mms6-pcDNA3.1 
transfected MSCs magnetism, these cells were investigated by Magnetic Force 
Microscopy (MFM) after 10, 15 or 21 days from the transfection with mms6-
pcDNA3.1 plasmid, to understand if the prolongation of the incubation time with the 
FeQ solution after the transfection could influence MSCs magnetism. 
MFM was used in these experiments to detect the presence of superparamagnetic 
nanoparticles created in mms6-pcDNA3.1 transfected MSCs by the expression of 
MTB mms6  gene in the MSCs. The surface of the samples was investigated by AFM 
in semi-contact mode, to detect any roughness corresponding to nanoparticles 
aggregates, which were then subjected to MFM measurement to determine their 
magnetisation. 
The experiments were performed using a magnetic probe in dynamic lift mode to 
detect the presence of nanoparticles in the presence of a weak external magnetic field 
(a few hundreds of Gauss). The observed magnetisation was very weak for 10 days 
mms6-pcDNA3.1 transfected MSCs (Figure 48), while it was observed a stronger 
magnetisation after 15 and 21 days respectively from transfection of MSCs with 
mms6-pcDNA3.1 (Figure 49 and Figure 50), indicating a time-dependent 
magnetisation process. 
In Figure 48, corresponding to 10 days mms6-pcDNA3.1 transfected MSCs, it was 
detected a small magnetic signal, pointed by arrow (Figure 48 b, and magnification 
of the signal in Figure 48 d).  In Figure 49, where the 15 days mms6-pcDNA3.1 
transfected MSCs were analysed, the magnetism increases (Figure 49 d). In Figure 
50, negative and positive signal contrasts are detected in correspondence of 
intracellular aggregates of 21 days mms6-pcDNA3.1 transfected MSCs, resulting in 
fraction/few degrees phase shifts, hence clearly detectable in the setup. It should be 
noticed that the magnitude of the cantilever deflection versus the tip-sample distance 
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follows the attenuation law typically observed when the lift distance is brought far 
from the Van Der Waals regime (Schreiber et al., 2008), hence confirming that it was 
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Figure 48. AFM/MFM of 10 days mms6-pcDNA3.1 transfected MSCs.  
Topographic AFM image obtained in semicontact mode (a) and its corresponding MFM phase image 
(b). c) magnification of semicontact mode, d) magnification of MFM  phase.  At this stage is possible 










Figure 49. AFM/MFM of 15 days mms6-pcDNA3.1 transfected MSCs.  
Topographic AFM image obtained in semi-contact mode (a, b, c) and its corresponding MFM phase 
image (d),  z scales: c) magnification of semi-contact mode (0 - 120 nm); d) (-3.0 to +2.5 degrees) at 
100 nm lift distance.  The magnetic intracellular aggregates are indicated by the arrow. Scale bars are 






Figure 50. AFM/MFM of 21 days  mms6-pcDNA3.1 transfected MSCs. 
 Topographic AFM image obtained in semi-contact mode (a) and its corresponding MFM phase image 
(b), obtained at 30 nm lift distance. Positive and negative signal contrast corresponding to intracellular 





In this chapter, it was determined if: 
1.  the transfection of MSCs with mms6-pcDNA3.1 could cause any 
detrimental effect on the cells by investigating MSCs stemness, MSCs 
proliferation and MSCs pluripotency 21 days post transfection; 
2. it is possible to express MTB genes mms6 and mmsF, alone or in 
combination, in human MSCs and if the genes expression inside the human 
MSCs creates magnetic structures. 
Regarding the point 1, flow cytometry experiments revealed that the MSCs stemness 
remains unchanged before and after transfection, except for the marker CD45, whose 
presence was found slightly higher in 21 days transfected MSCs. 
Also the study of the MSCs proliferation, that was investigated either qualitatively 
than quantitatively by the device Incucyte ZOOM System, revealed no remarkable 
differences between the three groups of MSCs analysed. 
MSC multipotency was tested by inducing the wild-type and the transfected MSCs in 
the osteogenic, chondrogenic and adipogenic lineage. After 21 days from 
differentiation induction, both the cell types were able to differentiate into the 
different cell lineages, as suggested by staining procedures of the typical 
differentiation markers for each lineage.  
Taken together these evidence show that 21 days post transfection with mms6-
pcDNA3.1 plasmid, the MSCs nature is unaffected by the expression of the bacterial 
genes. 
Gross differentiation defects were not detected, however, scientific evidence suggest 
that MSCs labelled with SPIONS show an impaired chondrogenesis and osteogenesis 
(Y. C. Chen et al., 2010; Kostura et al., 2004). It would be useful to compare the 
transfected cells with the wild-type ones,  analysing the expression of the major 
genes involved in the three considered differentiation pathway by qPCR. Another 
way to determine if the transfection could affect MSCs stemness and differentiation 
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ability could be to find the transcriptional differences among transfected and wild-
type cells by RNA deep sequencing (RNAseq), a technique which is used to find 
differences in levels of expression and structure of RNA (Goldman & Domschke, 
2014; Roson-Burgo et al., 2014).  
Although in this work the genome or the transcriptome of the transfected cells were 
not deeply analysed, there are previous studies by Goldhawk et al. which show that it 
is possible to transfect mouse and human cancer cell lines with magA, a MTB 
putative iron transporter gene, without affecting cells viability or proliferation. 
(Goldhawk et al., 2009; Sengupta et al., 2014). The viability of transfected cells and 
their capacity for active transport of iron were assessed by MTT assay and by 
measuring ATP content respectively. As magA is a gene which seems to share a lot 
of traits in common with mms6 -one above all the capacity to confer to the 
transfected cells the ability to become magnetic- these findings are encouraging also 
for the application of mms6 in human cells. 
 
 
Regarding point 2, RT-PCR experiments confirmed the expression of MTB genes 
mms6 and mmsF, alone or in combination, inside MSCs, validating the transfection 
success. 
TEM investigations revealed the presence of two types of intracytoplasmic vesicles, 
respectively inside wild-type MSCs cultured in FeQ doped medium and in the mms6-
pcDNA3.1, mmsF-pcDNA/4TO and mms6-pcDNA3.1+ mmsF-pcDNA/4TO co-
transfected MSCs. While the former contain disperse material (Figure 40f), the latter 
ones are filled with electron-dense content, indicating that FeQ solution uptake 
occurs in all the cells, but only the transfected ones can modify the FeQ solution in 
dense granules (Figure 41e, Figure 41f, Figure 42b). The observed vesicles are 
similar to the MG63 cells ones, and their shape resembles endosomes or lysosomes, 
as previously observed for the MG63 cells. The vesicles create spherical, 
multilamellar and multivesicular structures with the passing of time (Figure 41f), a 
process occurring when the intracellular vesicles age. These features, together with 
the lacking of tubules and the close-packed luminal vesicles, are typical of late 
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endosomes and lysosomes (appendix 8.10). The ImageJ analysis of the 
intracytoplasmic vesicles imaged at TEM of mms6 expressing MSCs reveals that  the 
number of the detected vesicles increases at day 21, while the percentage of electron 
dense material inside the vesicles increases at day 15 respect to day 10 to remain 
constant at day 21. 
SQUID analysis reveals that both MSCs and MG63 transfected cells show the same 
power of magnetisation (10
-5
), indicating a consistency in the magnetic behaviour 
after being transfected with the MTB genes. In MSCs, the higher magnetisation was 
registered for mms6-pcDNA3.1 transfected MSCs. 
The response of the intracytoplasmic vesicles of the transfected MSCs to an applied 
AMF was studied with the Hyperthermia experiments. The  measured rising of 
temperature for MSCs is very far from the one normally observed in MHT (≥42 °C) 
but it was noticed a mild temperature rising for transfected cells respect to the 
negative controls. The temperature rising observed for the transfected MSCs is in 
line with that registered for the MG63 transfected cells. However, for the MSCs, the 
temperature increasing is slightly lower than the cancer cell line. This behaviour 
could be due to the fact that the number of MSCs analysed by the hyperthermia 
experiment were less than the number of MG63 employed for the same experiment 
(4.5*10
6
 MSCs against 18*10
6
 MG63 cells). The higher temperature rising in MSCs 
was registered for mms6 expressing MSCs. 
The magnetism of mms6-pcDNA3.1 transfected MSCs was also confirmed by 
AFM/MFM measurements. MFM technique can detect the magnetic interaction 
between a probe and superparamagnetic nanoparticles in ambient condition. The 
superparamagnetic nanoparticles buried in a cell tissue cause weak cantilever 
deflection when a magnetic probe is brought close to the surface. MFM detects local 
phase shift of the cantilever oscillations as the tip scans across the sample, at a lift 
distance that is pre-determined to maximise such deflection; hence the detection of a 
non-zero signal is a signature of magnetic clusters/particles at the surface.  
It should be underlined that positive or negative phase variations detected within the 
intracellular medium, associated with the presence of superparamagnetic 
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particles/aggregates, are usually very small (less than a few degrees). Indeed, isolated 
20-200 nm large clusters of magnetic nanoparticles have shown the resulting net 
magnetisation corresponding to weak superparamagnetic signal contrast (less than 1 
degree phase variations when a magnetic field of few hundred Gauss is applied) 
(Schreiber et al., 2008). In the experiments, it was registered a genuine magnetic 
contrast, that was higher for 21 days mms6-pcDNA3.1 transfected MSCs. The 
increasing magnetism revealed at day 21 could depend on the higher number of 
vesicles found inside the 21 days transfected MSCs, together with the higher 
percentage of electro-dense material that the cells show at this time point, as revealed 
by the ImageJ analysis. 
Although the mechanism by which mms6, as a single gene, is able to provide the 
human cells with magnetic properties is still obscure, there are some specific 
properties of the Mms6 protein which could justify its ability to confer such 
fascinating properties to the cells. 
Mms6 was described as a protein able to bind iron and generate uniform magnetic 
crystals (Prozorov et al., 2007), with a high affinity for iron ions and bearing 
negative charges which give to the protein the peculiar ability to self-assemble and 
which make it a key regulator of crystal size and morphology (Amemiya et al., 2007; 
Arakaki et al., 2010; Arakaki et al., 2014). 
Moreover, Mms6 is not the only protein able to confer magnetic properties to 
mammalian cells. As previously said, the expression of the gene MagA into 
mammalian cells was found able to increase the iron retention and to create magnetic 
structures inside mouse and human cancer cells, as well as in human embryonal 
kidney cell line. The magnetic structures generated by MagA in the cells generated 
contrast at MRI of 11T, making it a reporter gene for MRI applications (Goldhawk et 
al., 2009; Sengupta et al., 2014; Zurkiya et al., 2008). These evidence support the 
idea that a single gene could be sufficient to impart magnetic properties to 
mammalian cells. 
Overall, it could be inferred from these experiments that: 
- mms6 gene could be expressed in MSCs; 
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- mms6 is responsible for the creation of intracytoplasmic vesicles in MSCs, 
which contain magnetic material; 
- the mms6-pcDNA3.1 transfected MSCs magnetism increases with the passing 
of time and reaches the higher value at day 21, which is the longest observed 
time in this experiment. 
Taken together, this findings suggest that mms6 expressed alone in MSCs gives the 










5. In vitro application of an 
AMF of 565.3 kHz on cell 
cultures arranged in 








In this chapter it was assessed whether the MNPs created inside the 21 days mms6-
expressing MSCs, called for simplicity mms6-expressing MSCs, could support an 
AMF of 565.3 kHz frequency in vitro, and if the effects of this interaction could 
induce MSCs cytotoxicity or death.  
The effects of the exposure were studied firstly on mms6-expressing MSCs 
monolayers and secondly on 3D cell population models. In the first case, the effect of 
the AMF exposure on cell viability was investigated by AlamarBlue Cell Viability 
Assay, whereas the cytotoxicity was assessed by Pierce LDH Cytotoxicity Assay. In 
the case of 3D cell population models, cell death was determined by Trypan Blue 
Exclusion Dye. 
Afterwards, in the attempt to create an in vitro model of an in vivo situation, in which 
MSCs are injected inside a tumour tissue and then subjected to an AMF application,  
3D models of mixed population of mms6-expressing MSCs and tumour cell lines 
MG63 cells and A431 ecad-GFP expressing squamous carcinoma cells were created 
and subsequently exposed to an AMF of 565.3 kHz frequency. The effects of the 
AMF on cell viability were studied using AlamarBlue Cell Viability Assay and 
Trypan Blue Exclusion Dye. In the case of  3D mixed population of  mms6-
expressing MSCs and MG63 cells, Trypan Blue Exclusion Dye results were also 
supported by fluorescent microscopy pictures analysis.  In the case of  the 3D mixed 
population of  mms6-expressing MSCs and A431 ecad-GFP expressing cells, the 
green fluorescence blur of GFP protein expressed by A431 ecad-GFP expressing 
cells made impossible to obtain quality fluorescent pictures to support the cell 
viability results, therefore they have been omitted from the chapter.  
Each test was repeated in three independent experiments.  For each experiment, a 
different flask of transfected cells, 21 days from transfection, was used. This was 
done to test if different batches of transfected cells were able to react in the same 





The hypothesis underlying the presented study was that MNPs created inside the 
mms6-expressing MSCs could support a MH effect when exposed to an AMF of 
565.3 kHz frequency, which could induce MSCs cytotoxicity or death in vitro either 
when they are arranged in a monolayer or 3D models. It was also hypothesised that, 
in the case of co-culture of mms6-expressing MSCs with cancer cells, the interaction 
of MNPs with the AMF is sufficient to induce the death of the neighbouring cancer 
cells.  
The effects of the interaction of the MNPs created inside the mms6-expressing MSCs 
with the AMF of 565.3 kHz frequency were studied investigating cell viability, cell 
cytotoxicity and cell death, using different assays: 
 In the case of mms6-expressing MSCs cell monolayers, cell viability was 
investigated by AlamarBlue Cell Viability Assay and cells cytotoxicity was 
assessed by Pierce LDH Cytotoxicity Assay.  
 In the case of mms6-expressing MSCs arranged in 3D models, cell death was 
determined by Trypan Blue Exclusion Dye. 
 In the case of  3D co-cultures  of mms6-expressing MSCs and MG63 cells, 
cell death was assessed by Trypan Blue Exclusion Dye and results were 
supported by  fluorescent microscopy pictures. 
 In the case of 3D mixed populations of mms6-expressing MSCs and A431 





5.3.1. The effect of one hour 565.3 kHz AMF on mms6-
expressing MSCs arranged in a monolayer. 
Determination of cell cytotoxicity by LDH Cytotoxicity 
Assay  
mms6-expressing MSCs seeded in Petri dishes in a monolayer were exposed  at 
565.3 kHz frequency for one hour, followed by Pierce LDH Cytotoxicity Assay. This 
frequency was chosen as it appeared the most effective, among the frequencies 
investigated, to determine cell death (appendix 8.13). 
The results of the experiments are illustrated in Figure 51, where the percentage of 
LDH cytotoxicity registered for the exposed cells is 44.4±1.9%, while for controls is 
5.5±0.8%. The results are statistically significant (p<0,0001) and reveal that one hour 
exposure to an AMF of 565.3 kHz frequency leads to a cytotoxic effect on the mms6-






Figure 51. Cell cytotoxicity evaluation by Pierce LDH Cytotoxicity Assay. 
mms6-expressing  MSCs were exposed at 565.3 kHz for one hour (grey column) or not exposed 
(controls-white column). Average of cytotoxicity of three independent experiments with standard 




5.3.2. The effect of one hour 565.3 kHz AMF on mms6-
expressing MSCs, arranged in a monolayer. 
Determination of cell viability by AlamarBlue Cell Viability 
Assay.  
mms6-expressing MSCs seeded in Petri dishes in a monolayer were exposed at 565.3 
kHz frequency for one hour, followed by cells viability determination by 
AlamarBlue Cell Viability Assay (Figure 52).  
In Figure 52a, Alamar Blue fluorescence intensity average of cells exposed to AMF 
is 51928±2716, against mean fluorescence intensity of 76060±1352 for unexposed 
ones (controls). The results are statistically significant (p<0.001). Cell viability 
percentage of exposed cells was calculated as a ratio between exposed and controls 
cells, and it is shown in Figure 52b, considering controls as 100% viable. Results 
reveal that the viability of exposed cells is 68.27±4.78% of that of controls. 
As a control, also wild-type MSCs were seeded in Petri dishes in a monolayer and 
then they were exposed at 565.3 kHz frequency for one hour, followed by cells 
viability determination by AlamarBlue Cell Viability Assay (Figure 53). The wild-
type MSCs were not doped with FeQ. Alamar Blue fluorescence intensity average of 
wild-type cells exposed to AMF is 61453±907, against mean fluorescence intensity 
of 62350±1778 for unexposed ones (controls). The results reveal that wild-type 
MSCs viability does not change after AMF exposure (exposed wild-type cells 













Figure 52. Cell viability evaluation by AlamarBlue Cell Viability Assay. 
mms6-expressing MSCs were exposed at 565.3 kHz for one hour (grey column) or not exposed 
(controls-white column). a) Average of fluorescence intensity of three independent experiments with 
standard deviation error bar, p<0.001. b) Average of three independent experiments of cell viability 




Figure 53. Cell viability evaluation by AlamarBlue Cell Viability Assay. 
Wild-type MSCs were exposed at 565.3 kHz for one hour (grey column) or not exposed (controls-
white column). The wild-type MSCs were not doped with FeQ. a) Average of fluorescence intensity 
of three independent experiments with standard deviation error bar. b) Average of three independent 
experiments of cell viability percentage of exposed cells against controls with standard deviation error 




5.3.3. Bright field microscopy investigation of the effect of the 
exposure for one hour to an AMF of 565.3 kHz frequency 
on Plain MSCs and mms6-expressing MSCs, arranged in 
a monolayer. 
The effect of AMF exposure at 565.3 kHz frequency on monolayers of mms6-
expressing MSCs was also investigated by bright field microscopy (Figure 54 and 
Figure 55). The cells taken in consideration were respectively: 
 Wild-type MSCs, exposed at 565.3 kHz frequency for one hour; 
 Wild-type MSCs, unexposed; 
 mms6-expressing MSCs, exposed at 565.3 kHz frequency for one hour;  
 mms6-expressing MSCs, unexposed.  
Bright field pictures indicate, by visual inspection, no differences  between  exposed 
and unexposed Plain MSCs arrangement (Figure 54a, b). mms6-expressing MSCs 
subjected to AMF treatment agglomerated in bunches, where dark spherical 
structures were observed (Figure 55a-f), while the unexposed mms6-expressing 
MSCs showed a regular pattern (Figure 55g). Moreover, in some points of the Petri 
dish, the entire layer of mms6-expressing MSCs subjected to AMF exposure 
detached from the plate bottom, leaving spots of the Petri dish completely uncovered 
from the cell monolayer (Figure 55a-f). This could be interpreted as a possible 










Figure 54. Bright field microscopy of wild-type MSCs.  
a) Cells exposed to an AMF of a frequency of 565.3 kHz for one hour; b) Cells unexposed to the AMF 
(controls). The wild-type MSCs were not doped with FeQ. Scale bar is 100µm. 
 
Figure 55. Bright field microscopy of mms6-expressing MSCs. 
a-f) Pictures of different Petri dishes containing mms6-expressing MSCs, arranged in a monolayer, 
exposed at 565.3 kHz for one hour and g) unexposed. It is possible to notice the tendency of the cells 
to accumulate in distinct points of the Petri dish, leaving around empty spots, where the layer of cells 
detaches from the Petri dish bottom (e, f). This behaviour was not observed for mms6-expressing 
MSCs unexposed to AMF, which show a regular pattern of distribution and fewer nanoparticles 
accumulation (g). Scale bar =100µm. 
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5.3.4. The effect of one hour 565.3 kHz AMF on 3D cultures of 
mms6-expressing MSCs. Treatment was repeated twice 
and followed by cell viability assessment by Trypan Blue 
Exclusion Assay. 
It was evaluated if an AMF of 565.3 kHz frequency applied on 3D cultures of  
mms6-expressing MSCs for one hour can cause cell death, investigated by Trypan 
Blue assay. In this experiment, due to the 3D arrangement of cells forming thick 
pellets, it was chosen to duplicate the AMF exposure, so the day after the first 
exposure, 3D cell pellets were exposed again at 565.3 kHz for 1 hour (double 
exposure). 
Trypan Blue assay shows a cell death percentage in 41.0 ± 9.5% of cell population 
exposed to AMF, while unexposed (controls) cells show a cell death percentage of 
9.3± 2.6 % (Figure 56). The results are statistically significant (p<0.01). 
  
Figure 56. Cell death evaluation by Trypan Blue assay. 
In vitro 3D cultures of mms6-expressing MSCs were exposed at 565.3 kHz for one hour twice (grey 
column) or not exposed (controls-white column). Average of Trypan Blue cells staining of three 
independent experiments with standard deviation error bars, p<0.01. 
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5.3.5. The effect of one hour 565.3 kHz AMF on 3D co-cultures 
of mms6-expressing MSCs and MG63 cells. Treatment 
was  repeated three times and followed by cell viability 
assessment by Trypan Blue Exclusion Assay. 
The aim of this experiment was to investigate the effect of an AMF of 565.3 kHz 
frequency on 3D co-cultures composed of mms6-expressing MSCs and MG63 cells, 
at 1:2 and 1:4 ratio. In total, the 3D mixed cell populations were exposed for one 
hour at 565.3 kHz frequency three times in two days. 
Trypan Blue assay showed a cell death percentage for ratio 1:2 respectively of 
39.8±3.7% for exposed cells and of 11.7±2.1% for control cells (Figure 57a). For 
ratio 1:4, exposed cells showed a death percentage of  43.5±4.0%, while for the 
controls it was 8.9±2.9% (Figure 57b). For both the studied ratios, exposed cells and 
controls cells are statistically different (p<0.001), but it was found no statistical 








Figure 57. Cell death evaluation by Trypan Blue Exclusion Assay. 
In vitro 3D cultures of mms6-expressing MSCs and MG63 cells were exposed at 565.3 kHz for one 
hour three times in two days (grey column) or not exposed (controls-white column). Two different 
MSCs/MG63 ratio were considered, 1:2 (a) and 1:4 (b). Average of Trypan Blue cells staining of three 
independent experiments with standard deviation error bars, p<0.001. 
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5.3.6. The effect of one hour 565.3 kHz AMF on 3D co-cultures 
of mms6-expressing MSCs + A431 ecad-GFP expressing 
cells. Treatment was repeated three times and followed 
by AlamarBlue Cell Viability Assay. 
In this experiment it was determined the effect of AMF exposure of 565.3 kHz 
frequency, on 3D co-cultures of mms6-expressing MSCs and A431 ecad-GFP 
expressing cells. In total, the 3D mixed cell populations were exposed for one hour at 
565.3 kHz frequency three times in two days. For these experiments, the chosen 
working ratio MSCs/A431 ecad-GFP expressing cells was 1:2. Cell viability was 
determined by AlamarBlue Cell Viability Assay (Figure 58). In Figure 58a, Alamar 
Blue fluorescence intensity average of cells exposed to AMF is 6664±1104, against 
mean fluorescence intensity of 14725±2120 for controls. The results are statistically 
significant (p<0.05). Cell viability percentage of exposed cells was calculated as a 
ratio between exposed and controls cells and it is shown in Figure 58b, considering 
controls as 100% viable. Results reveal that the viability of exposed cells is 















Figure 58. Cell viability evaluation by AlamarBlue Cell Viability Assay. 
3D co-cultures of mms6-expressing MSCs/A431 ecad-GFP expressing cells, at ratio 1:2, were exposed 
three times for one hour at 565.3 kHz frequency (grey column) or not exposed (controls, white 
column).  
a) Average of fluorescence intensity of three independent experiments with standard deviation error 
bar, p<0.01. b) Average of cell viability percentage of exposed cells against controls of three 




5.3.7. Fluorescent microscopy on 3D co-cultures of CellTracker 
CM-Dil Red stained mms6-expressing MSCs and 
CellTracker Green CMFDA Dye stained MG63 cells at 1:2 
ratio. 
To support the results obtained by the Trypan Blue Exclusion Assay, the effects of 
the AMF exposure of 565.3 kHz on 3D cell populations created by co-culturing 
mms6-expressing MSCs and MG63 cells in tubes, at 1:2 ratio, were investigated also 
by fluorescent microscopy (Figure 59). To distinguish the cells in fluorescent 
microscopy, red MSCs were stained with CellTracker Red CM-DiI Dye and green 
MG63 cells were stained with CellTracker CM-DiI Green CMFDA Dye, and all the 
cells nuclei were DAPI stained, as explained in the Materials and Methods section. 
3D co-cultures were exposed for one hour at 565.3 kHz frequency three times in two 
days and compared with not exposed co-cultures (controls). 
From the visual inspection of fluorescent microscopy pictures (Figure 59) it is 
possible to notice that the number of AMF exposed cells (Figure 59, panel c and d) 
appear reduced  respect to the number of not exposed cells(Figure 59, panel a and 
b). Also, the green cells (cancer cells) appear to be less in AMF exposed cells 
(Figure 59, panel c and d) respect to the not exposed ones (Figure 59, panel a and 
b). 
It was also determined: 
 The number of the total cells in the exposed tubes compared to the total cells 
in control tubes (Figure 60); 
 The ratio of MG63 cells/total cells in the exposed tubes, compared to 
unexposed controls (Figure 61). 
 The number of MG63 cells in exposed  tubes, compared to the number of 
MG63 cells in control tubes (Figure 62). 
Due to the sparse cytoplasmic distribution of red staining, it was difficult to precisely 
count the MSCs, so for this reason it was preferred to do not include the MSCs 







Figure 59. Representative fluorescence pictures of co-cultures of mms6-expressing MSCs and 
MG63 cells.   
a, b) cells not exposed to AMF; c, d) cells seeded in Petri dishes following 565.3 kHz 
exposure of one hour repeated three times. Not exposed cells (a, b) are visually more 
in number than exposed cells (c, d). Less green cells (cancer cells) are observed in 
AMF exposed cells (c,d) compared to not exposed cells (a,b).Scale bar=50 µm 
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The results indicate that: 
a) the average of the total nuclei (mms6-expressing MSCs + MG63 cells) of the 
AMF exposed cells is reduced by 60% compared to controls (average of 
306±177 total nuclei in the AMF exposed cells against 757± 207 total nuclei 
counted in controls- Figure 60).  
b) The ratio of MG63 cells/total cells in the AMF exposed cells is 
fundamentally unchanged by the treatment (0,58±0.08 in the AMF exposed 
tubes against 0,60±0.14 in the controls), as indicated in Figure 61. 
c) The number of MG63 cells counted in the AMF exposed cells is reduced by 
63% respect to controls (167± 76 in the AMF exposed tubes against 454± 139 
in controls - Figure 62).  
Results a) and c) are statistically significant (p<0.05). The result b) is not 
statistically significant (p>0.05). 
 Figure 60.  Effect of AMF on the total cell nuclei number. 
3D co-cultures of mms6-expressing MSCs/MG63 cells at 1:2 ratio were exposed at 565.3 kHz 
frequency (grey column) or not exposed (controls, white column).  Cells were seeded in quadruplicate 
and experiments were repeated 3 times. Statistical analysis was carried out using Student-t test. 













Figure 62.  Effect of AMF on MG63 cells number. 
3D co-cultures of mms6-expressing MSCs/MG63 cells at 1:2 ratio were exposed at 565.3 kHz 
frequency (grey column) or not exposed (controls, white column). Cells were seeded in quadruplicate 
and experiments were repeated 3 times. Statistical analysis was carried out using Student-t test. 
Results are shown with standard deviation error bars, p<0.05. 
 
 
Figure 61. Effect of AMF on the ratio MG63/total cell nuclei. 
3D co-cultures of mms6-expressing MSCs/MG63 cells at 1:2 ratio were exposed at 565.3 kHz 
frequency (grey column) or not exposed (controls, white column). Cells were seeded in quadruplicate 
and experiments were repeated 3 times. Statistical analysis was carried out using Student-t test. 





In this chapter, experiments were aimed to evaluate, in vitro, the effects of an AMF 
exposure applied firstly on single layers of mms6-expressing MSCs, and then on 3D 
systems created by mms6-expressing MSCs alone or co-cultured with cancer cells 
(MG63 and A431 ecad-GFP expressing cells respectively). 
As declared by Rabin, the nanoparticles retained inside a single cell are not sufficient 
to create the HT killing effect; however, it could be reached if the nanoparticles are 
present in an area of at least 1.1 mm diameter, either inside or outside the 
intracellular environment (Rabin, 2002). It is believed that nanoparticles, singularly 
or concentrated inside vesicles, deliver heat and cause cell damages, membrane 
breaking, apoptosis (J. Zhang et al., 2011) and cell necrosis (Asin et al., 2012). The 
effects of an AMF on MNPs loaded exposed cells have been investigated in previous 
studies by viability assays and LDH assay, as LDH is an indicator of loss of 
membrane integrity, of cell necrosis (Chan et al., 2013) and it is extremely sensitive 
to determine the completely lysed cells (Attar & Haghpanahi, 2016; Quinto et al., 
2015; Yan et al., 2014; J. Zhang et al., 2011). In this study, cell viability and cell 
death were determined by Alamar Blue assay and by Trypan Blue assay, while the 
loss of cell membrane integrity for single layers of mms6-expressing MSCs exposed 
to AMF was evaluated by LDH assay.  
The results of experiments performed on monolayers of mms6-expressing MSCs 
exposed for one hour at 565.3 kHz show that the AMF exposure causes cytotoxicity 
for the 44.4 ±1.9%, of the cells, while only 5.5±0.8%. of controls show cytotoxicity. 
Moreover, cell viability in exposed cells is also reduced by one-third (32%), respect 
to the unexposed controls. The correlation between the loss of viability and the 
higher LDH values registered for the exposed cells suggests that AMF exposure 
leads to cell death.  
When monolayers of plain MSCs, respectively exposed for one hour at 565.3 kHz 
and not exposed, were investigated in bright microscopy, no difference was noticed 
between the two groups, suggesting that AMF exposure does not influence the 
arrangement of monolayers of plain MSCs. However, when mms6-expressing MSCs 
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were investigated in bright field microscopy after AMF exposure, a weak cell 
attachment was noticed. The major caveat to interpreting results is that control wild-
type MSCs should have been doped with FeQ for 21 days to make them the 
appropriate control for the mms6-expressing cells. 
The poor cell attachment in cells exposed to AMF was reported by Quinto et al. and 
Yan et al. (Quinto et al., 2015; Yan et al., 2014). Quinto et al. observed a reduction in 
cell attachment in HeLa cells incubated with Doxorubicin (DOX)-loaded SPIOs and 
exposed to an AMF of 23.77 kA/m, 355 kHz. The cell death percentage registered 
was higher than 50%. Yan et al. observed an absent or poor cell attachment in 
hepatocarcinoma cells treated with Fe2O3 nanoparticles and irradiated with an AMF 
frequency of 200 kHz. In this case, they reported a maximum apoptosis very near to 
the 70% of the whole cell population.  
These two studies support the hypothesis that the AMF exposure causes cell 
detachment and cell death, as observed in this work. However, a caveat is that Quinto 
et al. used Doxorubicin, which complicated the interpretation and comparison of  
results. 
When the mms6-expressing MSCs were exposed twice for one hour at 565.3 kHz 
frequency in 3D models, the cell death occurred in 41.0 ± 9.5% of the cell 
population, a percentage very near to the cytotoxicity observed by LDH assay in 
mms6-expressing MSCs arranged in a monolayer and exposed to AMF (44.4 ±1.9%). 
When 3D co-culture of mms6-expressing MSCs+MG63 cells seeded at 1:2 and 1:4 
ratio were exposed  at  565.3 kHz frequency for one hour, and the exposure was 
repeated 3 times in two days, the rate of cell death was, respectively, near to 40% for 
1:2 ratio, and near to 44% for the 1:4 ratio. These results indicate that in both the 
cases, the extent of cell death is greater than that of the percentage of mms6-
expressing MSCs present in each experiment (respectively 33% for ratio 1:2 and 
20% for ratio 1:4), so also MG63 cells adjacent to MSCs were killed by the AMF 
application. 
Fluorescence microscopy analysis of 3D co-cultures of MG63 cells and mms6-
expressing MSCs supports these results, revealing that the total number of exposed 
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cells is reduced by the 60% respect to the not exposed ones. Moreover, the ratio 
between MG63 cells and total cells number is not influenced by the treatment, 
suggesting that the exposure killed both the cell populations. This result is confirmed 
by the analysis of the number of MG63 cells alone in exposed and controls 3D co-
cultures. The MG63 cells are reduced in number by 60% after the AMF exposure, 
validating the previous results. The highest number of dead cells observed in 
fluorescence microscopy, compared with the lower one indicated by in vitro assays, 
could be determined by the stress of the seeding procedure. Indeed, the cells arranged 
in 3D co-cultures were seeded in the multiwells plates in single layers to make 
possible the observation at the microscope, so the manipulation of the cells could 
have influenced their viability.  
These results obtained for 3D cell mixing are confirmed by co-culturing the mms6-
MSCs with A431 ecad-GFP cell at the rate of 1:2, where exposed cell viability is 
reduced by more than 50% respect to the controls, suggesting again that the AMF 
treatment also affects cancer cells, in addition to MSCs. 
The results of these experiments have been compared to previous studies, which 
investigated cells loaded with nanoparticles and exposed to AMF of various 
frequencies. Oh et al. reduce cell viability of more than 70% in breast cancer cells 
loaded with Doxorubucin (anti-cancer agent) conjugated with CoFe2O4 
nanoparticles, following the application of AMF amplitude of 30 kA/mat at fixed 
frequency of 307 kHz for 25 min (Y. Oh et al., 2017). De Escalona et al. killed 
around 50% of cells loaded with magnetic solid lipid nanoparticles made of iron 
oxide cores and exposed for one hour to a magnetic field with a frequency of 250 
kHz and an intensity of  4 kA/m (Munoz de Escalona et al., 2016). Quinto et al. used 
doxorubicin loaded SPIOs with a phospholipid-polyethylene glycol (PEG) coating, 
to kill around 64% of cells following AMF treatment (23.77 kA/m, 355 kHz) at a 
magnetic field for 1 hour (Quinto et al., 2015). Yan et al. irradiated Hepatocarcinoma 
SMMC-7721 cells with AMF (200 kHz, 4 kW, output current 300 A) for one hour 
and obtain apoptosis in around 70% of cell population, while inhibiting cell 
proliferation in more than 80% of population in cells loaded with 8 g/L ferrofluid 
containing Fe2O3 nanoparticles (Yan et al., 2014).  
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The percentage of dead cells obtained in previous studies is more extensive than the 
one obtained here, however the above studies used chemical MNPs, while  the aim of 
this study was to create MNPs self-expressing MSCs using an exogenous bacterial 
gene, and so the results achieved in this research are quite promising, even if they 
could be improved. 
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Table 13. Comparison between the results of this study and the literature findings. 
Literature findings report a percentage of dead cells respect to the whole population 
higher than the one obtained in this study. However, the cited studies used chemical 
MNPs, while in this scientific work were used MSCs able to de novo synthesise 
MNPs, using the mms6 bacterial gene. For this reason, the percentage of dead cells 







6. In vivo application of an 
AMF of 565.3 kHz on mice 
bearing tumours injected with 








After having investigated the effects of 565.3 kHz AMF applications in vitro, 
respectively on both single layer/3D cultures of 21 days mms6-expressing MSCs and 
on mixed populations of the former cells co-cultured with MG63 and A431 Ecad-
GFP cells, it was determined if the AMF application to tumours loaded with 21 days 
mms6-expressing MSCs causes tumour necrosis. To distinguish the 21 days mms6-
expressing MSCs population from the tumour cells, MSCs were labelled with red 
CellTracker CM-DiI Dye reagent, and named for simplicity "red mms6-expressing 
MSCs". To ascertain if tumours loaded with red mms6-expressing MSCs undergo 
necrosis after AMF application, it was chosen to work on CD-1 nude mice implanted 
subcutaneously bilaterally with A431 Ecad-GFP cells. Red mms6-expressing MSCs 
were intracardiac injected into mice seven days after being injected with cancer cells. 
The experiment was then carried on following the modality explained in the 





The aims of the experiment were: 
1. to determine the distribution within major organs (spleen, liver and lungs) of red 
mms6-expressing MSCs following intracardiac injection and establish whether red 
mms6-expressing MSCs reach sites of tumour growth in vivo. 
2. to provide proof of principle that the application of an AMF to tumours loaded 
with red mms6-expressing MSCs causes tumour cell death. 
The presence and distribution of red mms6-expressing MSCs in the mice body  was 
assessed by RT-PCR, Prussian Blue and fluorescence microscopy. 
The effects of the exposure on the tumours were evaluated by measuring the tumour 
size and volume. Tumour tissue was retrieved following sacrifice of the mice for 
assessment of red mms6-expressing MSCs, tumour cells death and non-tumour tissue 
response. 
Red mms6-expressing MSCs infiltration was investigated by Multiphoton 
microscopy imaging. The effect of AMF on tumour viability was investigated  by the 
uptake of the cell Fixable Viability Dye eFluor 450 followed by Multiphoton 
microscopy imaging, by activated caspase 3 expression and by H/E stained sections 
histomorphology. Non-tumour tissue response was determined by activated caspase 








6.3.1. Application of an AMF of 565.3 kHz for 30 minutes to 
mice bearing xenografts following intracardiac injection 
of red mms6-expressing MSCs is not dangerous for mice. 
AMF studies were carried out on four experimental groups of CD-1 nude mice 
implanted subcutaneously bilaterally with A431 ecad-GFP expressing squamous 
carcinoma cells seven days previously. Each group consisted of 4 mice, treated as 
follow: 
Group A - A431 Ecad-GFP cells s/c + Anaesthesia Only 
Group B - A431 Ecad-GFP cells s/c + magneTherm treatment, 565.3kHz Daily, x 
3 days 
Group C - A431 Ecad-GFP cells s/c + red mms6-expressing MSCs + Anaesthesia 
Only 
Group D - A431 Ecad-GFP cells s/c + red mms6-expressing MSCs + 
magneTherm treatment, 565.3kHz Daily, x 3 days 
 
 Experimental details are explained in the Materials and Methods section 2.8. Mice 
were anaesthetized during all the duration of the treatment. Mice skin temperature 
was monitored by infrared thermometer gun while mice core body temperature was 
monitored by rectal thermometer each minute (Figure 64). The mice tolerated the 
treatment well, and there was no increase in temperature on the skin surface or core 
body temperature of mice exposed to the AMF (Figure 65). 







Figure 63. A schematic time-line of all the experimental steps. 
Mice were implanted with A431 ecad-GFP cells (day 0), and seven days later were 
intracardiac injected with red mms6-expressing MSCs (day 7). Then, the day after 
the MSCs injection (day 8), mice were exposed to the Magnetherm treatment, 30 
minutes at day, for three consecutive days. The last day of treatment (day 10), mice 




Figure 64. Mice exposed to magneTherm AMF.  
a) magneTherm setup, with magneTherm system turned in an upright position, to fit the mouse inside 
the device. b) Mouse on the ruler, with the anaesthesia mask on. c) The mouse is inserted into the 
MagneTherm system. d) Particular of the mouse inside the MagneTherm device with the rectal 








Figure 65. Mice skin and core body temperature measurements. 
Mice were exposed (Group B and Group D) or not exposed (Group A and Group C) to an AMF of 
565.3 kHz for 30 minutes.  
a) Mouse skin temperature, monitored by infrared thermometer gun for all the groups;  
b) Mouse core body temperature, monitored by rectal thermometer in the exposed mice. All the values 




6.3.2. Red mms6-expressing MSCs home to sites of tumour 
growth following intracardiac injection  
To determine if red mms6-expressing MSCs could reach the site of tumour growth 
and their distribution within major organs (spleen, liver and lungs) when intracardiac 
injected into CD-1 nude mice, the distribution of the cells was assessed by Prussian 
Blue staining, fluorescence microscopy, RT-PCR and immunohistochemistry.  
As red mms6-expressing MSCs were engineered to produce and bear iron 
nanoparticles, Prussian Blue staining was used to detect the presence of iron in all the 
tissue investigated (liver, lungs, spleen and tumour xenografts) of mice injected with 
red mms6-expressing MSCs (Figure 66 and Figure 67). Iron, stained in blue, was 
detected in tumours and in all the mice organs. 
However, as iron could be naturally present in tissues, fluorescent microscopy was 
used to confirm the presence of red mms6-expressing MSCs in the tumour xenografts 
and in lungs, liver and spleen, although quantification was difficult due to the relative 
weakness of the CM-DiI Dye reagent labelling and to the auto fluorescence of the 
tissue (Figure 68). Red mms6-expressing MSCs were detected in all the organs and 
in the tumour xenografts (indicated by white circles), where A431 Ecad-GFP cells 
were identified by green fluorescence, as they expressed GFP.  The expression of 
mms6 gene in the tumour xenografts and in lungs, liver and spleen was also 
confirmed by RT-PCR using primers for the mms6 gene expression (Figure 69), 
revealing the presence of the gene in all the tissues investigated. 
 As red mms6-expressing MSCs origin is human, the presence of these cells in mice 
organs was also confirmed by immunohistochemistry, using Anti-human Nuclei 
Antibody Clone 3E1.3 (Figure 70). This experiment was not performed on tumours 
due to the limited quantity of the material at disposition. Positive control for 








Figure 66. Representative picture of Prussian Blue on Group C and Group D.  
a), c) e): liver, lung and spleen of group C (injected with red mms6-MSCs and not exposed to AMF). 
b), d), f): liver, lung and spleen of  Group D (injected with red mms6-MSCs and exposed to AMF). 





Figure 67. Representative picture of Prussian Blue staining on Group C and Group D.  
g), i): tumour right and tumour left of group C (injected with red mms6-MSCs and not exposed to 
AMF). h), l): tumour right and tumour left of group D (injected with red mms6-MSCs and exposed to 
AMF). m): negative control (lung of mouse not injected with MSC; n) positive control (liver which is 
naturally rich of ferritin and so it is stained with Prussian Blue). Inset, lower magnification of organs. 













Figure 68.  Representative pictures of frozen mice tissues sections imaged at fluorescence 
microscope in mice injected with red mms6-expressing MSCs.  
Cancer cells are green, as they express GFP, while cell nuclei were DAPI stained and so are blue. 
White circles indicate red mms6-MSCs. a) Tumour left; b) Tumour right; c) lung; d) liver; e) spleen. 













Figure 69. Representative picture of mms6 expression in mice organs and tumours. 
A) mms6 expression in: lung (lane1), tumour right (lane2), spleen (lane3), tumour left (lane4), liver 
(lane5). B) eEF2 (mouse housekeeping gene) expression in the same organs with the same order used 






Figure 70. Representation of Anti-human Nuclei Antibody Clone 3E1.3 staining in mice major 
organs.  
a) spleen of Group C; b) spleen of Group D; c) liver of  Group C; d) liver of  Group D; e) lung of  




6.3.3. Tumour size and volume do not reduce after the 
application of an AMF of 565.3 kHz to mice bearing 
xenografts following intracardiac injection of 21 days red 
mms6-expressing MSCs. 
Tumour size and volumes were measured for each group at different time points: 6 
days before the AMF/sham treatment (-6), 2 days before the AMF/sham treatment (-
2), and after 2 days from the AMF/sham treatment (2).  
Due to the busy schedule of the animal house technical staff, the mice groups have 
not been implanted with cancer cells all at the same time, but Group A and Group B 
were implanted a week after than Group C and Group D. This could explain the 
discrepancy between the starting size of tumours, as shown in Figure 71, where 
Group A and Group B have a starting tumour volume that is bigger than Group C 
and Group D, despite the number of the injected cancer cells was supposed to be the 
same (1x10
6
 per implant). 
Tumours volume measurements reveal that there is no difference between Group C 
(injected with red mms6-expressing MSCs but not exposed to AMF) and Group D 
(injected with red mms6-expressing MSCs and exposed to AMF) mice either before 
or after application of AMF (p>0.05), (Figure 71a). Statistical differences were 
found at day 2 between Group A and Group C and Group D respectively (p<0.05), 
and between Group B and Group C and Group D respectively (p<0.001).Tumour 
growth was not measured at day 0 for all the tumours, and so it was chosen to 
represent it in the graph with the value "1" (Figure 71b). Although the growth rate of 
tumours in Group D mice appeared to be decreased in comparison to those of Group 
A and B (without red mms6-expressing MSCs injection) this is not statistically 
significant (Figure 71b)  (p>0.05). 
Tumour tissue was immediately collected after sacrifice of the mice for assessment 




1. red mms6-expressing MSCs infiltration into the tumour environment was 
confirmed by Multiphoton microscopy in control group (Group C, unexposed) 
and compared to that of the AMF exposed group (Group D), (Figure 72). There 
was wide variation in the number of  red mms6-expressing MSCs per unit area in 
the tumours of the exposed and unexposed group (mean 51 range 7-95 vs mean 
46, range 14-73 respectively); this was not statistically significant (p>0.05).  
 
2. The effect of AMF on tumour viability was assessed by the uptake of the Fixable 
Viability Dye eFluor 450 followed by Multiphoton microscopy, by haematoxylin 
and eosin (H/E) staining and by activated Capsase-3 staining. 
 The results obtained using Fixable Viability Dye eFluor 450 reagent visually 
indicated a cell death of around 50% (appendix 8.15) which however does not 
coincide with the visual assessment of haematoxylin and eosin (H/E) stained 
sections of the exposed tumour which showed much less in the way of tumour 
cell death/necrosis  (Figure 73). Very limited necrotic regions were detected. 
Indeed, the degree of tumour necrosis in the AMF exposed  mice (Group  D) 
group was considerably less than that expected to be of clinical significance for 
standard chemo/radiotherapy (> 90% tumour necrosis).  
To determine whether AMF caused cell tumour apoptosis, tumours were 
subjected to immunohistochemistry for  Caspase-3 expression. Caspase-3 is a 
protein which plays a critical role in apoptosis, responsible for the cleavage of 
other important proteins. The antibody has a cytoplasmic and perinuclear 
localisation in apoptotic cells (Figure 74). Results indicate a wide variation of 
Capsase-3 stained cells in the tumours of the groups and no statistical difference 
between groups was found (percentage of caspase 3 activated stained nuclei is 
16.7 ±11.8 for  Group A, 12.8 ±9.4 for  Group B, 7.2 ± 3.7 Group C, 10.1 ± 5.9 
Group D, p>0.05; data not shown). 
 
3. Histological assessment of adjacent non-tumour tissue showed no 
histopathological abnormality. The tissue investigated appeared healthy and 
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activated Caspase-3 was not detected (Figure 75). Positive control for Caspase-3 










Figure 71. Tumours volume and growth measurements. 
Tumours volumes (panel a) and tumours growth (panel b) of Groups A, B, C, D. Results are shown as 










Figure 72. mms6-expressing MSCs tumour homing investigation by Multiphoton z-stack. 
a-b) Representation of Multiphoton z-stack pictures showing red mms6-expressing MSCs in the 
tumour site. a) not exposed mouse (Group C). b) exposed mouse (Group D). White circles indicate 
regions where the red stain was more concentrated. Red scale bar=50 µm.  
c) red mms6-expressing MSCs average number in the tumour xenografts of exposed and not exposed 







Figure 73. Representation of  H/E stained sections of an AMF exposed tumour. 
The exposed tumour shows limited cell necrosis (yellow square). A) 1.25 x magnification, scale bar= 
2.5 mm; B) Particular of the area of necrosis, 10x magnification, scale bar=250 µm. 
 
Figure 74. Representative picture of Caspase 3 activated staining for all the groups investigated. 
Capsase-3 antibody stains the apoptotic cells in brown, localising in the cytoplasm and in the 
perinuclear region of the cells. No statistical differences were observed between the number of 





Figure 75. Representative picture of a) H/E staining and b) activated Caspase 3 staining of 
adjacent non-tumour tissue.  
Scale bar=50µm  
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6.4.  Discussion   
In this chapter it was investigated if : 
- red mms6-expressing MSCs injected intracardiac in mice reach the site of 
tumour growth and if they are distributed in other major organs such as 
spleen, liver and  lungs. 
- red mms6-expressing MSCs in the tumour growth site could induce tumour 
cells death when the tumour is exposed to AMF of a frequency of 565.3 kHz, 
30 minutes a day for three consecutive days. 
 
MSCs have tumour-targeting properties, both in mouse (Khakoo et al., 2006; R. F. 
Pereira et al., 1998) than in human (Le Blanc et al., 2004; Koc et al., 2000). In this 
study Prussian Blue, RT-PCR, fluorescence microscopy and Multiphoton 
microscopy imaging could suggest the presence of MSCs in mice tumours, however, 
there is no evidence of homing or targeting of the MSCs to the tumour, as the 
accumulation of MSCs in the tumours may be due to the leaky vasculature of the 
tumour.  
RT-PCR of Group A and B tissue was not included in the study design, but it would 
have been a good negative control. 
Besides, it was observed the MSCs tendency to randomly accumulate in spleen, liver 
and  lungs. The non-specific migration of MSCs to other organs than tumours was 
already reported  in previous studies, where MSCs cells were shown to localise to the 
lung (Pereira et al., 1998; Devine et al., 2003; Kucerova et al., 2007; Fischer et al., 
2009), spleen (R. F. Pereira et al., 1998), liver (Devine et al., 2003; Gao et al., 2001), 
or in all of them (Duan et al., 2009; Allers et al., 2004; Chin et al., 2003; Detante et 
al., 2009; Kraitchman et al., 2005). The MSCs clearance from organs was studied by 
Studeny et al., who investigated the route of cell delivery of bone marrow-derived 
MSCs injected into the tail vein of  nude mice bearing  human A375SM melanoma 
cells growing in the lungs  (Studeny et al., 2002). In his study, Studeny et al. showed 
that MSCs localise in lung parenchyma and tumour nodules one day after their 
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intravenous  administration, to clear from lung after eight days from the injection, 
concluding that it is the tumour microenvironment and not the lungs to provide the 
right conditions for the survival and proliferation of MSCs cells. In my study, due to 
a strict time schedule, the MSCs localisation in organs was monitored only until the 
fourth day, making impossible to determine if the accumulation of MSCs in lungs 
stops after eight days. Moreover, it is worth to observe that the mice selected for the 
study are immune suppressed, which makes easier for MSCs to reach the organs 
without an active immune system (Eggenhofer et al., 2012). 
Next, it was examined if red mms6-expressing MSCs localised in the tumour site can 
kill cancer cells following AMF exposure. Tumours size and volume measurements 
showed no difference between the control and the AMF exposed group. Although 
this is not relevant for the experiment, it should be notice that group A and B 
tumours volume appears bigger than volume of groups C and D, due to the fact that 
mice of the two couples of groups were injected with cancer cells at two separate 
times, determining the observed variation among the couples of groups. Indeed, it is 
possible that the cells injected in Group A and Group B -injected one week later than 
Group C and Group D-were more in number than the ones injected in GroupC and 
GroupD, due to human error in cell counting/cell injection or simply due to the 
experimental variability. This could explain why the differences between averages of 
the tumour volumes between Group A and Group C and Group D respectively and 
between the Group B and Group C and Group D respectively were found statistically 
significant. 
 However, this discrepancy did not affect the overall outcome of the experiment, 
which showed no effect of AMF on tumour growth and volume. There is a number 
of possible reasons for the lack of tumour growth/reduction in AMF exposed mice, 
as: 
- the mice sacrifice occurred the same day of the last exposure, making it 
difficult to fully evaluate if  any effect was really produced from AMF 
exposure on tumours. 
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- the number of the injected red mms6-expressing MSCs able to reach the 
tumour site was too low to really lead to an appreciable necrosis effect  when 
tumours were exposed to AMF. 
- the mms6 gene is too low expressed in MSCs to determine enough Mms6 
protein to create MNPs able to create an appreciable effect when reacting to 
AMF. 
In tumour, cancer cells death investigated by Fixable Viability Dye eFluor 450 
revealed an high percentage of dead cells (near to 50%), in disagreement with the 
visual assessment of H/E stained sections. This discrepancy could be explained by 
the Multiphoton instrument high sensitivity for fluorescence (Schuh et al., 2016) and 
by the difficulty to completely separate the blue wavelength emission of dead cells 
from the green fluorescence background given by the tissue, due to the GFP 
expressed by cancer cells. These interferences have probably lead to a higher 
estimation of the dead cells number than the one that actually was. Multiphoton 
excitation microscopy had also been employed to investigate the effect of the AMF 
on MSCs. This technique was used to see if AMF is able, in vivo, to effectively 
excite the magnetic nanoparticles produced inside the MSCs by mms6 gene, causing 
the destruction of MSCs. The pictures analysed by Multiphoton instrument software 
showed red fluorescence, indicating that some MSCs could still be viable after the 
AMF treatment or, more likely, that the AMF exposure determined the death of  
MSCs, causing the rupture of cell membrane and the consequent leakage of the red 
dye. In this scenario, the red florescence would identify cellular debris and not living 
cells. Due to an unequal distribution of the red dye in the cell cytoplasm, it is 
challenging to determine if the MSCs are still viable or not. It is interesting to notice 
that the red fluorescence was more concentrated in some areas of the tumour tissue, 
suggesting the hypothesis that MSCs could be able to reach the tumours possibly 
because of their leaky vasculature, creating niches of cells in the tumour site (Figure 
72B). Although there are conflicting findings about the real effect of MSCs on 
tumour growth (Rhee et al., 2015), where some study support the thesis that MSCs 
could enhance the tumours growth (G. C. Li et al., 2016; Momin et al., 2010), while 
other suggest a tumour growth inhibitory effect (Beckermann et al., 2008), one 
hypothesis that could be done is that the presence of niches of MSCs in tumour site 
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could act as tumour suppressor, with the MSCs occupying the place of cancer cells. 
More studies are necessary to assess the effect of AMF on MSCs and to entirely 
















In MHT, stem cells are considered promising candidates for MNPs delivery, due to 
their tumour homing capability, they ability to mediate immunosuppression upon 
transplantation, and their anti-inflammatory properties (Durinikova et al., 2014). 
However, stem cells display a limited phagocytosis, which proves challenging to 
load this type of cells with external magnetic nanoparticles (Kim et al., 2010). In 
addition to that, the so far used MNPs are often chemicals, their uptake in MSCs 
population is not homogenous and they are diluted with cell divisions. All these 
issues represent challenges that need to be overcome to exploit MSCs potential in 
MHT. The goal of this research was to create MSCs able to self-express MNPs by 
genetically modifying them with MTB genes mms6 and mmsF, alone or in 
combination.  
•    In Chapter 3 and Chapter 4 it was demonstrated that mms6 and mmsF genes could 
be expressed both in MG63 cell line and in MSCs, and the magnetism of the cells 
was proven by different physical techniques. It was also established that gene mms6 
confers the higher magnetisation to MSCs in comparison to mmsF alone and to 
mms6+mmsF genes together. A better understanding of the response of the electron-
dense structures created inside the transfected cells to AMF could have been 
obtained by using a positive control for the SQUID and the HT experiments, for 
example by loading the cells with synthetic MNPs, such as SPIONS.  
Quantification of the amount of iron in cells could have been determined by mass 
spectrometry, an analytical technique that measures the mass of different molecules 
within a sample. It works by ionizing the chemical species and sorting the ions based 
on their mass-to-charge ratio; the mass spectrum indicates the masses within a 
sample (Glish & Vachet, 2003). In literature, mass spectrometry has been widely 
used to quantify the SPIONS amount in cells (Nold et al., 2017; Shi et al., 2009; 
White et al., 2015). 
•  In Chapter 4 it was also assessed that the expression of mms6 gene inside MSCs 
does not change cell stemness, proliferation and capability to differentiate into the 
osteogenic, chondrogenic and adipogenic lineage after 21 days from transfection. It 
should be stated that all the differentiation experiments were performed in absence of 
FeQ doping. It could have been useful to repeat the same experiments also in the 
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presence of FeQ solution, to determine if the FeQ presence could have affected the 
MSCs differentiation properties. Indeed, there are scientific works suggesting that 
SPIONS impairs chondrogenesis and osteogenesis in human MSCs. It was observed 
that human MSCs treated with Amine-surface-modified SPIONS show lower 
expression levels of osteogenic lineage marker genes RUNX2, osteocalcin, and type 
I collagen, inhibiting chondrogenesis and osteogenesis (Chang et al., 2012). These 
results collimate with previous research findings on inhibitory effect of  ferumoxide 
on chondrogenesis and osteogenesis (Farrell et al., 2008; Kostura et al., 2004) and 
ferucarbotran on osteogenic differentiation in human MSCs (Y. C. Chen et al., 2010) 
•    In Chapter 5 an AMF of 565.3 kHz frequency was applied to monolayers and 3D 
models of mms6-expressing MSCs. Cell viability is reduced by one-third when 
MSCs are exposed in monolayers, while when MSCs are arranged in 3D models cell 
death interested the 40% of the population. Registered cell death was 40% when 
MSCs were co-cultured with MG63 cancer cells and 50% when co-cultured with 
A431-ecad GFP expressing cells. Such results suggest a promising responsiveness in 
vitro of MNPs expressing MSCs to AMF which leads to cell death.  
A caveat to interpreting results is that  the control wild-type MSCs should have been 
doped with FeQ for 21 days to make them the appropriate control for the mms6-
expressing cells.  
Apoptosis, also defined as programmed cell death, is a very interesting and relevant 
response of cells to HT, which affects many of the cell components, ranging from the 
membrane to the nucleus. Typical apoptosis hallmarks are: cell shrinkage, membrane 
blebbing, mitochondrial alteration, metabolic changes, nuclear condensation and 
genomic DNA fragmentation, activated caspases, and the eventual engulfment of the 
cell by phagosomes. Apoptosis is different from necrosis as it does not involve the 
inflammatory response, and it is limited to individual cells in vivo (Cosentino & 
Garcia-Saez, 2014; S. Mukhopadhyay et al., 2014) . 
If more time were available, the apoptotic process could be investigated also in this 
study. Nowadays there are so many techniques available to determine if a cell 
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undergoes apoptosis, that providing a complete list of them would require an entire 
chapter: for this reason only some of them will be reported. 
  
 The plasma membrane changes could be investigated using AnnexinV, 
followed by fluorescence, confocal microscopy or, together with propidium 
iodide, by FACS (Gu et al., 2017).  
 The mitochondrial integrity could be stained with MitoTrackerRed, 
Rhodamine 123, JC1 or TMRE followed by confocal microscopy or FACS 
(Gorojod et al., 2017). 
 The metabolic changes could be investigated taking into account the variation 
of Ca
2+
concentration (fura-2, fluo-3, fluo-4) (Giorgi et al., 2015), or the 
intracellular acidification (SNARF-1, acetoxymethyl ester) (Lucien et al., 
2014). 
 Proteases activation could be studied by FACS or by fluorescent microscopy 
analysis of cleavage of fluorogenic substrates (PhiPhiLux), Western-blot or 
FACS analysis of Caspases-3 and PARP-1, since PARP-1 is cleaved by 
activated caspase 3 (Li Wang et al., 2013). 
 Chromatine condensation could be studied by Hoescht 33342 and propidium 
iodide, since Hoescht 33342 penetrates all cells and healthy cells exclude 
propidium iodide (DiBartolomeis & Moné, 2003);  
 DNA fragmentation could be investigated by TUNEL (terminal  
deoxynucleotidyl transferase mediated  dUTP nick end labeling) analysis 
followed by microscopy or by FACS (Kim & Lee, 2014). 
 Apoptosis related genes expression could be studied by Real-Time PCR and  
gene  microarray analysis (Kamiya et al., 2012). 
Since the Heat Shock Proteins (HSPs) like HSP70, HSP72 and HSP90 play a 
paramount role in the cellular heat stress response, (Sauvage et al., 2017; Sekihara et 
al., 2013), the effect of the Hyperthermia on cells could have been investigated also 
by studying the HSPs expression before and after the AMF application. Some of the 
techniques measuring the HSPs induction at the intercellular level are qRT-PCR, 
SDS-PAGE, Western Blot, immunofluorescence and enzyme-linked immunosorbent 
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assay (ELISA), as seen elsewhere (Bhayani et al., 2013; Jang et al., 2017; M. Moros 
et al., 2015; R. Yang et al., 2015). 
•   In Chapter 6, an AMF of 565.3 kHz frequency was applied in vivo, on mice 
bearing tumour xenografts intracardiac injected with mms6-expressing MSCs. mms6-
expressing MSCs were detected in tumours xenografts and mice major organs 
(spleen, liver, lungs). However, in exposed mice, it was not noticed any statistically 
significant reduction in tumour volume or growth, neither the tumour cells 
apoptosis/necrosis in exposed mice was different from the unexposed ones.  
Overall, this study demonstrates that it is possible to successfully express MTB genes 
in MSCs, creating magnetic and AMF responsive MSCs, without an adverse effect 
on critical cell functions. However, if mms6-expressing MSCs could be killed by 
AFM exposure in vitro, also causing the death of the adjacent cancer cells, the same 
effects was not noticed in vivo, where no tumour reduction was observed.  This could 
be due to several limitations: 
- The number of mms6-expressing MSCs able to reach the tumour in vivo was too 
small to give an appreciable response to AMF, able to kill a sufficient number of 
cancer cells and so to successfully reduce the tumour volume/growth. 
- The way that mms6-expressing MSCs react to the AMF could depend on cell 
arrangement. It is possible that cells are more responsive to AMF when directly 
exposed to AMF as cell monolayer/3D model, than when they are in a complex 
system as the animal body. 
- Due to the limited time, it was not possible to repeat the in vivo experimental 
part. A repetition of the experiment could have helped to improve experimental 




The use of magnetized MSCs could offer enormous advantages in the field of 
regenerative medicine and for the in vivo cell tracking. 
The MSCs properties to “home” toward tumours and the site of injury without 
rousing the immune system response boosted their use for cancer-specific gene 
delivery and tissue regeneration (Corsten & Shah, 2008; C. Tang et al., 2010). As a 
consequence, it is of paramount importance to accurately localize MSCs and to 
ensure their survival after MSCs targeting to the site of interest.  
Magnetic Resonance Imaging (MRI) is the imaging techniques commonly used for in 
vivo cellular imaging as it offers a good resolution with high anatomic background 
contrast, without ionizing radiation but with the need of a contrast agent (C. Tang et 
al., 2010). SPIONS are the most commonly used contrast agents in MRI. However, 
exocytosis and SPIONS dilution during MSCs cell replications lead to a decrease of 
the magnetic signals with the passing of time, making difficult to track the MSCs in 
the body and to determine their biodistribution and fate in stem cell-based 
regenerative therapies (Amado et al., 2005).  
The use of self-expressing magnetic gene MSCs could be an appealing strategy for 
the creation of magnetic MSCs, as it was shown that MRI system could magnetically 
guide the stem cells to the tissue of interest and then followed their fate in real-time. 
(Connell et al., 2015). 
Moreover, the stable expressing magnetic gene MSCs, able to de novo synthesise 
intracellular MNPs, could avoid the nanoparticles dilution with the cell divisions, and 
so the fading of the magnetic signal with the passing of time (Elfick et al., 2017). The 
magnetic gene could function as a reporter gene, which generates contrast depending 
on cell viability, survival and localization, providing useful information (S. M. 
Pereira et al., 2015).  
Another advantage of using magnetic MSCs for regeneration therapies is their 
retention in the injury site when a magnet is applied. Scientific evidences prove that 
the application of an external static magnetic field could enhance the engraftment 
and retention of magnetic MSCs in the target site, due to the magnetic interactions 
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between the magnetized cells and the magnetic field, which stimulates the expression 
of integrins and adhesion factors (Nakamae et al., 2010; Schäfer et al., 2010). With 
the application of a static magnetic field, SPION-labelled MSCs are better retained 
into cartilage degeneration sites, fibrocartilages (meniscus), muscles, and bones, 
which are body districts characterized by limited regenerative capacity and which are 
poorly targeted by systemic/local MSCs administration (L. H. A. Silva et al., 2017).  
In addition to that, the creation of magnetic MSCs offers a tremendous advantage to 
the magnetic force assisted engineering, as it makes possible to actuate MSCs from 
distance. This has helped studies of mechanical conditioning bioreactor culture of 
MSCs (Dobson et al., 2006) and intermittent mechanical activation for long-term 
bone cells growth (Cartmell et al., 2002). 
Magnetic MSCs could find application also in the magnetic manipulation of the 
biological systems, as they could be driven by an external magnetic force to create an 
ordered arrangement of cells (cell-patterning) or tailored 3D tissues, made of the 
required shape and size (magnetic-manufacturing) (Horie et al., 2017). 
This study could be interpreted as a proof of concept experiment regarding mms6 
expression into human MSCs and, regardless results obtained are encouraging, a lot 
of work is still needed to improve mms6 expression into MSCs, to enhance the MNPs 
production and to maximise the MSCs delivery to the tumour. 
The use of a specific Mms6-antibody, which was not sold by any company at the 
moment of the research, would have greatly improved the study. The Mms6-antibody 
could have been used in immuno-staining essays (immunohistochemistry, flow 
cytometry, Western Blotting) and in confocal microscopy investigations to determine 
the Mms6 protein expression in the transfected cells at different time points from the 
transfection. 
Next experiments will be finalised to the optimisation of  mms6 gene expression in 
MSCs, using new genome editing techniques, as CRISPR (clustered regularly 
interspaced short palindromic repeat)-Cas9(CRISPR-associated nuclease 9) system 
which could be utilised for sequence-specific integration of mms6 gene in MSCs 
genome. This technology relies on a synthetic sequence-specific nuclease which, 
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once transfected into cell, is able to recognise the target genomic site and to create a 
double-strand DNA break (DSB) at the site (Ding et al., 2016; Jinek et al., 2012; 
Voytas, 2013; Zhang et al., 2014). The  DSB will trigger the repair system which is 
ubiquitous in all the cells, and it is normally an error-prone non-homologous end-
joining pathway, which creates small deletion at the site, causing gene knockout.  If 
the gene of interest (mms6), is modified to contain homology to the flanking 
sequence, it could be integrated into the DSB by homology-directed repair using the 
donor DNA as a template. This technique has already been utilised in both mouse 
and human neural stem cells to knock-in epitope tags and fluorescent reporters 
(Bressan et al., 2017). Using this method, it would be possible to integrate the gene 
mms6 into MSCs genome in a more accurate and elegant way than transfection, 
obtaining a better gene expression and so stimulating more protein production (Ding 
et al., 2016). 
In addition to intracardiac injection, MSCs could reach the tumour by different 
delivery routes: subcutaneous injection, intravenous injection and intratumoral 
injection. Seo et al. observed that  MSCs,  which in their experiment expressed 
modified interleukin-12, gave the strong tumour-specific T-cell responses, together 
with anti-metastatic effects and inhibition of solid tumour growth when intratumoral 
injected (Seo et al., 2011). The intratumoral injection could be applied in future 
experiments as an alternative delivery route to intracardiac one. 
In conclusion, the presented study, although it does not lead to an efficient reduction 
of tumour volume/growth in vivo, contributed to our knowledge on the creation of 















8.1. mms6 gene description 
The Magnetospirillum magneticum AMB-1 mms6 DNA bacterial sequence was 
codon optimized for mammalian expression and a Kozak sequence added then 
synthesised. The optimized sequence was synthesised by MRGene GmbH 
(Germany) and cloned in their proprietary vector with SacI and KpnI restriction sites. 
The synthetic mms6 gene was cloned into a pcDNA3.1 expression vector 
(ThermoFisher Scientific) at BamH1 and EcoRI restriction sites and transfected into 
human fetal bone marrow derived MSCs with X-tremeGENE HP.  
Sanger sequencing data confirmed 100% identity of the DNA sequence of the initial 
synthetic mms6 gene inserted within the pcDNA3.1 vector used for transfection 
(Ref.mms6) and the gene expressed after 10, 15 and 21 days of transfection (Figure 
76). The Sanger sequencing data was obtained as per the following protocol. 
Sequencing samples were set up using a reaction volume of  0.5 µl BigDye 
Terminator v3.1 (Applied Biosystems). The buffers and primers and PCR products 
were mixed as following:  1.31 µl (x5) buffer, 1µl primer (5µM), 5.19 µl ddH2O, 2 
µl of DNA (per reaction). The samples were run on a peltier thermal cycler with an 
annealing temperature of 55°C, the final PCR products were precipitated in 95% 
ethanol and then washed with 70% ethanol dried and finally dissolved in water. 
Then, samples where run on the Applied Biosystems 3130 sequencer.  








Figure 76. CLUSTAL O (1.2.3) multiple sequence alignment. 
The pcDNA3.1 vector used for transfection (Ref.mms6) and the gene expressed by MSCs after 10, 15 





Figure 77. pcDNA™3.1 Vector map.  
Original picture taken from: https://tools.thermofisher.com/content/sfs/manuals/pcdna3_1_man.pdf 
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8.2. mmsF ligation into pcDNA4/TO 
vector 
1. mmsF gene PCR amplification  
mmsF gene used in this study belongs to Magnetospirillum gryphiswaldense 
bacterium. The genomic DNA of M. gryphiswaldense was purchased from DMSZ, 
Germany (product code: DMS 6361).  










To clone the mmsF gene into pcDNA4/TO vector, a PCR product of 375 bp was 
amplified by the following primers. The primers were designed in such a way that a 
EcoRI and NotI sites were added in the forward and reverse primers respectively. 
Primer Forward was designed to contain the Kozak sequence (gccacc) for improving 
mammalian translation efficiency. 
Primer Forward (5'-3'): 
GATCGAATTCGCCACCATGAAGAAGTCGAACTGCGCGACG 
Primer Reverse (5'-3'): GATCGCGGCCGCTCAGATCCGGTCGGCCACCCA 
EcoRI sequence: GAATTC, NotI sequence: GCGGCCGC, Kozak sequence: 
GCCACC 
Start Codon is ATG and stop codon is TGA. Both the primers contain the hanging 
sequence (gatc) for the plasmid integration.  
Primers lenght was chosen to improve specificity during PCR product amplification. 
PCR was performed with the use of Q5® High-Fidelity DNA Polymerase (NEB) and 
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dNTPs (Thermo Fisher Scientific) following the manufacture's protocol, and using 
the following program: 
 initial denaturation at 98°C for 30 seconds,  
 denaturation at 98°C for 10 seconds,  
 annealing at 60 °C for 30 seconds  
 extension at 72 °C for 30 seconds  
 final extension at 72 °C for 2 minutes. 





2. mmsF gene purification from agarose gel 
The gene mmsF was imaged at the UV image analyser, removed from it with a 
scalpel (Figure 78B), and put in a pre-weight microcentrifuge tube. Then, the 
excised gel band of mmsF gene was purified from the gel using QIAquick Gel 
Extraction Kit (Qiagen), according to the manufacture's protocol. Briefly, 3 volumes 
of Buffer QG were added to one volume of gel, incubating at 50 ºC for 10 minutes 
and vortexing the tube to dissolve the gel. A volume of isopropanol was added to the 
sample and mixed. The sample was then applied to a spin column containing a DNA-
binding membrane. The column was placed in a collection tube, and it was 
centrifuged for 1 minute at 10,000 xg in a table-top microcentrifuge. The wash-
A 
35 cycles 
Figure 78. Agarose gel electrophoresis of mmsF gene. 
A)Two PCR products were run on gel; B) The gene mmsF was cut with scalpel following gel UV 
exposure for gene purification. C) NEB DNA marker with bp indicated. 
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through was discarded and, to wash the membrane, 0.75 ml of Buffer PE were added 
to the column, and centrifuge again for 1 minute at 10,000 xg. The column was put in 
a clean 1.5 ml microcentrifuge tube, and mmsF gene was eluted by adding 30 µl of 
Buffer EB (10mM TrisCl, pH8.5) directly to the centre of the membrane. The 
column was left to stand at RT for 1 minute and then centrifuged for 1 minute at 
10,000 xg. The purified DNA was analysed on a 2% gel, by adding 1 volume of 
Loading Dye to 5 volumes of DNA (Figure 79).  DNA concentration and purity 
were determined by NanoDrop spectrophotometer (Labtech). 
 
 
3. Restriction enzymes digestion of the purified PCR product and of the 
pcDNA4/T0 vector 
To insert the mmsF gene into pcDNA4/TO vector, both the DNA were digested with 
EcoRI and NotI enzymes (NEB), according to the manufacture's protocol. Briefly, 
the mmsF PCR product (700ng)  and pcDNA4/TO vector (2 µg) were put in two 
separate tubes. Then, the following components were added to each tube: 5µl of  
NEBuffer 3.1(10x concentrated), 1 µl of EcoRI enzyme, 1 µl of NotI enzyme, 0.5 µl 
of BSA (100x concentrated) and water up to a final volume of 50 µl. Then, the two 
solutions were incubated at 37 ºC overnight. The day after, the enzymes activity was 
inactivated by incubating the solutions at 65 ºC for 5 minutes.  
4.Dephosphorylation of the pcDNA4/TO vector only  
pcDNA4/TO vector was dephosporylated and ligated to mmsF gene using the Rapid 
DNA ligation kit (Roche), according to the manufacture's protocol.  Before the 
ligation reaction, pcDNA4/TO vector was dephosporylated to prevent self-ligation. 
Figure 79. The purified mmsF  DNA was analyzed on a 2% gel. 




Briefly, 2µl of rAPid Alkaline Phosphatase Buffer and 1µl of rAPid Alkaline 
Phosphatase were added to 1µg of the vector, adding water to a final volume of 20 
µl. Then the solution was mixed thoroughly, briefly centrifuged and incubated at 
37°C for 30 minutes. At the end of the incubation time, rAPid Alkaline Phosphatase 
was inactivated by incubating the solution at 75°C for 2 minutes.  
5. Ligation of the pcDNA/4TO vector to the mmsF gene  
The dephosphorylated pcDNA4/TO vector and the mmsF insert gene were ligated. 
Briefly, 50 ng of  pcDNA4/TO vector and 150 ng of the mmsF gene were dissolved 
in the thoroughly mixed DNA Dilution Buffer (2 μl, 5x concentrated) and water, 
which was added to a final volume of 10 μl in a sterile reaction vial. Then, 10 μl of 
T4 DNA Ligation Buffer (2x concentrated) were added to the reaction vial and 
mixed thoroughly. Lastly, 1 μl of T4 DNA Ligase was added to the reaction vial, 
mixed thoroughly and let to incubate at RT for 15 minutes. A (negative) control 
reaction vial was prepared in the same way, omitting the mmsF gene insert that was 
replaced by water. The control reaction was prepared to verify that the vector with 
the insert ligation had many more colonies, when later transformed into competent 
bacteria,  than the vector alone. The ligation reaction was then transformed into 
competent cells.  
6. Bacteria transformation with the ligation reaction  
The ligation reaction was transformed into E. Coli  bacteria, using Subcloning 
Efficiency™ DH5α™ Competent Cells (Invitrogen). Aliquots of 50 µl of cells stored 
at -80°C were thawed on ice for 15 minutes before to use them. Then, 2 µl of ligation 
reaction were added to the competent cells in a microcentrifuge tube, and gently 
mixed. The tube was incubated on ice for 30 minutes, followed by heat shock in 
incubator at 42°C for 70 seconds and again by incubation on ice for 3 minutes. Then, 
900 µl of pre-warmed SOC medium (without antibiotic) were added to the cells, 
which were cultured in shaking incubator at 37°C  for 1 hour. In the meanwhile, agar 
plates containing ampicillin (1µl of 1000x  ampicillin /1ml agarose) were warmed up 
in 37°C incubator bottom up to avoid condensation. The cells were then centrifuged 
at 5000 rpm for 1 minute. 500 µl of supernatant were removed, and the pellet was 
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resuspended in the remaining medium and added drop by drop to plates in different 
concentration (50 µl, 100 µl, 200 µl) near to a Bunsen flame. For a homogenous 
distribution, drops were distributed with a sterile inoculation loop. Then, plates were 
incubated at 37°C overnight. 
7. Plasmids amplification 
The day after, bacteria colonies were visible in the plates, which were put in fridge to 
stop bacteria replication. 5 single colonies were picked from the plates to be grown 
overnight in different tubes containing 3 ml of selective LB medium (LB medium 
containing 1µl of 1000x  ampicillin /1ml LB medium). This is called starter culture. 
The caps of tubes were untied to favour the air passage, and then bacteria were 
grown at  37°C in a shaking incubator overnight. The day after, early in the morning, 
the cloudiness of the starter culture was visually inspected, as it is an indicator of the 
bacteria growth. Then, 100 ml of selective LB medium were inoculated with 100 µl 
of the starter culture (1/1000 dilution). Bacteria were grown at 37°C for 12–16 h with 
vigorous shaking (approx. 300 rpm). At the end of the incubation period, the tubes 
were incubated on ice for 10 minutes to stop bacteria growth. Then, 500 µl of 
solution were removed from each tube, and added to a 500 µl of a solution of sterile 
80% glycerol (80% pure glycerol and 20% sterile water) and then stored at -80°C to 
preserve transformed bacteria cells aliquots.  
8. Plasmid purification 
The plasmid was then purified using the "QIAGEN Plasmid Maxi Kit"(QIAGEN). 
Briefly, the solution contained in the different tubes was centrifuged at 6000 x g, at 
4°C for 15 minutes. The supernatant was then removed in a waste bottle containing 
disinfectant. For each tube, the bacteria pellet was resuspended in 10 ml of buffer P1. 
Then, 10 ml of buffer P2 were added, mixing vigorously by hand inversion for 4-6 
times. The solution was incubated at RT for 5 minutes, followed by addition of 10 ml 
of prechilled Buffer P3. The mixture was mixed and  incubated on ice for 20 
minutes, then it was transferred into clean tubes made for high speed and centrifuged 
at 20000 x g for 30 min at 4°C. The supernatant was re-centrifuged at 20,000 x g for 
15 min at 4°C, and applied to a QIAGEN-tip  previously equilibrated with 10 ml of 
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Buffer QBT, allowing it to enter the resin by gravity flow. The QIAGEN-tip was 
washed twice with 30 ml of Buffer QC, allowing it to move through the QIAGEN-tip 
by gravity flow. The plasmid was then eluted with 15 ml Buffer QF into a clean 50 
ml tube and precipitated by adding 10.5 ml RT  isopropanol. Then, it was centrifuged 
at 20000 x g for 30 min at 4°C and the supernatant was carefully decanted. The pellet 
(plasmid) was washed with 5 ml of RT 70% ethanol and centrifuged at 20000 x g for 
10 minutes, carefully decanting the supernatant. Then, the pellet was air-dried for 10 
minutes and redissolved in 50 µl of RNA/DNAse free sterile water. The plasmid 
concentration and purity were determined using NanoDrop spectrophotometer 
(Labtech), measuring the absorbance at the 260, 280 and 230 nm wavelength. The 
absorbance ratio of DNA samples at 260/280nm of ~1.8 and absorbance ratio at 
260/230nm in a range of  2.0-2.2 were considered as highly pure. 
The presence of the mmsF gene in each extracted plasmid was confirmed by PCR, 
using the same cloning primers. The PCR product was analysed on 2% agarose gel 






For a further confirmation of the success of the ligation reaction, the purified 
plasmids were digested with EcoRI and NotI enzymes. Briefly, to each tube 
containing 100 ng of plasmid were added the following components: 5µl of  
Figure 80. Agarose gel electrophoresis of mmsF gene. 
 A 1-5) Following plasmid purification from bacteria colonies, mmsF gene was visualised on 2%  
agarose gel electrophoresis. Arrow indicates gene size.  B) Digestion of pcDNA/4TO vector by NotI 
and EcoRI enzymes for each colony picked. 1,3,5,7,9: uncut vector; 2,4,6,8,10 cut vector. M: marker 
C) NEB DNA marker with bp indicated. 
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NEBuffer 3.1(10x concentrated), 1 µl of EcoRI enzyme, 1 µl of NotI enzyme, 0.5 µl 
of BSA (100x concentrated) and water up to a final volume of 50 µl. Then, the two 
solutions were incubated at 37 ºC overnight. The day after, the enzymes activity was 
inactivated by incubating the solutions at 65 ºC for 15 minutes. The digestion 
reaction was confirmed by agarose gel. In each tube, it was added 1 volume of 
loading dye for each 9 volumes of plasmid. Then, samples were loaded in a 2% 
agarose gel (Figure 80B). 
9. mmsF gene sequencing 
To check that the mmsF gene did not mutate during plasmid cloning, all the purified 
plasmids were sequenced by Sanger Sequencing method using the following primers: 
Primer Forward (5'-3'):  CGCAAATGGGCGGTAGGCGTG  
Primer Reverse (5'-3'):  TCAGATCCGGTCGGCCACCCA  
 
The protocol used for gene sequencing was the following: sequencing samples were 
set up using a reaction volume of 0.5 µl BigDye Terminator v3.1 (Applied 
Biosystems), adding the following reagents: 1.31 µl (x5) buffer, 1µl primer (5µM), 
5.19 µl dH2O, 2 µl of DNA (per reaction). Samples were run on a Peltier thermal 
cycler with an annealing temperature of 55 °C and then were precipitated using 95% 
ethanol and washed with 70% ethanol. Then, samples were run on the Applied 
Biosystems 3130 sequencer. 
The sequences were aligned with the original modified mmsF gene (Query) using 
Align Sequences Nucleotide BLAST tool (NCBI), and clone number 4 (Sbjct) was 
selected for cells transfection as 100% identical to the original modified mmsF gene 














Figure 81. BLAST alignement. 
Clone 4 (Sbjct) was aligned with the original modified mmsF gene (Query) using Align Sequences 
Nucleotide BLAST tool (ncbi). 
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  Figure 82. pcDNA4/TO Vector map.  
Original picture taken from: https://tools.thermofisher.com/content/sfs/manuals/pcdna3_1_man.pdf 
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8.3. Transfection S.O.P 
Reagents required for two T25 flasks: 
1. OptiMem Reduced Serum Medium (Gibco) 
2. Plasmid 
3. X-tremeGENE HP DNA Transfection Reagent (Roche) 
Procedure 
1. Keep out all the reagents at RT 1 hour before to start. Cells density in the 
flask should be around the 80%. 
2. Prepare 2 fresh Eppendorf vials (1.5 ml) and put 600 µl of Optimem Medium 
in each one. 
3. Put 6 µl of the plasmid (1000 ng/µl) in each Eppendorf vial and let it 
equilibrate at RT. In the case of co-transfection, also add the second plasmid. 
4. Vortex the Transfection Reagent before to add it. 
5. Add 18 µl of Transfection Reagent to each Eppendorf directly in the middle 
of the medium without touching the Eppendorf’s walls and tip gently to mix 
the compound. 
N.B. The Transfection reagent should NEVER touch the plastic walls of tube. 
Otherwise, its activity will be compromised. 
6. Let incubate for 20 minutes. In the meanwhile, change the medium to the 
flasks T25 with 6 ml of DMEM 20% FBS NO P/S.  
7. When 10 minutes of incubation are passed, tap gently again the Eppendorf to 
mix well the compound. 
8. When 20 minutes are passed, spin down for 3 sec the compound of each 
Eppendorf and add it in each flask gently trying to cover all the flask. Incline 
the flask so that the medium let uncovered the majority of the flask and you 
can add quickly the reagent drop by drop. 
9. Gently swirl the flask for 30 sec. 
10. Incubate in incubator O/N. 
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11. The day after, change the medium with fresh standard medium, without P/S 





8.4. Transfection Efficiency 
 
 
Figure 83. Representative picture of transfection efficiency.  
MG63 cells (a) and MSCs (b) were transfected with pmaxGFP plasmid using the X-tremeGENE HP 
Transfection Reagent and imaged 48 hours after transfection in fluorescence microscopy at 200x 


















Figure 84. Example of RNA integrity test.  
Two main bands of rRNA (28S and 18S 
respectively) were detected. Lane 1= 500 ng of 
rRNA loaded; lane2= 1 µg of rRNA loaded. 
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8.6. Nucleotide sequence of the 
primers used in this study for RT-
PCR. 
 
Table 14. Nucleotide sequence of the primers used in this study for RT-PCR.  
Primers were designed using PRIMER3 software. 
Gene (product size) Forward Primer 5'-3' Reverse Primer 5'-3' 




















mmsF for Sanger 
sequencing (375 bp) 
CGCAAATGGGCGGTAGGCGTG TCAGATCCGGTCGGCCACCCA 

















8.7. SQUID Protocol 
 
1) The sample should be in the capsule, inserted into the straw. 
2) Go to the pc. The temperature on the software shoud be T=300K. Click "set". 
3) Go to the instrument. There are 2 rings. 
4) Unscrew and pull up SLOWLY. When it stops and you feel some tension, 
ROTATE and pull it slowly. Never force it. 
5) When I can see the sample, switch it on "closed". The black handle is now 
horizontal. 
6) Pull away the long tube. The white dot should face me. 
7) Put it on the table, open it, push the sample in the orange pot of tube, making 
sure it doesn't fall. 
8) Then put back the blue cover with the dot facing me.  
9) Click "close"(the 2 wings should block the sample). 
10) Click "purge airlock". When the machine is ready, it appears the "ready" 
green button. 
11) When ready, open chamber (the handle should be vertical). Insert by rotations 
and grease it. 
12) Rotate the second ring and close the black screws 
13) Look at the graphic o the software. It should be "centre". Then push "DC", 
then "target field", then set field at 100 Oe, set "state charging", actual field 
100 Oe. 
14) Put the mass of the sample (in my case is 0.013 g = 13 mg) 
15) DC center --> initialise--> transport--> sample go to button "Full DC scan". 
16) Adjust position 5 cm. Adjust automatically. 
17) Adjust automatically until "Center Position" is exactly 3 cm--> close. 
18) Save on my personal folder. 
19) Set field "0", because I need "0" field cool. 
20) Cool down to 30K. 
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8.8. Flow cytometry antibodies 
Table 15. Flow cytometry antibodies 
Antibody Product code 
APC-conjugated CD34 130-098-139 (MACS Miltenyi Biotec) 
VioBlue-conjugated CD45 130-098-136 (MACS Miltenyi Biotec) 
PE-conjugated CD73 130-097-943 (MACS Miltenyi Biotec) 
PE-conjugated Vio770 CD90 130-099-289 (MACS Miltenyi Biotec) 







  a 
Figure 85. Example of gating strategy and staining for each antibody. 
a) Example of gating strategy. Minimum 50000 events were collected using an electronic gate to 
exclude debris and dead cells, so the data for a minimum of 10000 ‘live’ events occurred in the gate 




8.9. S.O.P. magneTherm Treatment 
1. Switch on water bath, then all other equipment except the magneTherm. 
2. Anaesthetise the mouse, put Lacrilube in the eyes, then put the mouse on the 
ruler with the face mask on. 
3. Slide the ruler into and slightly through the magneTherm to allow rectal probe or 
thermocouple wire to be inserted (use soft paraffin on these to aid insertion). 
4. Push the ruler back into the magneTherm so that the tumours are centrally 
placed. Note the reading on the ruler to ensure that further treatments are all 
placed the same. 
5.  Plug in the magneTherm. 
6. On the synthesised function generator (top) press “SHIFT+DUTY”. The reading 
should flash up as 50. Press “Hz/%” followed by the desired setting e.g. 565.3, 
then press “KHz”. 
7. On the laboratory power supply (middle) turn the “Coarse” and “Fine” dials for 
the voltage until the reading is ⅓ of the final required power voltage (for 
565.3KHz treatment this is approximately 8). 
8. On the synthesised function generator (top) adjust the top right dial until the 
current reading (right) on the laboratory power supply (middle) reads 1.9. 
9. On the laboratory power supply (middle) turn the “Coarse” and “Fine” dials for 
the voltage to the final required power voltage (for 565.3 KHz treatment this is 
23.1). This may be approximate – adjust to around this and the current is 
approximately 5.1. 
10. On the oscilloscope (bottom) use the vertical position dial (top left) to adjust the 
position of the waveform so that it is symmetrical. 
11. Treat in the magneTherm for 30 minutes. The magneTherm will take 5 minutes 
to warm up, so discount the first 5 minutes of the first mouse to be treated. 
12. Take skin temperature readings every 5 minutes during treatment. If a rectal 
thermometer is used take a note of the readings at every 5 minutes also, else if a 
thermocouple is used just check the reading. 
13. After 30 minutes, switch off the laboratory power supply (middle) by turning the 
“Coarse” and “Fine” dials for the voltage to 0, then unplug the magneTherm. 
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14. Slide the ruler slightly through the magneTherm to allow rectal probe or 
thermocouple wire to be removed, then back through the magneTherm to remove 
the mouse. 
15. Place mouse into the recovery box. 












Figure 86. TEM picture of late endosomes. 








Figure 87. AFM/MFM control experiments. 
AFM/MFM of FeCl3 powder (a, d). Fluid Mag DXS nanoparticles (b, e). MSCs incubated with Fluid 
Mag DXS (c, f). MSCs untransfected (g,h). In the upper row are shown the topographic images 
(AFM) whilst the in the lower are shown the equivalent MFM images. Magnetic particles are clearly 
identified in the MFM images as clusters of black spots due to attractive forces, showing the 
capability of MFM to detect magnetic particles inside the cells. The absence of any features on (d) 
indicates the non-magnetic nature of FeCl3 powder. Image widths: a,d) 7.1 µm, b,e) 20 µm, c) 25 µm 
f) 24 µm, g,h)12 µm. 
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8.12. Negative controls for OCN 
staining 
 
  Figure 88. Representative images for negative controls for OCN staining. 
Images were obtained by omitting the primary antibody. a) Negative control for wild-type MSCs 
(Plain), after 10 days of incubation with the osteogenic medium; b) Negative control for mms6-
pcDNA3.1 transfected MSCs, after 10 days of incubation with the osteogenic medium; c) Negative 
control for wild-type MSCs (Plain), after 21 days of incubation with the osteogenic medium; d) 
Negative control for mms6-pcDNA3.1 transfected MSCs,  after 21 days of incubation with the 
osteogenic medium. DAPI was used to stain the cell nuclei (blue). Images were taken using the 





8.13. Experimental setup determination: 
choice of the AMF frequency and of the 
medium FBS percentage 
To determine which AMF frequency was the most effective in causing cell death, 
four AMF frequencies were taken in consideration: 97.8 kHz, 296.4 kHz, 399.9 kHz, 
and 565.3 kHz. 
21 days mms6-expressing MSCs were seeded in Petri dishes as indicated in the 
Materials and Methods Chapter, incubated overnight and exposed at the different 
frequencies for one hour the following morning. Then, the cell death was determined 
by Trypan Blue assay (Figure 89). 
It was noticed that, when cells were cultivated in standard medium, supplemented 
with 20% FBS, the cell death percentage did not pass the 12% threshold (Figure 
89a). It was hypothesised that the high concentration of FBS (20%) present in  the 
medium could have a protective effect on AMF exposed cells, and so it was decided 
to lower it at 10% before the magneTherm exposure. Diminishing the FBS presence 
in the media, it was noticed a higher rate of cell death, as reported in the experiments 
below (Figure 89b). For this reason, the following experiments were performed 
using an exposure medium doped with 10% FBS instead of 20% FBS. 
Results show that 565.3 kHz is the frequency that provides the highest degree of cell 













Figure 89. Experimental setup determination for in vitro cells exposure to AMF. 
Cell death determination using Trypan Blue assay. a) 21 days mms6-expressing MSCs exposed at  
different AMF frequencies for one hour in presence of  20% FBS. b) 21 days  mms6-expressing MSCs 
exposed at different AMF frequencies for one hour in presence of 10% FBS. Three independent 
experiments were considered. Results were compared using One-way ANOVA test followed by 
Tukey's test and considered statistically significant when p value <0.05%. Statistically significant  
results are indicated by asterisks. 
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8.14. Positive controls for   
Caspase-3 and Anti-human Nuclei 





Figure 90. Positive controls for Caspase-3 and Anti-human Nuclei Antibody Clone 3E1.3 
staining. 
 a) Anti-human Nuclei Antibody Clone 3E1.3 staining of formalin-fixed, paraffin-embedded human 





8.15. Representation of Viability Dye 




Figure 91. Viability Dye eFluor 450 staining, followed by Multiphoton microscopy.  
Group C and Group D tumours were investigated  by cellular uptake of Viability Dye eFluor® 450, 
followed by Multiphoton microscopy. Dead cells are stained in blue, while living cells are green. 




8.16. Oral and Poster Presentation 
 
February 2015 
Bologna AIMAGN Conference- "MAGNET 2015".  
Poster Presentation: " Development and utility of magnetic nanoparticles production 
by mammalian cells." 
March 2015 
Glasgow Orthopaedic Research Initiative "GLORI 2015". 
Oral Presentation-"Development and utility of magnetic nanoparticles production by 
mammalian cells." 
December 2016 
London IET Engineering Biology Conference 2016. 
Oral Presentation-"Synthetic Biology for Cell-Based Anti-Cancer Therapies" 
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